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ABSTRACT 
 
The emergence of resistance to cancer treatments through methods that generate cell 
death by inducing DNA damage, such as chemotherapeutics and radiation therapy, is a major 
obstacle to overcoming the disease. Resistance occurs through the repair of single strand DNA 
breaks by the poly(ADP-ribose) (PAR) cycle, which is an enzymatic cycle that promotes DNA 
repair after mild DNA damage. In contrast, upon severe DNA damage, the PAR cycle is known 
to promote acute cell death, which can result in ischemia or neurological diseases. Therefore, 
proteins in this pathway are being studied as potential pharmacological targets for cancer and 
ischemic events. Poly(ADP-ribose) polymerase-1 (PARP-1), the enzyme that synthesizes PAR, 
inhibitors are currently in clinical trials as chemopotentiators, and as personalized treatments for 
patients with the BRCA-1/-2 mutation. However, there is a lack of small molecule inhibitors of 
other important enzymes and proteins in this pathway. Therefore, described herein is the 
discovery and evaluation of small-molecule inhibitors of poly(ADP-ribose) glycohydrolase 
(PARG), the enzyme that degrades PAR, and apoptosis inducing factor (AIF), a protein that 
orchestrates stage I chromatin condensation.  
 
Recognizing that the phosphate moiety, which is cell impermeable, is necessary for 
PARG recognition and binding, Chapter 2 describes how small molecules containing the 
rhodanine motif, a known phosphate replacement, were screened for PARG inhibition in hopes 
of discovering a cell permeable inhibitor of PARG. A compound was identified as a PARG 
inhibitor, and upon derivative synthesis, its properties were optimized to improve potency (IC50 
<10 mM) and solubility. After analyzing compound specificity, the rhodanine-containing PARG 
	   iii	  
inhibitors were tested in both cell lysate and cell culture to assess their ability to inhibit PARG in 
complex environments. In Chapter 3, compounds that prevented the ability of AIF to bind DNA 
were identified and chemically optimized. Although, the inhibitors of AIF proceeded with less 
success, the identified compounds were used in a proof-of-concept analysis of photonic crystal 
biosensors to identify aggregating compounds, and as a novel and facile mechanism to label 
proteins.   
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CHAPTER 1. 
CASPASE-INDEPENDENT CELL DEATH AND ITS ROLE IN DISEASE 
Cellular death in higher eukaryotes is sometimes described as a continuum including 
apoptosis, autophagy, and necrosis.1 However, apoptosis is not synonymous with programmed 
cell death, but rather just one form of programmed cell death. Apoptosis is triggered by cysteine 
proteases (caspases) and characterized by morphological changes such as chromatin 
condensation, shrinkage of cell size, and absence of an inflammatory response.2 Other modes of 
cell death proceed in a programmed fashion as well but are not activated by caspases, and 
therefore, not classically “apoptotic.”3 This thesis will focus on an alternate mode of 
programmed cell death through the activation of poly(ADP-ribose) polymease-1 (PARP-1). 
  
1.1 DNA Damage Repair and the Poly (ADP-Ribosylation) Cycle 
While the maintenance of genetic integrity is vital for life and the prevention of disease, 
DNA is susceptible to damage from both endogenous and exogenous sources. In particular, DNA 
damage arises from environmental sources (such as ultraviolet light and ionizing radiation),4 by-
products from normal cellular metabolism,5 and spontaneous hydrolysis or deamination of DNA 
bases.6 All three of these methods can cause mutations of the genetic material. Cells have four 
main pathways to repair DNA strand breaks, along with a mechanism to repair mismatched DNA 
bases; all of these are crucial for maintaining the integrity of the genome.4 Two methods that 
repair single strand breaks are nucleotide excision repair (NER) and base excision repair (BER), 
while double strand breaks are repaired by homologous recombination (HR) and non-
homologous end joining (NHEJ) (Figure 1.1).4,7 
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Figure 1.1. DNA Strand Damage Repair Mechanisms. Single or double DNA strand breaks are repaired 
through four main mechanisms. Single strand DNA breaks, which are caused by either environmental 
exposure or cellular toxins, are repaired through NER or BER pathways. Double strand DNA breaks are 
repaired by HR and NHEJ in S/G2 and G1 phases of cell cycle arrest, respectively. The PAR cycle, the 
enzymatic cycle of interest, is involved in the BER pathway. 
 
Single strand breaks arise from both exogenous and endogenous sources including UV 
light, chemical toxins, X-rays, and cellular metabolic by-products. NER is a versatile pathway 
that addresses lesions affecting base pairing that are typically caused by exogenous sources.4 In 
contrast, BER targets smaller chemical mutations generated from endogenous sources, thus 
preventing mutagenesis. More explicitly, BER uses PARP-1 activation to correct lesions that are 
caused by DNA methylation, deamination, hydroxylation, and reactive oxygen species (ROS).4,7 
The importance of the BER pathway is made apparent by its inherent redundancy, which helps 
explain why no known disorders have arisen due to an inherited BER deficiency.4  
 
Double strand breaks form as a direct result of damage induced by X-rays and anti-tumor 
agents, but can also arise from unrepaired single strand breaks.4 In general, they are more severe 
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than single strand breaks because the cell cannot use the complementary strand as a template for 
repair. Double strand breaks are controlled by the HR and NHEJ pathways.4 HR is the more 
accurate method of repairing double strand breaks; it is used in the S and G2 cell cycle phases 
where the sister chromatid can be used as a repair template. In contrast, NHEJ, the less accurate 
method of double strand break repair, dominates in the G1 phase.8 All four methods of DNA 
repair are complimentary and critical for cell survival. Due to the importance of DNA integrity, 
the ability of a cell to repair DNA is directly linked to the cell’s decision to undergo programmed 
cell death. This work will primarily focus on PARP-1 mediated programmed cell death and its 
role in repairing DNA strand breaks. 
 
1.1.1 The PAR Cycle and Its Role in Caspase-Independent Cell Death 
Poly(ADP-ribosylation) is a post-translational modification involved in many cellular 
functions including transcription, RNA metabolism, and telomere function;9,10 however, this 
thesis will focus on its involvement in DNA damage repair and cell death. As mentioned 
previously, PARP-1 is involved in the BER pathway. Upon recognition of DNA damage, the 
PARP-1 enzymatic activity is increased 10 to 500-fold above its basal level and utilizes β-NAD+ 
as a substrate to synthesize poly(ADP-ribose) (PAR), which then recruits DNA repair proteins to 
the site of DNA damage (Figure 1.2).11 PAR is a long chain, branched biopolymer that expands 
through a linear (on 2’-hydroxyl) and branched pattern (on the 2’’-hydroxyl); however, 
branching only occurred twice in 67 residue-containing PAR that was isolated from intact cells 
after DNA damage.12 While 90% of PAR is covalently linked to PARP-1 via automodification,12 
PAR also modifies histone H1,13 histone H2A/H2B,14 topoisomerase I,15 DNA polymerase α and 
β,16 along with a host of other nuclear proteins mainly through the γ-carboxyl group of glutamic 
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Figure 1.2. The PAR Cycle. DNA damage induces activation of PARP-1, which synthesizes PAR. PAR 
recruits DNA repair proteins to the site of DNA damage, and deactivates the activity of PARP-1. 
However, PAR is transient due to its rapid degradation by PARG. Upon PAR catabolism, PARP-1 is re-
activated allowing the cycle to reoccur. Recently, enzymes involved in the PAR cycle have been targeted 
for many disease states including cancer and ischemia. 
 
acid residues.17  PAR modification not only labels the sites of DNA damage, but through histone 
modification, the chromatin structure is opened to allow access for DNA damage repair proteins, 
such as X-ray repair cross-complementing protein 1 (XRCC1), DNA polymerase-β, and DNA 
ligase III, which are actively recruited to the sites of damage.9 Automodification of PARP-1, 
with PAR chains up to 200 units in size,12 creates an abundance of negative charge on PARP-1 
causing an electrostatic repulsion and dissociation from the negatively charged DNA, ultimately 
leaving PARP-1 inactive.18 However, this process is transient in nature due to the activity of 
poly(ADP-ribose) glycohydrolase (PARG).19 PARG catabolism of PAR occurs in both an exo- 
and endoglycosidic manner through hydrolysis of the ribosyl-ribose bond to form free ADP-   
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Figure 1.3. PARG Cleavage of PAR. PAR is enzymatically synthesized by PARP-1 using NAD+, and is 
comprised of linear and branched ADP-ribose subunits, which can become ~200 units long. PAR is 
degraded by PARG both linearly and through a debranching mechanism in an exoglycosidic and 
endoglycosidic fashion, to form single ADP-ribose units and a single ADP-ribose bound to the modified 
protein. 
 
ribose (Figure 1.3). The degradation of PAR by PARG occurs on the minute timescale, with 
complete degradation taking between seconds and hours depending on polymer size and 
complexity.17,20-22 Once PAR is degraded, PARP-1 is reactivated, allowing the cycle to reoccur 
(Figure 1.2). 
 
The PAR cycle plays a major role in caspase-independent cell death. Although not fully 
elucidated, severe DNA damage causes the activation of PARP-1, and the synthesis of PAR. 
Next, PAR is chaperoned from the nucleus to the cytoplasm by an unidentified protein, where it 
acts upon the mitochondria to cause the release of apoptosis inducing factor (AIF).23 AIF is a 
protein that resides in the inner mitochondrial membrane space, and upon cleavage by calpain, 
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 6 
translocates to the nucleus and causes stage I chromatin condensation.24 A second pool of AIF 
was recently discovered that is associated with the outer mitochondrial membrane on the 
cytosolic side.25 This pool of AIF, which consists of approximately 30% of the total AIF, is now 
thought to be directly released by PAR, leading to a cascade of events that ultimately causes cell 
death. 
 
1.1.2 Biochemical Properties of PARP and Its Isozymes 
The PARP family of enzymes is comprised of 17 members, the majority of which have 
been shown (upon activation by stimuli) to transfer mono- or poly(ADP-ribose) to acceptor 
proteins.26 Despite the large size of the PARP family of proteins, there are few similarities across 
the whole family, including their function. The name of this class of proteins, PARPs, would 
imply that all of its containing members would synthesize poly(ADP-ribose), but in fact, only 
PARP-1, PARP-2, PARP-3, PARP-4, and PARP-5a, and -5b, (also known as tankyrase-1 and -2 
respectively), participate in poly(ADP-ribosylation).  The remaining members of the PARP 
family transfer a single unit of ADP-ribose and therefore would more accurately be called 
mono(ADP-ribose) transferases.  Due to this flaw in nomenclature, there is a movement in the 
PARP community to reclassify PARPs and accurately name them ADP-ribosyltransferases 
(ARTs).27 However, this document will continue to address this family of enzymes as PARPs. 
 
PARP-1, discovered nearly 50 years ago,28 is a 113 kDa protein comprised of three 
distinct domains. Starting from the N-terminus, PARP-1 contains a 42 kDa DNA binding domain 
(comprised of two zinc fingers) and a nuclear localization sequence. Next is an automodification 
domain that contains 15 essential glutamate residues that are acceptors for poly(ADP-
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ribosylation), and lastly is the 55 kDa catalytic domain, located at the C-terminus, which houses 
the NAD+ binding domain.29-31 Additionally, a third zinc finger was recently discovered by 
crystallographic analysis and mutagenesis studies that is thought to facilitate contacts within 
PARP-1 that are necessary for DNA-dependent activity and chromatin compaction.32,33 Of the 
two enzymes that coordinate PAR formation and degradation, PARP-1 is by far the most studied, 
and it currently has inhibitors that are in clinical trials for the treatment of cancer.34-37 
 
PARP-1 has the greatest similarity with PARP-2, the only other DNA damage 
recognizing protein in the PARP family.  PARP-2 has a 60% sequence homology with PARP-1; 
however, they are least similar in the DNA binding domain.38 Due to this high sequence 
homology, it is no surprise that PARP-1 and PARP-2 show some redundant cellular functions 
that allows either PARP-1 or PARP-2 single knockout mice to be viable. However, the PARP-
1/PARP-2 double knockout is embryonic lethal, suggesting that other family members cannot 
replace the essential cellular roles of PARP-1 and PARP-2.39 Even though there is some inherent 
redundancy between PARP-1 and PARP-2, PARP-2 does not have the capacity to synthesize 
PAR to the same extent as PARP-1, and it carries its own distinct roles in spermatogenesis, 
adipogenesis, and T cell development.38 Additionally, like PARP-1, PARP-2 is emerging as a 
potential pharmacological target due to hypersensitivity seen with alkylating agents,39 including 
the development of PARP-2 specific inhibitors.40 
 
Tankyrase-1 and -2 have very intriguing functions outside of DNA damage repair. 
Similar to the DNA binding PARPs, the tankyrases have overlapping functions. The single 
knockout of tankyrase-1 or -2 is viable but the double knockout has proven to be embryonic 
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lethal in mice.41 The tankyrases mainly function as a part of cell development, including mitotic 
spindle function and Wnt signaling. Both proteins are also involved in telomere formation, more 
specifically, the lengthening of telomeres, and are able to modify TRF1, a telomeric protein, 
through poly(ADP-ribosylation).42 In a similar fashion as the other PARPs previously discussed, 
tankyrases are also being targeted by small molecule inhibitors in order to further study their 
function.43  
 
1.1.3 Biochemical Properties of PARG and Its Function 
Unlike PARP-1, PARG does not belong to a large protein family, and is encoded by a 
single gene. PARG efficiently catalyzes the hydrolysis of PAR to produce ADP-ribose units. 
Due to alternative splicing or promoter selection, at least 5 different human PARG isoforms are 
known, which reside in three different locations in the cell (Figure 1.4). However, biochemical 
studies of PARG have been hindered by its low abundance in the cell, making it difficult to 
isolate. Additionally, PARG is sensitive to proteases, which makes it difficult to express 
recombinantly, plus no three-dimensional (3-D) structure has been solved.44 Lastly, the impact of 
PARG’s loss of function in the cell is unknown because it is embryonic lethal (E3.5) upon 
knockout.44 Despite these challenges, insights into PARG’s function within the cell have been 
gained by the study of PARG knockdowns using shRNA/siRNA, and knockouts of particular 
isoforms of PARG by genetic ablation of distinct exons of the gene.  
 
The full length, 111 kDa hPARG (110 kDa in mice) is located in the nucleus, and 
contains a nuclear localization sequence in exon 1 that consists of approximately 7 amino acids  
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Figure 1.4. PARG Isoforms. Although PARG is made from a single gene, to date, 5 PARG isoforms have 
been discovered in three cellular locations. Full length PARG (PARG111) is located in the nucleus and is 
thought to be involved in the maintenance of normal cell function.  PARG102 and PARG99 are located in 
the cytoplasm and are involved in DNA damage response. PARG60 and PARG55 are located in the 
cytoplasm and mitochondria, and their exact function is still being elucidated, although PARG60 has been 
implicated in a shuttling mechanism. 
 
(Figure 1.4).45,46 Despite its location in the nucleus (where PARP-1 modifies proteins), a GFP- 
tag on the 110 kDa PARG revealed that upon DNA damage by gamma irradiation in live cells, 
PARG110 translocates to the cytoplasm.47 Mouse models where exon 1 has been deleted, thus 
eliminating full length PARG (but not the other isoforms), have proven to still be viable.48-50 
When exon 1 was targeted by an antisense phosphorodiamidate morpholino oligonucleotide 
(PMO) to silence full length PARG, no change in the cytoplasmic PARG activity was seen, and 
PARG mRNA, 18 exons 
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PAR was still degraded.45 Although the primary role of PARG110 is not DNA damage repair, it 
is likely involved in regulatory function of the cell. Additionally, there is a highly debated effect 
seen when PARG110 is knocked out in models of ischemic injury, which will be discussed 
further in section 1.2.3. 
 
PARG102 and PARG99 lack the N-terminal nuclear localization sequence, which is 
encoded by exon 1, and are the most abundant and active forms of PARG; in fact, these PARGs, 
which are located in the cytoplasm, account for 85% of the PARG in the cell.51 Their location in 
the cytoplasm, away from where PAR is synthesized and ultimately degraded in the nucleus, is 
likely due to their regulatory function.52 It was demonstrated that as PARG110 exits the nucleus 
upon DNA damage, cytoplasmic PARG translocates to the nucleus to degrade the newly 
synthesized PAR.47 This same effect was seen in brain tissue where PARG was 
compartmentalized in the mitochondria and cytoplasm until PARP-1 was activated through 
excitotoxic injury by N-methyl-D-aspartic acid (NMDA), which led to PARG translocation to the 
nucleus.53 This mechanism establishes a strict balance and regulation of PAR under cellular 
stress.  
 
The most recently discovered PARGs were found within the mitochondria, PARG60 and 
PARG55.54 Although PARG60 was initially thought to be the cleavage product of a longer length 
PARG, the isolation of cDNA from RNA reveals that it too is a splice variant. PARG60 was 
found to be located in multiple compartments in the cell including the mitochondria, while 
PARG55, another splice variant, was found only in the mitochondria. By examining the 
mitochondria targeting sequences in exon 4, it is hypothesized that PARG60 is capable of 
shuttling between the mitochondria and nucleus providing yet another mechanism for PAR 
degradation. 
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Lastly, 2006 brought the discovery of a new gene that yielded a 39 kDa enzyme that was 
also able to degrade PAR, termed ADP-ribosylhydrolase 3 (ARH3).55,56 Although it functions 
similarly to PARG, it bears little structural resemblance (19% amino acid sequence homology) 
and it degrades PAR with less efficiency. Additionally, the embryonic lethality seen with PARG 
knockouts suggests that ARH3 alone is not sufficient to degrade PAR. Like PARG, ARH3 was 
located in both nuclear and cytosolic fractions of lysed cells. However, unlike PARG, ARH3 was 
found to efficiently cleave O-acetyl ADP-ribose, a signaling molecule, into acetate and ADP-
ribose,56 and it was hypothesized to play a regulatory role in the cell based on its ability to 
degrade PAR within the mitochondria.57 However, the exact function and utility for this 
glycohydrolase is still being elucidated.  
 
Unfortunately, to date there is no published crystal structure of PARG, and thus further 
insight into the individual roles for different PARG isoforms and the understanding of their 
complementary function has been prevented. Despite not having a crystal structure some 
structural information about PARG is known through site-directed mutagenesis and cross-linking 
studies with an ADP-ribose analog. 
 
Mutagenesis was employed to discover important residues in the catalytic domain. 
Knowing that glycosidases traditionally have acidic residues to promote catalytic activity, Patel 
et al. performed site-directed mutagenesis on 9 residues within a highly conserved portion of the 
enzyme and discovered three acidic residues that were essential for catalytic activity: aspartic 
acid 738, glutamic acid 756, and glutamic acid 757.58 Coupling this information with the 
discovery of a glycine rich region in the catalytic domain (G745-G746-G747) that was found to 
play an important role in the function of PARG,59 vital information about the catalytic site was 
extracted without the aid of a crystal structure. 
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An azido-derivatized ADP-ribose analog (Figure 1.13, 1.1, see section 1.3.3 on PARG 
inhibitors) was photocrosslinked to the catalytic fragment of recombinant bovine PARG. After 
tryptic digestion and mass spectrometry analysis, tyrosine 796, which is highly conserved in 
PARG from many organisms, was identified as the amino acid modified by the compound.60 
Site-directed mutagenesis yielded PARG where the tyrosine residue of interest was replaced with 
an alanine (PARG Y796A). Surface plasmon resonance revealed that the PARG inhibitor 8-
(aminohexyl)amino-adenosine diphosphate (hydroxymethyl)pyrrolidinediol (8-AH-ADP-HPD), 
which was capable of being immobilized on the surface (Figure 1.12, 1.2), had a ~20-fold 
reduced affinity for PARG Y796A (KD = 170 nM) than wild-type PARG (KD = 8.2 nM).  
However, when the tyrosine was mutated to a tryptophan, no difference between the binding 
constant of the mutated (PARG Y796W) protein and the wild-type protein was observed. These 
results indicate that tyrosine 796 plays an important role in the catalytic activity of PARG, and 
ADP-ribose analogs may bind at this residue through a ring stacking interaction. 
 
Most recently, a regulatory domain of PARG, that is separate from the catalytic domain, 
was identified within the mitochondrial targeting sequence (MTS).61 Upon identifying the 
minimum segment of PARG required for activity, which contained the 16-residue MTS, site-
directed mutagenesis was used to identify two hydrophobic residues, leucine 473 and leucine 
474, within the MTS that were required for activity. Additionally, the deletion of the MTS from 
full length 110 kDa PARG caused a complete loss in activity, proving that this sequence is 
critical for PARG activity and regulation. Lastly, it is a potential site for other proteins, such as 
PARP-1, to interact with PAR and regulate its activity. 
 
In summary, the study of PARG has been hindered by the absence of a 3-D structure. 
However, mutagenesis studies have revealed information about the structure of PARG, as it 
relates to its activity. Interestingly, instead of engineering multiple proteins to degrade PAR, the 
cell has specific variants of PARG that are compartmentalized and shuttled based on the state of 
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the cell. A strict balance of PARG isoforms is necessary in order to maintain normal cellular 
function under homeostasis or to repair damaged DNA under oxidative conditions. Although it is 
not fully understood why there is only one enzyme to carry out PAR degradation in multiple 
cellular states, it exemplifies the efficiency and effectiveness of PARG. 
 
In lieu of a crystal structure, a small molecule inhibitor of PARG could help in the study 
of its cellular function. For example, the 16 amino acid MTS/Reg sequence is an ideal target for 
small molecule inhibition, and warrants further investigation. The design of such an inhibitor to 
this region of the protein will help in the study its regulatory function and potentially help 
positively identify necessary interactions with PARG and proteins that interact with PARG at 
this sequence. Additionally, a small molecule inhibitor would help in studying the biochemical 
function of PARG, its pathways in the cell, and the role of PARG under DNA damaging 
conditions. Such studies would help establish a more definitive role for PARG in the cell, 
especially in reference to disease states. 
    
1.2 The PAR Cycle as a Disease Target 
The inhibition of the synthesis and degradation of PAR is being investigated as a strategy 
for both the treatment of cancer and ischemia. Because PARP-1 activation and subsequent PAR 
synthesis play a role in the repair of DNA single strand breaks, upregulation of the PAR cycle 
was hypothesized to play a role in resistance to some of today’s chemotherapeutics. 
Additionally, the hyperactivation of PARP-1 was shown to cause depletion of cellular ATP and 
ultimately plays a role in cellular necrosis, especially in ischemia. This section will outline the 
major mechanisms of PARP and PARG inhibition and their role as disease targets. 
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1.2.1 PARP as an Anticancer Target 
Since the discovery of the first PARP inhibitor (see section 1.3.1), a synergistic effect of 
PARP inhibitors and DNA alkylating agents has been noted. Today’s success with PARP 
inhibitors was foreshadowed when Durkacz et al. observed increased cytotoxicity when PARP 
inhibitors were co-treated with dimethyl sulphate, a DNA alkylator, in L1210 mouse leukemia 
lymphoblast cells.62 In fact, the discussion of this pivotal paper concludes that “poly(ADP-
ribose) polymerase inhibitors may be of use in the treatment of human leukaemia.” As predicted, 
continued research over the next 30 years in this field led to the emergence of two mechanisms 
of PARP inhibition with clinical applications for cancer. 
 
1.2.1.1 Potentiation of Chemotherapeutics and Radiation 
Radiation and many chemotherapy drugs induce cell death in rapidly dividing cells by 
causing DNA damage. Due to the lack of selectivity for cancer, these harsh treatments come at a 
cost, including debilitating side effects, hair loss, and sickness. Ultimately, these side effects can 
be detrimental to the cancer treatment, limiting the amount that can be given to patients. Another, 
significant drawback of these frontline methods of treatment is cellular resistance. One 
mechanism of resistance is through the activation of DNA damage repair pathways, including the 
PAR cycle, which ultimately renders these therapies ineffective.  
 
The inhibition of PARP-1 prevents the synthesis of PAR and prohibits the recruitment of 
proteins to repair the damaged DNA caused by the chemotherapeutics (Figure 1.5). By inhibiting 
PARP-1, cells are sensitized to DNA damaging agents, such as DNA alkylating agents, 
topoisomerase I inhibitors, and X-rays, which activate the BER pathway. This event causes the 
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DNA damaging agents to be more potent and effective with greater cell death yielded at lower 
concentrations. The potentiation effect has been seen in both PARP-1 knockouts and PARP-1 
inhibition by small molecules. Masutani et al. showed using embryonic stem (ES) cells derived 
from PARP-/- mice that the lack of PARP-1 potentiates both chemotoxins and irradiation.63 This 
effect was confirmed by the use of small molecule inhibitors of PARP as described in much of 
the early literature.62,64 This potentiating effect has launched many PARP inhibitors into clinical 
trials, which will be discussed in section 1.3.2.1.  
 
 
Figure 1.5. PARP Inhibition Potentiates Chemotherapeutics. The PAR cycle promotes the repair of 
damaged DNA, which is damaged by certain chemotherapeutics, ultimately causing cancer resistance. 
Therefore, enzymes in this pathway have been targeted for chemopotentiators. The inhibition of PARP-1 
prevents the synthesis of PAR, thus inactivating the PAR cycle. Therefore, PAR is unable to recruit DNA 
repair proteins, preventing DNA damage repair, and rendering the chemotherapeutics more effective. 
 
1.2.1.2 Single-Entity Agents in Breast Cancer Susceptibility Protein (BRCA) Deficient Cells 
In 2005, two seminal papers appeared back-to-back in Nature describing the use of PARP 
inhibitors in BRCA-deficient cell lines.65,66 BRCA1 and BRCA2 are breast cancer susceptible 
proteins that are involved in the repair of double strand DNA breaks through a pathway known 
as homologous recombination (HR), and are thought to be associated with tumor suppression. 
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When these genes are mutated, the cells are more susceptible to uncontrolled growth and cancer 
due to an increased rate of mutation caused by the lack of DNA repair. Two separate groups 
reported seeing increased death in BRCA-deficient cell lines when PARP-1 activity was 
inhibited. This effect was first noted when PARP-1 was knocked down by siRNA in a BRCA-
deficient ES cell line; a reduction in clonogenic survival was seen, when compared to a wild-type 
ES cell line.66 Increased cell death was again observed when PARP-1 was inhibited by a small 
molecule.65,66 This led to the conclusion that PARP inhibitors could be used as a single entity 
agent in BRCA-deficient cells. 
 
 Combined deficiency in both single and double strand break repair results in cell death. 
PARP-1 inhibition prevents single strand DNA breaks from being repaired, and unrepaired 
single strand breaks became double strand breaks during replication. With the loss of BRCA1 or 
BRCA2 function, the double strand breaks cannot be repaired, which causes general genomic 
instability and cell death (Figure 1.6). This lethality is only seen when both mechanisms of DNA 
repair (HR through BRCA mutation and BER through PARP inhibition) are compromised. 
BRCA mutations are inherited defects more prevalent in breast and ovarian cancer. Additionally, 
triple-negative breast cancer (estrogen receptor negative, progesterone receptor negative, and 
Her2 negative), the most resistant form of breast cancer, displays some of the same phenotypes 
and PARP-1 inhibition sensitivity as BRCA-/- cells.67,68 Since these mutations can be identified 
by biopsy, PARP-1 inhibitors offer personalized treatment to a targeted group of patients that 
were previously very difficult to treat.  
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Figure 1.6. PARP-1 Inhibition Causes Synthetic Lethality in BRCA1/2 Deficient Cells. The inhibition of 
PARP-1 in BRCA1 or BRCA2 deficient cells caused general genomic instability and cell death due to the 
loss of both single strand and double strand DNA repair mechanisms. 
 
The discovery that PARP inhibitors could be used as single entity agents did not occur 
until 25 years after PARP inhibitors were discovered as chemopotentiators. Therefore, the 
structures of the PARP inhibitors had already been optimized and were proceeding through 
clinical trials. This allowed the very rapid validation of PARP inhibitors as single entity agents in 
BRCA-deficient cells in cell culture, animal models, and ultimately in clinical trials. The success 
seen in this model will be described further in section 1.3.2.1. 
 
1.2.2 PARP as a Target for Ischemia 
The activation of PARP-1 and subsequent production of PAR is thought to play an 
important role in necrotic cell death. PARP-1 is activated under ischemic conditions through the 
damage of DNA by nitric oxide and ROS. This causes hyperactivation of PARP-1, rapid 
synthesis of PAR, and subsequent depletion of NAD+ and ATP. Once ATP, the energy source for 
the cell, is depleted, the cells die from necrosis (Figure 1.7). The resulting necrotic cell death 
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causes severe damage in heart attack, stroke, and inflammation. Therefore, there is a therapeutic 
need for new and innovative treatments for ischemia. 
 
 
Figure 1.7. PARP Inhibition and Ischemia. Under ischemic conditions, PARP is hyperactivated, which 
causes the rapid synthesis of PAR and the depletion of NAD+. Because NAD+ is synthesized from ATP, 
the hyperactivation of PARP causes the loss of ATP (the energy stores for the cell), which ultimately 
causes necrotic cell death. 
 
If PARP-1 is inhibited, the damaged cells will not be able to synthesize PAR nor drain 
the ATP stores of the cell. Although this would keep the cells alive by preventing necrosis, 
without DNA repair, these cells could be left in a damaged state. However, PARP-1 knockouts 
show protection in ischemic models, suggesting this mechanism as a way to prevent necrotic cell 
death associated with ischemia.69 One in vitro model that is commonly used to replicate the 
process of vascular stroke is through oxygen-glucose deprivation and NMDA neurotoxicity. 
PARP-/- cerebral cortical neurons from PARP-/- mice were subjected to ischemic injury and 
almost completeprotection was seen in the PARP-/- cultures compared to wild-type cultures.69 
Similar protection was seen in PARP-/- mice compared to their wild-type littermates, when the 
infarct volume was measured following a stroke model. Therefore, PARP inhibitors entered into 
clinical trials for the treatment of ischemia at a similar time as PARP inhibitors as a cancer 
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treatment, although with less success (section 1.3.2.2). Many factors probably contribute to the 
discontinuity between the bench and the clinic with PARP inhibitors in ischemia. However, these 
results simply highlight the limitations in the animal models for acute cell death, preventing 
translation of lab results to the clinic. Despite these limitations, PARP inhibitors are still being 
pursued in clinical trials for ischemia. 
 
1.2.3 PARG as a Novel Target for the Inhibition of Poly(ADP-Ribosylation)  
PARP’s counterpart, PARG, is also being investigated as a target for drug development. 
Instead of targeting the synthesis of PAR through PARP inhibition, the degradation of PAR also 
seems to play a pivotal role in disease progression. However, there are some distinct advantages 
and disadvantages of PARG inhibition compared to PARP inhibition. In general, much less 
information about PARG is available. The study of PARP was enhanced by crystal structure 
analysis, thorough biochemical studies, and knockout mouse models, all of which are 
unavailable or underdeveloped with respect to PARG. Despite the fact there is less known about 
PARG overall, there could be some advantages in inhibiting PARG over PARP-1. PARG is the 
lone enzyme responsible for the degradation of PAR. Therefore, PARG is an attractive target 
because specificity would not be a concern, where as PARP inhibitors are designed to bind the 
NAD binding site, which is present in many of the PARPs and other non-related enzymes. 
Additionally, the inhibition of PARG could specifically inhibit PARP-1. Because PARP-1’s 
affinity for DNA and target proteins is sharply reduced when it is automodified by PAR, and its 
affinity is restored upon glycosidic cleavage by PARG, the inhibition of PARG would 
presumably lead to PARP-1 inhibition.70 Therefore, PARG inhibition is currently being studied 
in three mechanisms for applications in cancer and ischemia. Like PARP inhibition, PARG 
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inhibition is being investigated as a potentiator of chemotherapeutics and radiation, as a single 
entity agent in BRCA-deficient cells, plus a third mechanism where PARG could be used as a 
single entity agent in solid tumors. Although uses for PARG inhibition and cancer are clear, the 
utility of PARG inhibition in ischemic injury remains to be elucidated. 
 
1.2.3.1 PARG Inhibition and Cancer 
PARG inhibitors may be able to function in a similar manner as PARP inhibitors as both 
chemopotentiators and as single entity agents in BRCA-deficient cell lines. Inhibition of PARG 
disrupts the PAR cycle, prevents the regeneration of active PARP-1, and should prevent the 
repair of single strand breaks (Figure 1.8). Therefore, PARG inhibition may sensitize cells to 
chemotherapeutics and irradiation similar to PARP inhibitors.  
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Figure 1.8. PARG Inhibition Could Potentiate Chemotherapeutics. PARP-1 is deactivated once PAR 
becomes significant in length, resulting in electrostatic repulsion from DNA, and the inhibition of the 
PAR cycle until PARG efficiently degrades PAR. Therefore, the inhibition of PARG would indirectly 
inhibit PARP-1 and the PAR cycle, ultimately preventing the damaged DNA from being repaired. 
Thus, PARG inhibition is hypothesized to act as a chemopotentiator. 
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This potentiating effect was observed using PARG110-/- ES cells, derived by the 
disruption of exon 1 of PARG. The knockout cells and their wild-type counterparts were 
subjected to a host of DNA alkylating agents and gamma-irradiation.49 The PARG110-/- ES cells 
were more susceptible to dimethyl sulfate, cisplatin and gamma irradiation treatment as 
compared to the wild-type cells, when cell death was assessed by a clonogenic survival assay. 
Interestingly, increased lethality was not seen with gemcitabine and camptothecin, two 
chemothereuptics commonly used in combination with PARP inhibitors. Similar potentiation 
effects were seen when PARG null embryonic trophoblast stem (TS) cells were subjected to UV 
radiation and DNA modifying agents such as cyclophophamide, cisplatin, and epirubicin.71 In 
this case, as high as a 4-fold increase in cell death was observed when the PARG null cells were 
treated with the DNA modifying agents. These results confirm that indeed PARG is a potential 
pharmacological target for potentiation with DNA damaging agents. 
 
PARG inhibition has also been hypothesized to cause synthetic lethality in BRCA-
deficient cells based on the phenomenon seen with PARP inhibitors. Because PARG inhibition 
would ultimately inhibit the PAR cycle preventing the repair of single strand breaks, the same 
genomic instability and cell death would result in the presence of BRCA mutations. However, 
the concept of synthetic lethality with PARP inhibition and BRCA deficiency is hardly 5 years 
old, and therefore, no literature has emerged to support this claim with PARG inhibition. 
 
A third mechanism, which is unique to PARG inhibition, is the use of a PARG inhibitor 
as a single entity agent in solid tumors (Figure 1.9). Once DNA is damaged, PARP-1 is activated 
causing the rapid production of PAR. However, when PARG is inhibited, reduced PAR 
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degradation would lead to a build-up of long chain PAR. This build-up of PAR was shown to be 
persistent for up to 90 min when PARG was knocked down using shRNA.72 Additionally, 
Andrabi et al. have shown that PAR itself can function as a death signal.73 By artificially adding 
PAR to cells using a Bioporter system, caspase-independent cell death was triggered by longer 
chain PAR (60-mer) in a dose dependent manner (>80% cell death seen with 160 nM PAR). 
Therefore, the inhibition of PARG would cause the build-up of long chain PAR, which could 
then serve as a death signal, ultimately allowing PARG inhibitors to be utilized as single entity 
agents in not just BRCA-deficient cells but also in more traditional solid tumors. 
 
1.2.3.2 PARG Inhibition and Ischemia 
Although PARG inhibition with respect to ischemia has been well studied, results have 
shown PARG inhibition to be both cytoprotective and cytotoxic. As mentioned previously, 
necrotic cell death proceeds through the rapid activation of PARP-1, which leads to the depletion 
of ATP and subsequent cell death. Although PARP-1 arose as a viable cytoprotective target for 
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Figure 1.9. PARG Inhibitors as Single Entity Agents. Because the inhibition of PARG could cause the 
indirect inhibition of PARP-1, and the build-up of PAR, PAR could serve as a death signal to the cell, 
causing a cascade of cellular events, leading to cell death through AIF-mediated caspase-independent 
cell death. 
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necrotic cell death, there were concerns that the cells would remain in a damaged state. However, 
in the case of PARG inhibition, active PARP-1 would synthesize PAR that would not be cleaved 
rendering PARP-1 inactive. Therefore, not only would the PAR cycle be inhibited thus 
preventing further depletion of ATP, the synthesized PAR would allow for the recruitment of 
DNA repair proteins to mend the damaged DNA.  
 
In opposing fashions, Blenn et al. showed that PARG knockdown cells were protective 
against H2O2 treatment,74 while Fisher et al. found the cells to be more sensitive to oxidative 
damage.75 First, Blenn et al. knocked down PARG using siRNA in mouse embryonic fibroblasts 
(MEFs) and treated the cells with 0.05 – 1 mM H2O2 for 15 min.74 They noted that the PARG 
knockdown cells were more viable and exhibited greater resistance to oxidative stress than the 
wild type cell line. Additionally, they saw an accumulation of PAR (longer than 15 mer) at the 
early stages of treatment, concluding that the inhibition of PARG protected the cell against 
oxidative damage. In contrast, Fisher et al. knocked down PARG in human A549 cells, and after 
treating the cells with 100 µM H2O2 for 20 min, they saw increased DNA damage and cell death 
compared to the wild type cells.75 These results show that PARG inhibition promotes cell 
sensitivity and not protection to H2O2. Although these results are conflicting, PARG inhibition 
clearly has an effect under oxidative conditions but the exact nature of this effect needs further 
investigation. Ideally, the effects of PARG inhibition could be further elucidated using a small 
molecule PARG inhibitor, highlighting the need for such a molecule.  
 
1.3 Modulation of Poly (ADP-Ribosylation) 
As mentioned in section 1.2, there are efforts employed to affect poly(ADP-ribosylation) 
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through the development of small molecule inhibitors of PARP and PARG. This section will 
discuss the development of PARP inhibitors from the bench to the clinic, highlighting some of 
the most successful results to date. As for PARG inhibition, this section will outline the major 
classes of PARG inhibitors, and limitations associated with each class. 
 
1.3.1 The Development of PARP Inhibitors: Potency and Specificity 
In 1971, approximately 10 years after the discovery of PARP-1, nicotinamide (Figure 
1.10, 1.3), a by-product of the synthesis of PAR from NAD+, was seen to weakly inhibit PARP-1 
(IC50 = 210 µM).76 As the first inhibitor of PARP-1, nicotinamide was used to study PARP-1’s 
function and investigate PARP-1’s role as a pharmacological target. In order to produce more 
potent inhibitors of PARP-1, the nicotinamide core structure, benzamide (1.4), was used as a 
scaffold to ultimately select for compounds that bound in the NAD+ binding site. Through a 
screen of benzamides with functionalization at the 3-position, 3-aminobenzamide, 3-AB (1.5, 
IC50 = 30 µM, Ki = 1.8 µM), was identified as a PARP inhibitor with a 7-fold improvement in 
potency over nicotinamide.77 Albeit a weak inhibitor, 3-AB was the most prominent PARP 
inhibitor for over a decade, and was a springboard for later development of more potent and 
specific inhibitors of PARP-1.  In order to improve the potency and specificity with 3-AB, 
Banasik et al. performed a large-scale survey of compounds, where they discovered novel 
frameworks for PARP inhibitors.78 These included bicyclic and tricyclic structures, including 
isoquinolinones (1.6), quinazolinones (1.7), and phenanthridones (1.8), all of which inhibit 
PARP in the single digit micromolar range or less, with the most potent compound having an 
IC50 value of 0.18 µM. Many of the modern PARP inhibitors that are in the clinic today evolved 
from the core structures that emerged from this important work, as shown in Figure 1.10.  
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Figure 1.10. PARP-1 Inhibitors. Originating from nicotinamide, PARP inhibitors were designed to 
inhibit PARP-1 in the NAD+ binding pocket. Since their initial development, potent amide and lactam-
based potent PARP-1 inhibitors have been discovered, leading to the development of clinical trials with 
compounds 1.10, 1.11, 1.14. 
 
Besides the original benzamide (1.4) core structure and the cyclic rings discovered in the 
screen (1.6 – 1.8), the 1990’s also brought about more unique cyclic frameworks that potently 
inhibited PARP-1 including imidazole carboxamides (1.9).79 Nearly all second and third 
generation PARP inhibitors had humble beginnings from one of these cyclic structures. One of 
the most prominent PARP inhibitors, BSI-201 (1.10, Iniparib) from BiPAR Science, contains the 
simple benzamide core structure.80,81 This compound is successfully being administered in 
clinical trials, although its mode of action is controversial and will be discussed in greater details 
in the next section. Discovered from leads in a high throughput screen, the core structure of 
AZD2281 (1.11, Olaparib),82 developed by AstraZeneca, bears close resemblance to the 
isoquinolinones originally discovered by Banasik et al. Much press surrounds the success of 
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Olaparib and details of its clinical trials will be discussed in the next section.  NU 1025 (1.12), a 
quinazolinone that was optimized at the University of Newcastle, was one of the first second 
generation PARP inhibitors to show success in a variety of cancer cell lines.79 However, its lack 
of solubility kept it from proceeding past pre-clinical stages. The phenanthridone structure 
emerged in a prominent PARP inhibitor from Inotek, PJ34 (1.13).83 The structure of PJ34 was 
further optimized to yield INO-1001 (structure is proprietary), which has proceeded to clinical 
trials for ischemia. Lastly, the imidazole carboxamide structure forms a pseudoring through a 
hydrogen bond formed between the imidazole nitrogen and the carboxamide hydrogen.79 Abbott 
Laboratories has developed a compound, ABT-888 (1.14, Veliparib), which contains this 
pseudoring structure.84 Veliparib proceeded through the first phase 0 clinical trial for oncology, 
and has quickly moved into phase I and phase II trials. More information on phase 0 trials and 
results from subsequent trials will be discussed further in a future section. The imidazole 
carboxamide structure has also evolved to a class of compounds with tricyclic lactams, which 
includes Pfizer’s AG014699 (1.15), a compound currently in phase I clinical trials as a 
chemopotentiator.85 For a more detailed description of PARP inhibitors, please see the reviews 
written by Ferraris, Rouleau et al., Underhill et al., and Sandhu et al.34-37 
 
Although PARP inhibitors were rapidly being optimized through screens and rational 
modifications, mechanism of inhibitor binding was not elucidated until Ruf et al. reported the 
first X-ray co-crystal structures of four PARP inhibitors (including NU 1025, 1.12) with cPARP-
1 (PARP-1 derived from chicken).86 This work proved that most PARP inhibitors were indeed 
binding in the NAD+ binding pocket.  The binding site was further elucidated to show that the 
amide or the lactam ring of the inhibitors, which is essential for PARP inhibition, is stabilized 
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through a complex hydrogen bonding network between Gly863-N, Gly863-O, and Ser904-OG.  
Subsequently, Tyr896 and Tyr907 were found to play a role in forming the walls of the binding 
pocket. These two aromatic amino acids are able to have a π–electron stacking system 
interaction with fused aryllactam rings providing an explanation for the increased potency seen 
in fused aromatic rings over simple arylamides.  Next, Glu988 and Tyr907 on the backside of the 
binding pocket are able to form hydrogen bonds with polar side chains on the aryl ring, possibly 
providing a reason for the increased specificity and potency of compounds containing this motif.  
Lastly, a large hydrophobic binding pocket that is adjacent to the NAD+ binding site termed the 
adenosine binding pocket was discovered,87 which is now commonly utilized to improve 
pharmacological properties of PARP inhibitors such as solubility, potency, and specificity. 
 
With the information extracted from crystal structures,86,87 a simple pharmacological 
model has been developed for potent PARP inhibition.  An essential bicyclic or tricyclic lactam 
ring binds directly to the NAD+ binding site and also increases potency through π–stacking.  
Heteroatoms on the aryl ring increase potency along with the exploitation of large, diverse 
groups to improve pharmacological and pharmacokinetic properties of the molecule.    
 
NAD+ is used as a substrate by a myriad of proteins, including the PARP family of 
proteins, and therefore many PARP isoforms contain similar enzymatic binding sites.20 Because 
PARP inhibitors were designed to compete with NAD+, problems with selectivity have arisen, 
especially between the binding of PARP-1 verses PARP-2.  Although both PARP-1 and PARP-2 
are activated after DNA damage, clonogenic studies have shown that PARP-1 (and not PARP-2) 
is responsible for cellular protection against cytotoxins,65 and therefore PARP-1 should be 
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specifically targeted over other PARPs.  In fact, many of the negative side-effects initially seen 
with the second generation PARP inhibitors in pre-clinical models were attributed to a lack of 
potency coupled with a lack of specificity.35 By utilizing structural information from many X-ray 
crystal structures, third generation PARP inhibitors now display increased specificity for PARP-
1 over other PARPs.  For example, compounds containing the quinazolinone scaffold,88,89 and 
the isoqunolindione scaffold90 have shown 10-37 fold and 100-fold selectivity, respectively, for 
PARP-1 over PARP-2.  However, many of the PARP inhibitors that are showing clinical success 
do not have these same levels of selectivity.  Therefore, the necessity and the extent of PARP-1 
specificity in the clinic is not fully known. 
 
1.3.2 Ongoing Clinical Trials with PARP Inhibitors 
As discussed previously, there are many PARP inhibitors currently in clinical trials 
(primarily with cancer but also with ischemia). Major pharmaceutical companies including 
AstraZeneca,82 Pfizer,85 Abbott,84 and Merck,91 as well as smaller, specialized companies, are 
moving drugs rapidly through clinical trials. The results that are emerging from clinical trials are 
very promising; however, for brevity, this work will only detail the three most successful drugs.   
 
1.3.2.1 Drugs in Clinical Trials Targeting Cancer 
The majority of PARP inhibitors bind PARP-1 at the NAD+ binding site, consistent with 
the inclusion of the benzamide motif.  However, one of the most successful PARP inhibitors, 
which will probably be the first to receive FDA approval, does not fit this paradigm. Iniparib 
(BSI-201, 1.10) is a nitro-containing compound that upon entering the cell is reduced to a nitrso 
group. This metabolite is thought to modify PARP-1 in the zinc finger preventing it from binding 
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to DNA and rendering the enzyme inactive.80,81 Although this modification has been traditionally 
thought to be an irreversible covalent interaction, recent unpublished results from Pfizer hint that 
Iniparib could be acting as a reversible inhibitor.92 Conventional thought leads one to believe that 
Iniparib is not selective for PARP-1 and has the ability to modify other proteins, however, the 
compound has been successful in phase I clinical trials. 
 
Iniparib was given to patients with advanced solid tumors intravenously in a phase I 
clinical trial.93 Twenty-three people were enrolled in the trial to determine safety and tolerability 
of the drug. Although Iniparib was eliminated rapidly with a half-life of 4 min, PARP was 
inhibited in peripheral blood cell mononucleocytes by >50% after a single dose and >80% after 
multiple doses.  In 26% of the patients, the disease was stabilized for at least 2 months.  Because 
of these promising results, Iniparib entered a phase 1B trial in combination with topotecan, 
gemcitabine, temozolomide (TMZ), and carboplatin/paclitaxel to assess safety and determine a 
maximum tolerated dose.94 Although a few adverse events were seen, Iniparib was deemed safe 
and as determined by modified Response Evaluation Criteria in Solid Tumors (RECIST), tumors 
showed a complete response after 6 months in 1 patient and 5 other patients showed a partial 
response.  These results have launched more clinical trials with Iniparib including an active 
phase 1/1B trial (NCT00298675) with Iniparib as a single agent or in combination with 
Irinotecan.95 
 
Some of the most inspiring results are in the treatment of patients with triple negative 
breast cancer. In a phase II trial with Iniparib in combination with gemcitabine/carboplatin (G/C) 
compared to G/C treatment alone,96 the combination therapy saw an improved clinical benefit 
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rate, progression-free survival, and overall survival compared to G/C treatment alone. Plus, there 
was no increase in toxicity seen with addition of Iniparib in the treatment.  These results cover 86 
of a planned 120 patients and the PARP community is anxiously awaiting the final summary of 
this trial. In the meantime, Iniparib has advanced to a phase III trial (NCT00938652) in 
combination with gemcitabine or carboplatin to assess overall survival, and the trial is expected 
to finish in June 2012. As of May 2010, Iniparib was made available, through extended access 
(NCT01130259), in combination with gemcitabine or carboplatin for patients with serious 
disease states or conditions that does not allow them to qualify for the controlled clinical trial.95 
These emerging results are a strong validation for PARP-1 inhibition as a target for cancer.  
 
Although AstraZeneca is currently optimizing and funding the clinical efforts of 
Olaparib, this successful PARP inhibitor was originally marketed by KuDOS under the name 
KU0059436, a pharmaceutical company in Cambridge.82 Synthetic optimization of Olaparib 
(also AZD2281, 1.11) proceeded through 2 prior lead compounds (Figure 1.11, 1.16, 1.17) in 
order to produce a more bioavailable compound for long-term treatment.  After synthesizing a 
series of compounds derivatized on a piperazine ring, Olaparib was chosen for further 
investigation due to its increased bioavailability in both rats and dogs.82 Although it is a very 
potent inhibitor, Olaparib showed no selectivity for PARP-1 over PARP-2 (IC50 = 5 nM for 
PARP-1 and IC50 = 1 nM for PARP-2).  In preclinical models, Olaparib proved to be potent in 
both BRAC-1 deficient cell lines as a single entity agent and in combination therapy with TMZ, 
showing an 80% reduction in tumor size with SW620 xenografted tumors.82 These promising 
results prompted a phase I clinical trials. 
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 After AstraZeneca purchased KuDOS in 2006, clinical trials were conducted and 
produced very exciting results. In a phase I clinical trial (NCT00516373) to assess 
pharmacodynamic properties, and to determine dosing, patients with and without known BRCA1 
or BRCA2 mutations were enrolled (60 patients, 22 were carriers of a BRCA1 or BRCA2 
mutation). All the patients were treated with 200 mg of Olaparib twice daily, and only patients 
with known BRCA mutations showed positive antitumor activity through RECIST. Additionally, 
neither group experienced debilitating side effects. These results were seen in patients with a 
variety of cancers including ovarian, breast, and prostate cancer.97 Due to these positive results, 
phase II clinical trials were launched to assess efficacy, safety, and tolerability in women with 
ovarian cancer (NCT0049442) or breast cancer (NCT00494234) who have documented BRCA1 
or BRCA2 mutations.98,99 In both clinical trials, the women were treated orally with 400 mg of 
Olaparib twice a day and many were responsive to the treatment as determined by RECIST with 
minimal side effects: the ovarian cancer trial had a 33% response rate98 while the breast cancer 
trial had a 41% response rate.99 Response rate is defined by the objective response, which is the 
combined number of patients with either a complete response or partial response (>30% 
response) as determined by RECIST.100 Currently, there are 4 active clinical trials with Olaparib 
including a phase II trial with cotreatment of carboplatin and paclitaxel in ovarian cancer 
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Figure 1.11. The Development and Optimization of Olaparib. Starting from a modified isoquinolinone 
core, Olaparib proceeded through two intermediate compounds (1.16, 1.17) before the development of 
a functionalized piperazine derivative with the desired potency and bioavailability. 
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(NCT01081951), a phase I trial with cotreatment of cisplatin and gemcitabine in unressectable or 
metastatic solid tumors (NCT00678132), a single entity treatment phase II trial in platinum 
sensitive serous ovarian cancer (NCT00753545), and a single entity treatment phase II trial in 
BRCA mutated ovarian, and breast cancer, and triple negative breast cancer (NCT00679783).95 
A few trials have recently beeen completed including a cotreatment phase I trials with 
dacarbazine (NCT00516802) and topotecan (NCT00516438), and many more trials are currently 
recruiting patients.95 Hopefully the results from the recently completed trials will be made 
available soon.  
 
Lastly, Abbott Laboratories has been investigating the inhibition of PARP for over 5 
years. Initially attracted to the benzimidazole carboxamide scaffold due to its low molecular 
weight and high potency, Abbott identified a preclinical lead candidate 1.18 (Figure 1.12).101 In 
an effort to improve enzyme and cellular potency along with pharmacokinetic properties, a series 
of compounds with modifications at the tertiary carbon adjacent to the imidazole ring were 
synthesized.84 From these compounds, Veliparib (ABT-888, 1.14) was identified based on its 
potency in C41 whole cells, which is a cell line derived from a human squamous carcinoma of 
the uterine cervix. Additionally, Velibarib displayed good pharmaceutical and safety properties, 
including good aqueous solubility and oral bioavailability, and was efficacious in preclinical 
mouse models.84 It was also considered a highly favorable compound due to its ability to cross 
the blood brain barrier for potential treatment of gliobastoma, where promising results were seen 
in rat glioma models.102 Veliparib inhibits both PARP-1 and PARP-2 with an EC50 of 2 nM and a 
Ki of 5.2 nM for PARP-1 and a Ki of 2.9 nM for PARP-2.102 Veliparib has proven effective in 
combination treatment with DNA damaging agents,84,102 or ionization,102 and as a single entity 
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agent with BRCA1 or -2 mutations in B16F10 murine models, HCT-116 colon carcinoma 
models, and MX-1 breast xenograft models, respectively.84,102 
 
In 2006, Veliparib was the first drug in oncology to enter phase 0 clinical trials under the 
Exploratory Investigational New Drug (IND) Guidance.103 The IND was established by the US 
Food and Drug Administration in order to increase the rate of promising drugs entering phase I 
clinical trials. Phase 0 trials are used to determine pharmacokinetics and pharcodynamics based 
on subtherapeutic dosing to a small group of humans.103 Abbott enrolled 24 patients with 
advanced malignancies into this trial and pharmacokinetic data revealed that peak plasma levels 
occurred between 0.5 h and 1.5 h after dosing and the unchanged drug was rapidly cleared 
through the urine.  In patients, a statistically significant decrease in PAR levels and PARP-1 
activity was seen in tumor biopsies and peripheral blood mononuclear cells, respectively, in both 
a 25 mg and 50 mg single dose.103 These promising results led to a 10 mg, twice-a-day dosing 
recommendation with a DNA-damaging agent for phase I clinical trials based on when the 
greatest reduction of PAR levels were seen post-treatment and available capsule strengths.  In 
fact, 13 months after the initiation of the phase 0 clinical trial, Veliparib was in a phase I clinical 
trial in combination with chemotherapeutics, providing a proof-of-concept model for the new 
IND protocol.   
 
Currently, Veliparib is in phase I and II trials, including a phase II trial (NCT00804908) 
in combination with TMZ to evaluate efficacy in patients with metastatic melanoma, a phase I 
trial (NCT00810966) to evaluate side effects and dosing of Veliparib in combination with 
cyclophosphamide in leukemia patients, and a phase I trial (NCT00526617) in combination with  
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TMZ to evaluate side effects and dosing in cancer patients (non-hematologic malignancies, 
metastatic melanoma, breast cancer, ovarian cancer, primary peritoneal cancer, fallopian tube 
cancer, and hepatocellular cancer).95 Along with these ongoing trials, another ~20 phase I trials 
are currently recruiting patients for co-treatment of Veliparib with chemotherapeutics or single 
entity use in patients with BRCA1 or BCRA2 mutations. Even with promising results, 
continually investigating any methods of resistance to these treatments is important. Abbott was 
able to generate cells that are resistant to Veliparib/TMZ treatment, and found that the cells had 
decreased levels of PARP-1 and elevated Rad51 expression levels, which the cells depended on 
for proliferation and survival.104 Although this experiment was done as a laboratory exercise, 
resistance via regulation of PARP-1 expression levels should be thoroughly investigated. 
 
1.3.2.2 Drugs in Clinical Trials Targeting Ischemia 
Although the majority of PARP inhibitors are being used in the treatment of cancer, there 
is evidence to support the effective use of PARP inhibitors in ischemic models.  The most 
characterized PARP inhibitor in preclinical ischemic models is PJ34 (EC50 = 35 nM). Although 
PJ34 has a plethora of data showing it protects cells from insult,83 it was INO-1001, a 3rd 
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Figure 1.12. The Development of Veliparib. Originating from the imidazole carboxamide core, 
Veliparib proceeded through one intermediate (1.18) before a focused library was synthesized and 
screened. From that library, Veliparib was identified due to its optimal pharmcokinetic and 
pharmacodynamic properties that it displayed. 
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generation derivative of PJ34 whose structure has not been revealed, that entered clinical trials. 
In a phase I clinical trial (NCT00271765) for safety, pharmacokinetics, and pharmacodynamics, 
INO-1001 showed a  >90% reduction in PARP-1 activity at all doses (200 mg, 400 mg, and 800 
mg) as well as signs of reduced inflammation in patients with ST-elevation myocardial 
infarction.105 Pharmacokinetic data confirmed that INO-1001 reached maximum plasma 
concentration when administered by intravenous bolus, and the drug had a half-life of 7.5 hrs.105 
Because of these promising results, in December of 2005 INO-1001 entered a phase II clinical 
trial (NCT00271167) for patients undergoing heart-lung bypass surgery.  Although the study was 
projected to be completed in June of 2006, as of today, no results from this trial have been 
published.   
 
As seen with the other PARP inhibitors, INO-1001 is also able to potentiate doxorubicin 
in tumor models.106 These results led to the launch of a clinical trial (NCT00272415) in 
combination with TMZ in patients with melanoma, but the trial was terminated in March of 2009 
due to myelosuppression and an increase of liver transaminases.107 
 
In conclusion, PARP inhibitors represent a possible treatment for cancer and ischemia. 
The amide based core structure has been optimized in order to improve the therapeutic potential 
and biological properties of this compound class. Although PARP inhibitors were originally 
investigated as chemopotentiators, they arguably show the most promise in BRCA-deficient 
cells. As more is learned about PARP-1 and its role in cancer, more uses for these potent 
compounds could be discovered. 
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1.3.3 The Development of PARG Inhibitors 
In stark contrast to PARP inhibitors, which have been highly studied, optimized, and 
tested, inhibition of PARG by a small molecule is still in its infancy. Although PARG 
knockdown models, as described in section 1.2.3, show that PARG inhibition could have 
therapeutic benefits, difficulties have arisen in discovering a scaffold that can be optimized to 
produce potent, specific, and cell permeable PARG inhibitors. Many factors have limited the 
discovery of novel PARG inhibitors, including limited studies on PARG’s cellular function, lack 
of facile recombinant expression systems, the absence of a crystal structure for PARG, and low 
throughput PARG enzymatic assays. However, despite these intrinsic obstacles, a few classes of 
PARG inhibitors have been explored, including DNA intercalators, tannins, and a substrate 
mimic. 
 
Although DNA intercalators are a broad class of compounds, a select few of them have 
been investigated further for their ability to inhibit PARG. Proflavine (Figure 1.13, 1.19), and 
Tilorone R10,556 (1.20), inhibit PARG with Ki values of 36 µM and 7.3 µM, respectively.108 
Additionally, their potency was determined to be independent of their ability to interact with 
DNA, supported by the fact that a classic DNA intercalator, ethidium bromide, did not show this 
same inhibitory ability.108 In 2003, a second-generation derivative of Tilorone was developed by 
Guilford Pharmaceuticals, GPI 16552 (1.21).109 With an IC50 value of 1.7 µM and the ability to 
penetrate the cell membrane, GPI 16552 was reported to have reduced the infarct volume in a rat 
model of focal cerebral ischemia by 40-53%.109 In a similar manner, GPI 16552 was also 
reported to sensitize cells to chemotherapeutics.110 A 3-fold increase in potency of TMZ was 
seen in B16 melanoma cells treated with TMZ plus 6 µM GPI 16552 compared to TMZ 
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treatment alone.  In a mouse tumorgenesis model, a combination treatment of TMZ and GPI 
16552 resulted in reduced tumor size as well as a decrease in metastases compared to TMZ 
alone.110 Despite these encouraging results, the utility of GPI 16552 is highly debated in the 
literature. Falsig et al. found it only inhibited 40% of PARG activity and deemed it ineffective in 
astrocyte death models.111 Ironically, no publication shows how the IC50 of GPI 16552 value was 
determined. 
 
Figure 1.13. PARG Inhibitors. To date, three classes of PARG inhibitors have been identified including 
DNA intercalators, which lack specificity, tannins, whose mechanism of action is under question, and 
ADP-ribose mimics, which are not cell permeable.  
 
Even more recently, a quantitative dot blot assay was developed and optimized in order 
to overcome the obstacles associated with high throughput screens with PARG. Using their 
assay, Okita et al. performed a screen of an in-house library and identified two xanthene-
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containing compounds (Figure 1.13, 1.22, 1.23) that inhibit PARG with IC50 values of 1.9 µM 
and 5.0 µM, respectively.112 However, the planarity of xanthene indicates they may also be DNA 
intercalators, although the authors do not address this possibility. Despite the fact this class of 
compounds has many of the attributes of an optimal PARG inhibitor including cell permeability 
and potency, the probable lack of specificity for PARG will likely lead to toxicity in more 
advanced models, therefore preventing this class from leading to true clinical candidates. 
 
A second class of compounds, commonly known as tannins, has been thoroughly 
investigated as inhibitors of PARG. Tannins belong to a larger class of compounds known as 
phenolic phytochemicals that are isolated from plants such as green tea and oak gall. These high 
molecular weight, dendritic like compounds, have been shown to inhibit PARG in vitro 
(gallotannin, 1.24, IC50 = ~30 µM),113 and in HeLa cell extract.114 Additionally, gallotannin has 
been shown to have protective effects in oxidative stress models.115 However, this class of 
compounds is also accompanied by controversy. The cytoprotection seen with gallotannin is 
thought to be due not to its ability to inhibit PARG but rather with its radical-scavenging 
ability.111 In fact, gallotannin enhanced DNA damage in combination with MNNG instead of 
showing protection. Furthermore, Sigma, a manufacturer of gallotannin, has commented that 
gallotannin forms insoluble complexes that bind to proteins. Therefore, despite the promising 
results seen with tannins, the specificity and mode of action of this class of compound is in 
question, preventing it from being suitable for further study of PARG and its function. 
 
The third class, substrate analogs, were specifically designed to inhibit PARG.  A small 
molecule analog of ADP-ribose was synthesized that both potently and specifically inhibits 
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PARG.116 Adenosine diphosphate (hydroxymethyl)pyrrolidinediol (ADP-HPD, 1.25) is a partial 
non-competitive inhibitor of PARG with an IC50 value of 120 nM.116,117 A structure-activity 
relationship was developed through the synthesis of derivatives of ADP-HPD, but no inhibitor 
was synthesized that showed an increase in potency.118 Through these SAR studies, they 
determined that the hydroxyl groups on the pyrrolidine ring were necessary for potency and 
modifications at the 8-position on the purine ring were well tolerated.118 Unpublished work from 
the Hergenrother lab also found the phosphate moiety of ADP-HPD necessary for PARG 
recognition and binding.119 Despite the potency and specificity seen with this compound, it lacks 
the ability to permeate the cell membrane and therefore has not been used in cell culture or in 
vivo. For a more detailed account of PARG inhibitors, including studies with inhibitors and the 
drawbacks of each compound, please refer to the thesis of Dr. Amanda Boye119 and a review 
written by her on the same topic.120 
 
There clearly is a need for PARG inhibitors in order to study the function of PARG and 
to validate its potential therapeutic effects. A potential PARG inhibitor is currently being 
developed in the Jacobson lab, the same lab that synthesized ADP-HPD, that non-competitively 
inhibits PARG (IC50 = 42 µM), but also competitively inhibits PARP-1.121 Despite the evidence 
that supports PARG as a potential therapeutic target for ischemia and cancer, to date, there are no 
potent, specific, and cell permeable PARG inhibitors to test this hypothesis.  
 
However, our laboratory has discovered a new class of PARG inhibitors that uses a 
phosphate replacement, rhodanine, as its core structure. Ideally, such a replacement allows the 
compounds to recognize and bind PARG, while overcoming some of the pitfalls typically 
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associated with phosphate groups, such as cell impermeability. These results will be discussed in 
Chapter 2. 
 
1.4 Rhodanines: Promises, Pitfalls, and Phosphate Replacements 
As stated in section 1.3.3, the phosphate moiety of ADP-HPD seems to be necessary for 
PARG recognition and binding. Therefore, it was hypothesized that a novel, cell permeable 
PARG inhibitor could be identified by screening small molecules with phosphate mimics. This 
section will discuss rhodanines as a phosphate mimic, along with some of the limitations 
associated with the rhodanine motif including lipophilicity, and reactivity. 
 
1.4.1 Rhodanine-Based Small Molecule Inhibitors 
Rhodanine (2-thioxo-1,3-thiazolidin-4-one, Figure 1.14, 1.26), and its analogs 1,3-
thiazolidine-2,4-dione (1.27), and 2-imino-1,3-thiazolidin-4-one (1.28) have frequently appeared 
in lead compounds in many drug discovery platforms, in both academic institutions and 
pharmaceutical companies. With very little similarity between targets, rhodanine containing 
compounds are reported to possess antibacterial, antifungal, antiviral, antimalarial, anti-
inflammatory, antitumor, cardiotonic, herbicidal, and insecticidal activity to name a few.122  
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Figure 1.14. Rhodanine and Its Closely Related Analogs. Rhodanine (1.26) and its analogs, 1,3-
thiazolidine-2,4-dione (1.27), and 2-imino-1,3-thiazolidin-4-one (1.28) appear as inhibitors of a variety 
of targets, and therefore, their specificity is under investigation. 
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Rhodanines are very attractive structures due to their ease of synthesis, and multiple 
points for reactivity and diversification, thus they are frequently found in screening libraries. In 
fact, over 6,000 rhodanine-containing compounds have been screened in diverse bioassays, and 
these compounds have ~20% hit rate for a variety of targets.123 Although the hit rate seems very 
high, it is difficult to correlate promiscuity and frequency of hits looking at such a wide variety 
of targets that does not take into account replicates in targets, assays, or compounds. Even still, 
their sheer abundance and varied targets has many research groups actively pursuing rhodanines, 
cautiously. For this work, only a few rhodanines with interesting reactivity or structures will be 
discussed, but first, assays for determining compound specificity, a major concern of rhodanines, 
will be explained. For a more comprehensive review of rhodanines and their protein targets, 
please see the review written by Tomasic et al.122 
 
1.4.2 Potential Problems with Rhodanines: Aggregation and Non-Specificity 
Due to the rate of appearance of rhodanines in new lead compounds, as well as the 
diversity in the targets these compounds can inhibit, questions have arisen about their specificity 
and whether they form compound aggregates in buffered solutions. An aggregating compound 
can form large, colloid-like particles typically at micromolar concentrations. The aggregates then 
will sequester the target protein’s activity, giving the impression that the compound is inhibiting 
the target protein through a specific binding mechanism. Because aggregators inhibit the target 
protein through a non-specific mechanism, they possess the ability to promiscuously inhibit 
multiple enzymes. Aggregating compounds are becoming ever more prevalent in compound 
screening libraries, thus reviews have been written by Shoichet124 and Baell et al.125 to warn 
researchers of these “nuisance” compounds124 or “PAINS”.125 This section will describe the rise 
 42 
of compound aggregates in screens, assays to determine if a compound is an aggregating 
compound, and more specifically, rhodanines as aggregating compounds.  
 
1.4.2.1 Aggregating Compounds in High Throughput Screens 
Academic institutions and pharmaceutical companies commonly use high throughput 
screens to identify lead compounds for new targets, typically protein targets. Although high 
throughput screens can rapidly comb through hundreds of thousands of compounds to produce 
“hit” compounds, many of these hits are false positives that have to be individually analyzed 
through secondary screens. However, many methods have been employed to rapidly rule out 
false positive hits, and to hone in on the more bioavailable and thus “drug-like” compounds. A 
drug-like compound was first defined by Christopher Lipinski in the rule of 5 that bears his 
name. These rules account for molecular weight, the number of hydrogen bond donors and 
acceptors, and calculated LogP of a compound in order to predict drug solubility and 
permeability.126 Although these algorithms have proven useful to pharmaceutical companies for 
flagging compounds that are not druggable, they do not include every problematic compound nor 
do many academic institutions use the same type of advanced computational methods to evaluate 
hits. Therefore, as high throughput screens become more commonplace, so do the appearance of 
promiscuous inhibitors, which are characterized by steep IC50 slopes, flat structure-activity 
relationship (SAR), and increased sensitivity to buffer conditions, and enzyme concentration.124   
 
Dynamic light scattering (DLS) revealed that these aggregates were typically >200 nm in 
diameter, and were significantly larger than the enzymes they were to inhibit. The aggregating 
compounds also showed a decrease in enzyme inhibition under conditions of high ionic strength, 
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suggesting that the aggregates disintegrated under these conditions. Thus, the ability for an 
aggregator to inhibit the activity of an enzyme was determined to be reversible, proving the 
aggregates were not causing the enzyme to unfold or to be modified.124 Coan et al. used flow 
cytometry to determine a “critical aggregating concentration,” and concluded that aggregates are 
densely packed molecules comprised of approximately 108 small molecules per aggregate.127 
Using this model, they observed that one aggregate is able to attract approximately 10,000 
enzymes, thus sequestering the enzymes’ activity (Figure 1.15).  
 
 
Figure 1.15. Mechanism of Protein Inhibition by a Compound Aggregate. Aggregating compounds can 
form large colloidal particles that absorb proteins and sequester their activity. Therefore, aggregating 
compounds are problematic due to their mechanism of inhibition and lack of specificity. 
 
Seidler et al. tested 50 commercially available drugs to see if any approved drugs 
displayed attributes of aggregating compounds.128 Of the 50 compounds tested, the majority of 
the compounds were not promiscuous; however, 4 of the compounds (Figure 1.16, 1.29 – 1.32) 
promiscuously inhibited β-lactamase, chymotrypsin, and malate dehydrogenase in a time- 
dependent manner, were sensitive to detergent, and showed the presence of aggregates by DLS at 
100 µM or less. Three other compounds (1.33 – 1.35) showed these same features at 400 µM.  
Despite this non-specificity, these compounds are effective in humans. Although the 
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promiscuous nature of these compounds were seen in vitro, it does not necessarily translate to in 
vivo models due the presence of serum proteins and bile salts which could cause the 
disassociation of aggregates. Additionally, the therapeutic window of these compounds was 
much lower than their aggregating concentration. Despite this rationalization, it is very important 
to investigate the promiscuity of any hit compound upon identification, otherwise many hours 
and dollars can be wasted in developing a compound that lacks specificity. 
 
Figure 1.16. Known Commercially Available Compounds with Aggregating Properties. 50 commercially 
available drugs were analyzed in a series of assays to investigate any aggregating properties. Of the 50 
compounds a) 4 compounds were non-specific inhibitors at concentrations of less than 100 µM, and b) 3 
more compounds showed promiscuity at concentrations of less than 400 µM.  
 
1.4.2.2 Assays to Determine Aggregation 
Although no single assay can rule a compound an aggregator, there are at least seven 
different experiments that can be conducted and together the results can suggest small molecule 
aggregation (Table 1.1). These assays include: detergent sensitivity, promiscuity with non-
related enzymes (such as β-lactamase and chymotrypsin), co-precipitation of enzyme and 
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compound by microcentrifugation, appearance of colloid-like molecules by DLS, loss of activity 
with increased enzyme concentration, loss of activity with the addition of a non-related protein, 
and compound-to-enzyme stoichiometry determination by surface plasmon resonance (SPR). 
                         
 
Table 1.1. Assays to Determine Compound Aggregation. Seven assays have been outlined to determine 
whether a compound is inhibiting a protein target in a non-specific manner. 
 
One of the most definitive ways to determine if a compound is inhibiting a protein 
through an aggregation-based mechanism is by the addition of a detergent such as Triton X-100. 
Detergents are able to break up the aggregates thus preventing aggregates from inhibiting the 
enzyme. Feng et al. validated this hypothesis through the addition of 0.01% Triton X-100 into a 
screen of 70,563 molecules from the National Institutes of Health Chemical Genomic Center.129 
Of the 1274 hits identified, 1204 were detergent sensitive, and therefore, 95% of the hits were 
aggregating compounds, which were eliminated on that criterion. Until recently, low Triton X-      
100 concentration (0.01%) was thought to be able to disintegrate all aggregators. Jadhad et al. 
proved that there are “detergent-hardy” aggregators whose inhibitory effects attenuate only after 
the addition of 0.1% detergent.130 Therefore, the authors recommend that any high throughput 
Method
Off-Target Assays
A Positive Result for an Aggregator
Loss of inhibition in the presence          
of detergent
Loss of compound inhibition
Inhibits non-related enzymes
Loss of compound inhibition
Increased stoichimetric binding
On-Target Assays
Assay
Detergent-sensitivity
Enzyme promiscuity
Co-precipitation
Increase target enzyme concentration
Add non-related protein
Enzyme is precipitated out of solution 
upon microcentrifugation
Apperance of colloidal molecules that 
are greater than 200 nm
Determine binding stoichiometry
Visualization of aggregates
Physical Properties
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screen be conducted with at least 0.01% Triton X-100 and all hits be re-tested for activity in the 
presence of 0.1% Triton X-100. Although very indicative of compound specificity, the lack of 
detergent-sensitivity alone cannot be enough to conclude that a compound is not an aggregator.  
  
Testing a hit compound against a myriad of non-related enzymes is a common secondary 
screen for the identification of aggregating or promiscuous compounds.124 Because of its 
mechanism of inhibition, an aggregating compound does not show a preference for one enzyme 
over another. Aggregating compounds typically have similar IC50 values against a host of 
enzymes, along with steep IC50 curves indicative of the “critical aggregating concentration.” 
Normally these assays are also done in the presence of detergent to determine if there is a loss of 
activity upon addition of detergent. Coupled with detergent sensitivity, a compound that non-
specifically inhibits a variety of enzymes is conclusively an aggregator, although aggregators 
may not inhibit all enzymes. 
 
The co-precipitation of an enzyme and compound by centrifugation or the appearance of 
colloid-like molecules by transmission electron microscopy (TEM) or DLS also supports the 
notion of aggregation. McGovern et al. first started dissecting the mechanism of non-specific 
protein inhibition when they discovered that the treatment of an enzyme with an aggregating 
compound followed by centrifugation yielded a precipitate.131 Upon analyzing the precipitate by 
gel electrophoresis and visualizing the gel by silver stain, they observed a protein band on the 
gel. However, the supernatant from the same enzyme and compound treatment did not produce a 
protein band. Therefore, it was concluded that all the target enzyme was absorbed by the 
aggregator, which precipitated from solution. To further support that hypothesis, enzyme was 
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treated with vehicle alone or a specific inhibitor, and upon gel electrophoresis, it was concluded 
that the enzyme remained in the supernatant. Therefore, enzyme is only identified in the pellet 
when it is treated with an aggregating compound, which absorbs proteins and can be precipitated. 
In a similar manner, the protein aggregate itself can be observed by TEM or DLS. As explained 
earlier, these compound aggregates can be 200 nm or larger and are easily detected with DLS 
and visualized with TEM. Although the appearance of compound aggregates alone does not 
definitively mean the compound will be a promiscuous inhibitor, it is alarming and should be 
investigated further with the other assays explained in this section. 
 
Another method to survey compound aggregates is by adding a large excess of protein to 
the assay. By increasing the concentration of the target enzyme or adding a non-related protein 
(such as bovine serum albumin, BSA) into the assay, a decrease in potency of the aggregating 
compound is observed.132 In both cases, the stoichiometry of the assay was shifted from a large 
excess of compound (10000:1) to a more even distribution of compound and enzyme (500:1). 
Therefore, excess protein competes for binding sites on the aggregate, freeing the enzyme of 
interest to process the substrate. This ultimately causes a shift in IC50 value, with the observation 
that the compound is now less potent under these conditions. However, a similar shift in IC50 
value for a non-aggregator would not be observed because a compound that specifically inhibits 
an enzyme should only lose potency once the compound to enzyme ratio is less than 1:1. 
 
The last method to determine compound aggregation is through SPR, in which protein is 
attached to the surface of a chip and compound is flowed over using microfluidics. Giannetti et 
al. described how they evaluated 13 known aggregating compounds with respect to seven 
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different enzymes.133 Through SPR, they observed “superstoichiometric” binding (binding ratio 
greater than 5:1 of compound to protein) with the aggregators to the proteins. They also declared 
that upon the addition of 0.005% Tween-20 (a detergent) to the buffer, which is half the 
recommended amount of detergent, aggregating compounds only rarely lost the complete ability 
to bind the model enzyme. However, based on this work, SPR is now being utilized as another 
method to reliably identify aggregating compounds. 
 
As described, there are many methods to identify aggregating compounds. Unfortunately, 
no single method is reliable enough to positively declare a compound as an aggregator. 
Therefore, one must test a suspicious compound through multiple assays until enough evidence 
mounts to verify its specificity. 
 
1.4.3 Rhodanines: Specificity and Stability 
As stated in section 1.4.1, there are many diverse enzymes for which rhodanine-based 
small molecule inhibitors have been identified. Extensive work has not been conducted to 
conclude that these naturally lipophilic compounds act as aggregators. Additionally, rhodanine-
based compounds are typically highly colored, which can interfere with colormetric readouts, 
thus they can appear as false-positives in screens.125 However, caution is recommended with 
rhodanine hit compounds, as they have a known ability to undergo 1,4-conjugate addition or 
react with light.  
 
The specificity of rhodanine-based compounds is under-investigated.122 As described in 
section 1.4.2, lipophilic compounds can form colloidal aggregates in aqueous buffers. When 
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pursing a rhodanine-based compound, assay modifications, such as detergent or BSA addition, 
should be employed to verify compound specificity. Szewczuk et al. demonstrated the 
importance of eliminating aggregating compounds early in the discovery process.134 After 
performing an in silico screen of a 1.2 million compound library that was docked into the active 
site of the X-ray structure of serotonin N-acetyltransferase (arylalkylamine N-acetyltransferase, 
AANAT), a series of rhodanine containing compounds were identified. Next, the lead 
compounds were tested in vitro in the presence of 0.01% Triton X-100. Although many false 
positive hits were identified, 5 compounds did emerge as inhibitors of AANAT. A rhodanine-
based compound (Table 1.2, 1.36) was shown to inhibit melatonin production in a dose-
dependent manner in penial cells, and displayed specificity towards AANAT. Although many of 
the rhodanine-containing compounds were found to aggregate (1.37), they did discover a 
rhodanine that is not an aggregator and that could potentially be useful in the treatment of mood 
disorders. In a separate screen, Dallmann et al. discovered a class of rhondanine-based 
compounds that inhibited bacterial proteins through a   novel multi-target high-throughput 
screen.135 Upon testing these compounds against 8 other non-related enzymes, they identified 
compounds that were specific inhibitors of bacterial replicases in E. coli strains (1.38), while 
other compounds of similar structure (1.39) lacked specificity all together. 
 
The 1,4-conjugate addition of thiols into the exocyclic double bond of rhodanines has 
been well documented.136-138 Thiol addition into rhodanines was best captured when Powers et 
al. resolved the crystal structure of their lead rhodanine-containing compound (Table 1.2, 1.40) 
in an adduct with the target enzyme, hepatitis C virus NS5b RNA polymerase (HCV NS5b).138 
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Structure Promiscious Test Ref
No, -Doubled enzyme [134]
Non-aggregation concentration
-Added 0.01% Triton X
Yes, -Added 0.01% Triton X [134]
Aggregation
No, -Specific for E. coli [135]
Specific replicases
Yes, -Non-specific toward [135]
Non-specific bacterial enzymes and
other DNA polymerases
Yes, -Observed by UV-Vis [136]
1,4-Conjugate Spectroscopy
addition
Yes, -X-ray crystallography [138]
1,4-Conjugate
addition
Yes, -Did not inhibit [138]
1,4-conjugate other cysteine  
addition, with proteases
some specificity
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"photochemically -X-ray crystallography [139]
enhancement,"
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Table 1.2. Rhodanine-based Inhibitors of Known Enzymatic Targets. Rhodanine-based compounds 
have been known to aggregate, form thiol adducts, and react with light, although some rhodanine-based 
compounds (1.36, 1.38) do not have these liabilities and are specific enzyme inhibitors. 
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Despite this covalent interaction at Cys366, which is 8 Å from the known active site, they found 
the bond to be reversible. Also, they confirmed that these compounds reacted with the active site 
cysteine but not other cysteines in the protein. In fact, 1.41 (an analog of 1.40) did not inhibit 
known cysteine proteases including cathepsin B, calpain, human caspases 1, 3, 6, 7, and 8, or 
aldose reductase. Using knowledge obtained from the crystal structure, they were able to 
optimize the lead compound in order to improve the potency and pharmacokinetic properties. 
Although a covalent inhibitor of an enzyme is not always detrimental, a non-specific mechanism 
of inhibition is worrying. Therefore, Abbott Laboratories flagged rhodanines (along with other 
core structures), using an NMR technique, as problematic structures due to their ability to serve 
as Michael acceptors thus reacting with proteins.137  
 
Rhodanines are also known to be photochemically reactive, potentially through radical 
anion formation. This phenomenom was observed after Carter et al. (DuPont Pharmaceutical 
Company/ Bristol-Meyer Squibb) performed a screen for disruptors of the tumor necrosis factor 
alpha (TNF-α) and the type-1 TNF receptor (TNFRc1) interaction, which is implicated in 
inflammation, and retrieved rhodanine-based compounds as their lead inhibitors.139,140 However, 
upon further experimentation and X-ray crystal structure analysis, they discovered that 1.42 
(Table 1.2) bound weakly and reversibly to TNFRc1, and then in the presence of light, the 
compound covalently modified TNFRc1 at the main chain nitrogen of Ala62. Thus, it was this 
covalent modification that caused the potent inhibition initially seen in the in vitro assays. Based 
on SAR analysis, the authors concluded that the 5-arylalkylidenerhodanine structure likely 
accepted a single electron from a nearby aromatic amino acid side chain of TNFRc1 to form a 
radical anion, which ultimately reacted with the N-anion of Ala62 resulting in the photochemical 
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modification. This mechanism, known as “photochemically enhanced” inhibition, can be 
selective due to the fact it is driven by the initial weak reversible inhibition of the compound to 
the target. Again, although this photochemical modification can be specific as seen in this case, 
the reactivity seen with the rhodanine core is troublesome.  
 
Despite these problems, rhodanines still have potential as lead compounds, but they first 
must be thoroughly investigated. No single rhodanine-containing compound has had its 
mechanism of action scrutinized for aggregation, specificity, and reactivity (both conjugate 
addition and photochemical reactivity). For example, 1.36 was determined to not inhibit AANAT 
through an aggregation-based mechanism because it did not lose its inhibitory ability in the 
presence of 0.01% Triton X-100. However, no single assay can determine if a compound is an 
aggregator, and therefore, a more thorough investigation should have been done. Additionally, 
1.36 contains an exocyclic double bond making it susceptible to 1,4-conjugate addition, but the 
authors do not address any potential issues of reactivity. In the same manner, no data was 
published on 1.40 – 1.42, the compounds that were shown to be either susceptible to conjugate 
addition or photochemically reactive, to indicate whether they had aggregating properties. 
Unfortunately, there is no way to structurally examine a rhodanine-containing compound and 
determine its ability to aggregate. In fact, compounds of very similar structure has been shown to 
have very different aggregating and specificity properties (1.36 compared to 1.37, and 1.38 
compared to 1.39). In contrast, reactivity is more predictable. Ordinarily, the presence of an 
exocyclic double bond is indicative of a compound that is susceptible to 1,4-conjugate addition 
such as thiol addition by cysteine proteases. However, there are examples of rhodanine-
containing compounds with an exocyclic double bond (1.41) that are liable to some cysteine 
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containing proteins but not others. Therefore, in order to get a better understanding of the 
rhodanine scaffold in inhibitors, each compound must be tested individually for aggregation, and 
reactivity, all of which can be influenced by the nature of the molecule. 
 
1.4.4 Rhodanines as Phosphate Replacements 
Despite the negative attributes associated with rhodanines, including their reactivity and 
their propensity to aggregate, rhodanines are thought to possess the ability to serve as a 
phosphate replacement. Many natural enzymatic substrates contain a phosphate moiety that is 
used for protein recognition and binding.141 However, the phosphate group’s negative charge 
hinders cell permeability and the oxygen-phosphorous bond is susceptible to enzymatic cleavage 
thus preventing it from being a very tractable motif in a small molecule inhibitor of an enzyme. 
Therefore, there is much merit in the discovery of an organic molecule that can mimic the unique 
properties of a phosphate group. Rhodanines have been used as a suitable phosphate replacement 
in small molecules that inhibit proteins, whose natural substrate contains a phosphate group, 
although it is unknown if they truly mimic the phosphate group.  
 
MurG, an enzyme involved in the final intracellular step of the biosynthetic pathway that 
transfers sugars from nucleotides to acceptor proteins, is thought to be involved in many 
biological processes, including pathogenic processes.  Therefore, a screen was employed that 
monitored the displacement of a fluorescence-based diphosphate-containing substrate, UDP-
GlcNAc.142 A 48,877-member compound library was screened in order to identify a compound 
with the structural elements necessary to mimic the natural phosphate-containing substrate. 
Interestingly, 7 of the 11 compounds identified contained the rhodanine core structure, and upon 
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docking the compounds into the UDP-GlcNAc binding site, inhibitors were best accommodated 
when the rhodanine ring was in close proximity to the phosphate-binding site. Similar results 
were seen when rhodanine-containing compounds, which were previously shown to have activity 
against Mycobacterium tuberculosis RmlC (an enzyme involved in cell wall synthesis) in whole 
cells,143 were docked with RmlC.144 The rhodanine-containing compounds, which had MICs of 
128-16 µg/mL, bound near the phosphate-binding site, and showed similar electrostatic 
potentials as other known diphosphate mimics in the transition state. Although crystal structure 
analysis would have to be done to verify where rhodanines are binding definitively, it is 
intriguing to find two separate binding studies that suggest rhodanines bind at or near the 
phosphate-binding site of enzymes. 
 
Despite mounting evidence from docking studies, there is also speculation that the 
rhodanine is simply occupying the nucleotide-sugar binding site and not functioning as a true 
phosphate mimic. Carlson et al. used a fluorescence polarization assay to screen for compounds 
that inhibited UDP-galactopyranose mutase from Mycobacterium tuberculosis, UGMMyco.136 
They synthesized a directed library of rhodanine-based compounds and found compounds (Table 
1.1, 1.43) that specifically inhibited their target enzyme. They conducted docking studies as well, 
where they saw that the rhodanine core participated in hydrogen-bonding in a similar fashion as 
the phosphate group, but they believed that the rhodanine was closer to the nucleotide-sugar 
binding site. Although there is not conclusive evidence that rhodanines are indeed phosphate 
mimics, they do seem to serve as suitable phosphate replacements. For a more detailed account 
of organic compounds as phosphate mimics, please see a review by Nottbohm et al.145 
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1.4.5 Known Rhodanine-Containing Drugs and Bioactive Agents 
Although there are questions about the reactivity and stability of rhodanines, this core 
structure appears in a clinically approved drug in Japan for diabetic neuropathy. Epalrestat 
(Figure 1.17, 1.44) is a rhodanine containing drug that noncompetitively and reversibly inhibits 
aldose reductase, which reduces sorbitol accumulation in the polyol pathway. Epalrestat not only 
improves symptoms associated with diabetic neuropathy, such as abnormalities in sensory and 
motor senses and abnormal changes in the heart beat, but also potentially delays the progression 
of the disease.146 It has also been deemed safe for long-term use in a 3-year,147 and a 5-year 
study.148 Although the side effects seem to be minimal, there are reports of increased liver 
enzyme levels as well as nausea and vomiting. Interestingly, the compound does contain the 
exocyclic double bond that is susceptible to 1,4-conjugate addition; however, no reports thus far 
have shown covalent reactivity to be associated with its mechanism of action. Additionally, 
pharmacokinetic data showed that the drug was excreted through the urine unchanged along with 
2 metabolites.146  
 
Figure 1.17. Known Drugs that Contain a Rhodanine or a Rhodanine Analog. Epalrestat (1.44) is a 
rhodanine-containing (1.26) compound that is approved for use in Japan for the treatment of diabetic 
neuropathy. Troglitazone (1.45), Rosiglitazone (1.46), and Pioglitazone (1.47) are 1,3-thiazolidine-2,4-
dione-containing (1.27) compounds that are FDA approved for the treatment of type II diabetes. 
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Additionally, a set of drugs containing a similar heterocycle, thizaolidine-2,4-diones 1.27, 
is also making headlines for the treatment of type II diabetes. The thiazolidinedione (TZD) 
containing compounds, troglitazone (1.45), rosiglitazone (1.46), and pioglitazone (1.47), were 
approved by the FDA for use in patients with type II diabetes in the U.S. (Figure 1.17). They 
essentially lower glucose amounts by activating peroxisome proliferator-activated receptors 
(PPARs), which alters the transcription of insulin sensitive genes.149 Activation of this receptor 
improves sensitivity to insulin. The first of the TZDs to be approved was troglitazone, which was 
first marketed by Parke-Davis, a subsidiary pharmaceutical company of Pfizer, in the 1990’s. 
However, reports of severe liver damage caused this drug to be withdrawn from the market by 
the FDA in 2000.150 The next drug to gain FDA approval was rosiglitazone, marketed by 
GlaxoSmithKline under the name Avandia. Despite working through the same mechanism as 
troglitazone, rosiglitazone did not cause the same toxicity to the liver. However, the popularity of 
rosiglitazone sharply declined after it was associated with an increased risk of cardiovascular 
disease.151 Lastly, pioglitazone entered the market through the activation of the same PPAR 
pathway. Marketed under the tradename Actos, it was the 10th best selling drug in 2008.152 
However, like its predecessors, pioglitazone comes with some side effects. It is associated with 
increased ischemic events compared to placebos but was deemed comparable to other diabetic 
drugs. Recently, results from a 10-year study showed there may be a correlation between 
pioglitazone and bladder cancer, which in September 2010, caused the FDA to start a formal 
review of the drug.153 For now, however, pioglitazone is considered safe and continues to be 
used. Although this class of drug seems to be associated with some serious side effects, their side 
effects have not been attributed to reactivity, and no promiscuity data is available. 
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1.5 Summary 
The PAR cycle plays an important role in DNA damage repair and is involved in the BER 
pathway. The activation of the PAR cycle has been implicated in resistance to chemotherapeutics 
and cell death in ischemia. Therefore, many of the enzymes of this pathway are being studied as 
potential pharmacological targets. PARP inhibitors have been well developed and optimized and 
are proceeding through clinical trials in combination with chemotherapeutics and as single entity 
agents in BRCA-deficient cells. PARG, the other major player of this enzymatic cycle, is also 
being investigated but to date, no suitable PARG inhibitors that are potent, specific, and cell 
permeable have been developed. Because the phosphate moiety of ADP-HPD, an ADP-ribose 
analog and a known potent but impermeable inhibitor of PARG, is necessary for PARG 
recognition and binding, our laboratory sought to identify compounds with a phosphate 
replacement, rhodanine, that would inhibit PARG. Despite some inherent problems with 
rhodanines, we obtained some promising data with our rhodanine-containing PARG inhibitors in 
vitro and in cell culture. The majority of this thesis will describe the results of these experiments.  
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CHAPTER 2.  
THE IDENTIFICATION AND EVALUATION OF RHODANINE-CONTAINING 
SMALL MOLECULE INHIBITORS OF POLY(ADP-RIBOSE) GLYCOHYDROLASE 
The work in this chapter would not have been possible without the help of Dr. Amanda Boye, 
Dr. Kathryn Partlow, Dr. Matthew Brichacek, and Claire Knezevic, all who have contributed 
greatly to this project. 
 
2.1 Introduction 
A number of rhodanine-containing compounds have the ability to inhibit enzymes whose 
natural substrate contains a phosphate moiety (see chapter 1.4.4).1-8 Therefore, we investigated 
the ability of rhodanine-containing compounds to inhibit PARG. Dr. Amanda Boye screened 224 
unique compounds from the Chembridge library, all containing the rhodanine motif, in a 
radiometric PARG TLC assay.9 Briefly, compounds (0.025 mg/mL) were pre-incubated with 
PARG (0.014 ng/µL), and upon the addition of synthesized 32P-PAR (5 µL), the solutions were 
incubated at 37 °C for 2 h. After quenching, each sample was analyzed using a radiometric 
PARG TLC assay, which was visualized by radiography. When simply treated with vehicle 
(DMSO), PARG was able to completely degrade 32P-PAR to ADP-ribose, which migrated to the 
top of the TLC plate upon elution. However, in the absence of PARG, 32P-PAR remained intact 
and was located where spotted. Similar fates of 32P-PAR were seen when inactive and active 
compounds were incubated with PARG, respectively. Whereas inactive compounds did not 
inhibit PARG’s activity, and therefore, the conversion of 32P-PAR to ADP-ribose units was 
observed, PARG inhibitors were identified by their ability to prevent 32P-PAR degradation. 
Initially Dr. Amanda Boyed identified 16 hit compounds from the screen, and upon re-testing, 
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four compounds emerged as dose-dependent inhibitors of PARG. Of the four compounds, 2.1 
was determined to be the lead compound due to its potency (Figure 2.1). Further studies were 
done to develop a structure-activity relationship (SAR) of 2.1, and to investigate the mode of 
action and activity of its derivatives in cell culture and cell lysate. 
              
Figure 2.1. Identification of Lead Rhodanine-Containing Compound. 2.1 (0.025 mg/mL) was identified 
as an inhibitor of PARG (0.014 ng/µL) in a screen of an in-house library of 224 rhodanine-containing 
compounds using the radiometric PARG TLC assay. Next, 2.1 was shown to inhibit PARG in a dose 
dependent manner (IC50 = 21 µM). IC50 values were determined by densitometry of the intact 32P-PAR, 
and quantified using ImageJ. By probing the structure of 2.1, a structure-activity relationship was 
developed and more potent rhodanine-containing PARG inhibitors were identified. 
 
In order to understand the SAR of compound 2.1, Dr. Amanda Boye synthesized a first 
generation library of 37 compounds that contained N-acetic and N-propionic acid rhodanines.9 
First, a variety of commercially available isatins were N-alkylated under basic conditions with 
benzyl halides, and the resulting compounds (2.2) were purified via column chromatography 
(Scheme 2.1). Next, the decorated isatins (2.2) were condensed under acidic conditions with N-
acetic and N-propionic acid rhodanines, and upon crystallization, 37 structurally diverse 
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rhodanine-containing compounds were obtained (Scheme 2.1). The benzyl halides were varied 
and included bicyclic rings, allyl groups, and benzyl rings that were functionalized with 
halogens, nitro groups, and alkyl groups. Additionally, a single isatin derivative was not N-
alkylated, in order to determine the necessity of the benzyl ring. The isatin ring, too, was 
decorated with a variety of halogens, and alkyl groups mainly at the 5- and 7-positions. 
 
           
Scheme 2.1. Synthesis of Rhodanine-Containing Compounds. 37 diverse rhodanine-containing 
compounds were synthesized in order to develop a structure-activity relationship. From this first library of 
compounds, insight into an optimized structure was provided. 
 
Initially, Dr. Amanda Boye investigated the 37 rhodanine-containing compounds at 5, 10, 
50 and 100 µM in the radiometric PARG TLC assay to assess their ability to inhibit PARG’s 
catalytic activity. Four compounds (2.3, 2.4, 2.5, and 2.6, Figure 2.2) inhibited PARG with IC50 
values below 10 µM. All of these compounds had similar structural characteristics. They all 
contained chloro groups in the 2- and 6-positions of the benzyl ring, and a substituent in the 5-
position on the isatin. Additionally, all four compounds had the longer N-propionic acid chain 
amended to the rhodanine ring.  However, many of these compounds were insoluble in both 
organic and aqueous solutions, making their use problematic.  
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Figure 2.2. Identification of Four Potent Rhodanine-Containing PARG Inhibitors. After screening the 
first 37 structurally diverse rhodanine-containing compounds, four compounds (2.3, 2.4, 2.5, and 2.6) 
were found to inhibit PARG below 10 µM. All below compounds contained chloro groups in the 2- and 
6-positions on the benzyl ring along with a substituent in the 5-position on the isatin ring. Therefore, a 
second more focused library was synthesized with 70 compounds with similar substitutions.  
 
Therefore, Dr. Amanda Boye synthesized a more focused library containing 
approximately 70 rhodanine-containing compounds.9 Ten commercially available isatins 
containing halogens, nitro groups, and alkyl groups were alkylated with three different halogen 
functionalized benzyl halides (2,6- dichloro, 2,5-difluoro, and 2-chloro-6-fluoro). The resulting 
alkylated isatins were condensed with rhodanines that had varying lengths of carboxylic acid 
chains (N-propionic, N-butyric, and N-valeric acid) to afford 70 structurally diverse rhodanine-
containing compounds. 
 
 Not only did Dr. Amanda Boye make the initial discovery of a novel class of rhodanine-
containing PARG inhibitors, she started the initial assessment of their potency in hopes of 
determining a SAR. Despite her efforts, a lot was still unknown about the compounds. This 
included a full SAR analysis of the synthesized derivatives, determination of their mode of 
action, investigation of their activity in cell lysate and whole cells, and analysis of their activity 
in combination with chemotherapeutics, all of which have been challenging. 
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2.2 Assay Optimization and Compound Evaluation 
With 70 rhodanine-containing compounds in hand, they were evaluated for both potency 
and solubility in order to improve on the drug-like characteristics of the 1st generation 
compounds. However, the substrate proved difficult to consistently synthesize, and therefore, 
assay optimization was first performed. By methodically changing variables such as time, 
concentrations of β-NAD+, and DNA, the process revealed that the synthesis of 32P-PAR is 
sensitive to both the DNA source, which must be sufficiently damaged to activate PARP-1, and 
the ratio of β-NAD+ to 32P-β-NAD+. The latter is due to the very high energy and rapid decay of 
32P-β-NAD+. Therefore, an excess of 32P-β-NAD+ affected the stability of the 32P-PAR. 
 
 
Figure 2.3. Analysis of 32P-PAR Integrity. 32P-PAR was synthesized enzymatically by activated PARP-1 
using both β-NAD+ and 32P-β-NAD+. Once synthesized, its integrity was tested with and without PARG 
at increasing concentrations. Optimization of 32P-PAR synthesis allowed for consistent preparation of 
substrate and reliable assay results. 
 
Ultimately, it was found that PARP-1 (20 U) activated by damaged DNA (23 µg) 
enzymatically synthesized 32P-PAR within 30 min most consistently, using both cold β-NAD+ 
(50 mM) and 32P-β-NAD+ (75 µCi).10,11 The integrity of the 32P-PAR was analyzed by testing 
PARG:      +     -    +    -    +    -    +      -   +    - 
 PAR (µL):    1         2          3          4          5     
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increasing amounts of 32P-PAR in the presence and absence of PARG in the TLC-based assay 
(Figure 2.3). With 32P-PAR in hand, the second-generation compounds were tested in the 
radiometric PARG TLC assay. 
 
 
Figure 2.4. Identification of Nine Potent Rhodanine-Containing PARG Inhibitors. After testing the 
second-generation library at both 10 µM and 50 µM, nine structurally related compounds were identified 
as inhibitors of PARG with IC50 values less than 10 µM. These compounds were analyzed for solubility, 
specificity, and activity in cell lysate and whole cells.  
 
In order to determine relative potency, compounds were initially tested at 10 µM, based 
on the potency of the first generation compounds, followed by a subsequent evaluation at 50 µM. 
Fifteen compounds were found to inhibit PARG at 10 µM. Next, these 15 compounds, from both 
first and second-generation libraries, were tested at multiple concentrations between 0.5 µM and 
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10 µM. Nine compounds were determined to inhibit PARG with IC50 values below 10 µM (2.3, 
2.6, 2.7, 2.8, 2.9, 2.10, 2.11, 2.12, and 2.13, Figure 2.4). 
 
Evaluating activity at two concentrations revealed trends for inhibition. For example, 
three of the nine potent inhibitors, 2.7, 2.8, and 2.9, only differ in structure by the number of 
methylene groups in the carboxylic acid chain. Additionally, 2.3 and 2.13 are related in the same 
manner (Figure 2.4). Three of the other potent inhibitors of PARG (2.6, 2.10, and 2.12; IC50 <10 
µM), had derivatives that inhibited PARG between 10 and 50 µM (2.14 – 2.18, Figure 2.5).  
 
 
Figure 2.5. Inhibitors of PARG Between 10 and 50 µM. Three of the nine potent PARG inhibitors (IC50 
<10 µM) had structurally similar derivatives (which differed in the number of methylene groups in the 
carboxylic acid chain) that inhibited PARG between 10 and 50 µM. 
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The assessment of the full library of compounds revealed more information about 
compounds that were inactive against PARG when tested at 50 µM (Material and Methods, 
Figure S2.1). For example, isatins that were derivatized at the 5-position with a sulfonic acid or a 
trifluoromethoxy, in general, were inactive. Also, isatins modified at the 5-, and 7-positions with 
chloro groups also suffered the same fate. Again, this same trend of inactivity was observed 
when the benzyl group, which was alkylated to the isatin ring, was not modified with halogens. 
All of this evidence supports the notion that an active rhodanine-containing PARG inhibitor must 
have halogens in the 2- and 6-positions on the benzyl ring as well as a halogen in the 5-position 
on the isatin ring. 
 
 
Another goal of the second-generation library was to find more soluble rhodanine-
containing compounds that also have increased cell permeability. Although all of the compounds 
assessed in the radiometric PARG TLC assay were soluble in 10 mM DMSO stock solutions, 
difficulties in solubility still arose when these compounds were further used in biological 
evaluations. Therefore, Claire Knezevic synthesized tetrazole derivatives (2.19 and 2.20) of two 
of the more potent carboxylic acid derivatives, 2.3 and 2.6. Tetrazoles are bioisosteres of 
carboxylic acids; increased solubility and cell permeability is seen in this motif due to the 
distribution of negative charge over the ring.12 Both tetrazole compounds 2.19 and 2.20 inhibited 
PARG (Figure 2.6, IC50 = 12.3 ± 2.2 µM, IC50 = 4.5 ± 2.1 µM, respectively) within range of their 
carboxylic acid counterparts. Additionally, two structurally similar but inactive compounds, 2.21 
and 2.22 (Figure 2.6), were utilized in biological testing as structurally similar inactive controls. 
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Figure 2.6. Evaluatoin of Tetrazole Derivative PARG Inhibitors. Tetrazoles, which are bioisosteres of 
carboxylic acids, often improve increased solubility and cell permeability compared to carboxylic acids. 
Therefore, tetrazole derivatives of some rhodanine-containing PARG inhibitors were synthesized and 
evaluated in the radiometric PARG TLC assay. Compounds 2.19 and 2.20 were found to inhibit PARG 
with similar potency as their carboxylic acid counterparts, and were used in biological assays. 
Furthermore, 2.21 and its tetrazole derivative 2.22, were identified as inactive derivatives that could be 
used as controls.  
 
2.3 Specificity of Rhodanine-Containing PARG Inhibitors 
As discussed in Chapter 1, compound aggregation is a huge concern with compounds 
identified in screening libraries.13-15 Aggregators suppress an enzyme’s activity, giving the 
appearance of specific inhibition.14 Although no single test can conclusively declare a compound 
as an aggregator, a series of experiments have been outlined to help positively conclude whether 
or not a compound forms aggregates. These test include identification of large particles by 
dynamic light scattering,14 disintegration of aggregators with detergent addition,16,17 competition 
of inhibitors with the addition of a large excess of a non-related enzyme to the enzymatic 
reaction,18,19 promiscuous inhibition of non-related enzymes,20 and lastly, determination of 
binding stoichiometry by surface plasmon resonance (SPR).21 Although this list of experiments 
is labor intensive, validation in a number of tests is necessary to be confident a potential lead 
compound is not an aggregator. Because rhodanines have been flagged as potential “nuisance” 
compounds,22,23 nearly all of the different assessments were utilized to evaluate inhibition 
specificity. Of the seven assays first outlined in Table 1.1 of Chapter 1, three of the assays were 
conducted to determine compound aggregation along with a single assay to analyze compound 
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specificity, and another assay to look at its ability to under thiol addition (Table 2.1). This 
section outlines the work that was conducted to confirm that this class of rhodanine-containing 
PARG inhibitors was not simply aggregators, but were specific inhibitors of PARG. 
                
 
Table 2.1. Assays to Determine Aggregation of Candidate Lead Compounds. Of the seven assays used to 
determine compound aggregation, three of the assays were used to assess the aggregative properties of the 
rhodanine-containing PARG inhibitors. The assays that were conducted are highlighted. 
 
2.3.1 Assessment of PARG Inhibitors Against AIF, Caspase-3, and β-Lactamase 
Some rhodanine-containing compounds are known to lack specificity for a single 
macromolecular target due to their ability to mimic phosphate groups, undergo nucleophilic 
attack, and form compound aggregates. Although non-specificity can be problematic, 
promiscuity due to aggregation is the most troublesome. Therefore, the identified rhodanine-
containing PARG inhibitors were tested against apoptosis inducing factor, a protein known to 
bind DNA,24 to investigate their ability to inhibit the function of other phosphate binding 
proteins. In addition, the compounds were tested against caspase-3, an enzyme with a cysteine in 
its active site, to investigate their ability to undergo 1,4-conjugate addition, and β-lactamase, a 
non-related enzyme, to assess non-specificity due to aggregation (Table 2.1).  
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Apotosis inducing factor (AIF) is a protein involved in PARP-dependent cell death. AIF 
binds to DNA through electrostatic interactions, and facilitates stage I chromatin condensation 
(details of this process are described in greater detail in Chapter 3).25 Although AIF has a 
different function than PARG, both AIF and PARG bind negatively charged, phosphate-
containing polymers, DNA and PAR, respectively. Therefore, compounds 2.3, 2.6, 2.7, 2.8, 2.9, 
2.10, 2.11, 2.12, and 2.13 were tested in a gel-shift assay to assess their ability to inhibit the AIF-
DNA interaction.26 Briefly, increasing concentrations of compounds (1-100 µM) were pre-
incubated with AIF (Δ1-128, 15-30 µg) for 30 min at room temperature. Next, 60 ng of 
linearized pUC19 DNA was added and incubated for an additional 15 min.  After addition of 
loading dye, the samples were electrophoresed for 1 h in a 1% agarose gel. Detection of DNA 
was performed by SYBR green I post staining overnight. 
 
The nine rhodanine-containing PARG inhibitors that inhibited PARG at <10 µM were 
tested in the gel-shift assay for the disruption of the AIF-DNA interaction. Of the nine 
compounds tested, six of the compounds inhibited the AIF-DNA interaction at 25 µM or less 
(Figure 2.7). Compounds 2.3, 2.6, and 2.7 showed some partial inhibition at 50 µM or higher, 
and thus have the most selectivity for PARG. Structurally, those three compounds have two 
methylene groups in the carboxylic acid chain, compared to the three or four methylene groups 
that are in the six less specific compounds. Therefore, compound specificity was thought to be 
linked to the carboxylic acid chain length. Interestingly, ADP-HPD, a known PARG inhibitor, 
also potently inhibited the AIF-DNA interaction as low as 1 µM; however, full inhibition was not 
observed at 100 µM (Figure 2.8). Overall, we found three compounds that had greater specificity 
(>25 fold) specificity for PARG than ADP-HPD. 
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Figure 2.7. The Analysis of Rhodanine-Containing PARG Inhibitors against AIF.  In order to determine 
each compound’s ability to prevent the AIF-DNA interaction, the nine rhodanine-containing PARG 
inhibitors (1-100 µM) were incubated with AIF(Δ1-128). After the 30 min pre-incubation period at RT, 
60 ng of pUC19 DNA was added and the solution incubated further for 15 min. The mixture was 
separated via electrophoresis in a 1% agarose gel, and stained overnight with SYBR Green I. The length 
of the carboxylic acid chain was important for compound specificity, where only 2.3, 2.6, and 2.7 showed 
specificity for PARG over AIF. D: DNA alone with 1% DMSO. A: DNA plus AIF with 1% DMSO. 
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Figure 2.8. The Analysis of ADP-HPD Against AIF. a) ADP-HPD (1-100 µM) was incubated with 
AIF(Δ1-128). After the 30 min pre-incubation period at RT, 60 ng of pUC19 DNA was added and 
incubated for an additional 15 min. The mixture was separated via electrophoresis in a 1% agarose gel, 
and stained overnight with SYBR Green I. ADP-HPD inhibited the AIF-DNA interaction at all five 
concentrations. D: DNA alone with 1% DMSO. A: DNA plus AIF with 1% DMSO. b) The structure of 
ADP-HPD. 
 
Some rhodanines are known to undergo 1,4-conjugate addition of thiols across the 
exocyclic double bond.2,27,28 This could cause compounds to non-specifically inhibit cysteine-
containing enzymes, especially cysteine proteases. Because little is known about the exact amino 
acids that are involved in the cleavage of PAR, it was important to investigate whether these 
rhodanine-containing compounds are susceptible to 1,4-conjugate addition and could potentially 
deactivate PARG by modifying a cysteine in the catalytic domain. Therefore, 2.3, 2.7, and 2.20 
were analyzed for their ability to inhibit caspase-3, a cysteine protease. Briefly, compounds (5-
100 µM) were incubated in caspase-3 buffer in the presence of 1 µM caspase-3 at 37 °C for 1 h. 
After this incubation period, the cleavage of caspase-3 substrate Ac-DEVD-pNA was monitored 
at 405 nm for 1 h.  
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Figure 2.9. Compound Inhibition of Caspase-3. Compounds 2.3, 2.7, and 2.20 were tested in a caspase-3 
kinetic assay in order to assess their ability to inhibit caspase-3, potentially through modification by the 
cysteine protease through a 1,4-conjugate addition across the exocyclic double bond. The percent 
inhibition of caspase-3 (1 µM) by compound (5-100 µM) was monitored by the cleavage of its substrate, 
Ac-DEVD-pNA (200 µM) over 1 h at 405 nm. Significant inhibition of caspase-3 was observed at 25 µM 
and higher with all 3 compounds.  
 
All three compounds showed significant inhibition of caspase-3 at 25 µM and higher 
(Figure 2.9), suggesting these compounds could potentially inhibit cysteine proteases through a 
1,4-conjugate addition. In order to determine if PARG was inhibited through a similar 
mechanism, rhodanine-containing compounds that do not inhibit PARG that contain an exocyclic 
double bond (Figure 2.10 a, 2.23, 2.24, obtained from the lab of Dr. Tanaji T. Talele at St. John’s 
University) were tested in the caspase-3 assay. Both 2.23 and 2.24, inactive PARG inhibitors 
(Figure 2.10 b) that contain an exocyclic double bond, inhibited caspase-3 to the same extent as 
the active PARG inhibitors, 2.3, 2.7, 2.20 (Figure 2.10 c). Furthermore, a compound that does 
not have the exocyclic double bond (2.25) did not inhibit caspase-3. Therefore, it was concluded 
that although the exocyclic double bond was necessary for caspase-3 inhibition, it was not 
sufficient for PARG inhibition, but this mechanism of thiol addition could still be problematic 
for studies in cell culture and in vivo. 
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Figure 2.10. Compound Inhibition of Caspase-3. a) Compounds were obtained from the lab of Dr. Tanaji 
T. Talele at St. John’s University and were tested for PARG inhibition in the radiometric PARG TLC 
assay. Both compounds 2.23 and 2.24 contain an exocyclic double bond while, 2.25 does not have the 
rhodanine in tact. b) None of the compounds (2.23, 2.24, 2.25) were able to inhibit PARG at 50 µM. c) 
These same compounds were tested in the caspase-3 kinetic assay, to see if caspase-3 inhibition correlated 
with the presence of an exocyclic double bond attached the rhodanine. As suspected, only the compounds 
containing the exocyclic double bond (2.23, and 2.24) showed a significant amount of inhibition. 2.25 did 
not affect caspase-3 activity. 
 
 
These results were further confirmed by Claire Knezevic who monitored the change in 
absorbance from 300 nm to 550 nm (Figure 2.11) for the addition of dithiothreitol (DTT, 20 
mM) into active compounds 2.3, 2.7, and 2.20 and inactive compound 2.21 (40 µM). This 
addition is apparent by the continuous decrease in absorbance at 440 nm in all three compounds 
(Figure 2.11 a, b, c, d). Although this addition should be reversible, an increase in that same peak 
was not captured on the 50 min timescale. Overall, since both active and inactive compounds are 
susceptible to thiol addition, the presence of the exocyclic double bond does not directly 
correlate with PARG inhibition. Additionally, the necessity of the exocyclic double for PARG 
inhibition is unknown because the reduction of that bond leads to a compound that is instable and 
cannot be isolated (Claire Knezeic, unpublished data).  
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Figure 2.11. DTT Addition into Rhodanine-Containing Compounds. DTT (20 mM) was added to 
compound (40 µM) and thiol addition to the compound was monitored for 50 min between 300 nm and 
550 nm. The thiol addition was observed into a) 2.3, b) 2.7, c) 2.20, and d) 2.21 as indicated by the 
decrease in absorbance at 440 nm.    
 
The rhodanine-containing compounds were tested for enzyme specificity against β-
lactamase. β-lactamase is an enzyme responsible for resistance to β-lactam antibiotics such as 
penicillin and has no functional similarity to PARG. Due to the ease of its expression (and 
therefore, low cost of purchase), and the availability of a colorimetric substrate, β-lactamase is 
commonly used to test a compound’s promiscuity.20 Therefore, two carboxylic acid containing- 
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Figure 2.12. Compound Evaluation for β-Lactamase Inhibition. All the rhodanine-containing compounds 
(5-50 µM), including carboxylic acids and tetrazoles that inhibit PARG and a structurally similar 
carboxylic acid and tetrazole that do not inhibit PARG, were tested for their ability to inhibit β-Lactamase 
(0.006 U/mL), which was monitored by the cleavage of its substrate, CENTA (200 µM). None of the 
rhodanine-containing compounds a) 2.3, b) 2.7, c) 2.19, d) 2.20, e) 2.21, or f) 2.22 appreciably inhibited 
 β-Lactamase in the presence or absence of detergent. However, Congo Red, a known aggregator (g), 
inhibited  β-Lactamase at 50 µM, but this inhibition was ablated in the presence of 0.1% Triton X-100. 
Error bars represent SD (n=3) from 3 independent experiments. 
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rhodanines, 2.3, 2.6, and two tetrazole containing-rhodanines, 2.19, 2.20, all of which potently 
inhibit PARG, were tested in an enzyme kinetic assay for β-lactamase inhibition. Two 
structurally similar, inactive rhodanines, 2.21, and 2.22, as well as Congo Red, a known 
aggregator, were tested alongside as controls. Additionally, the compounds were tested in the β-
lactamase assay in the presence of increasing amounts of detergent, Triton X-100, in order to 
disrupt the effect of an aggregating compound. In increasing amounts of detergent, an aggregate 
can be dissociated, ultimately allowing the enzyme to regain its ability to process the substrate. 
 
Briefly, compounds (5-50 µM) were incubated in PARG buffer both in the presence and 
absence of Triton X-100 with 0.006 U/mL β-lactamase at 37 °C for 30 min. Upon completing the 
incubation, β-lactamase activity was monitored by observing the cleavage of its substrate, 
CENTA (200 µM) for 30 min at 405 nm. None of the rhodanine-containing compounds (2.3, 2.6, 
2.19, 2.20, 2.21, and 2.22) showed any appreciative amount of inhibition with increasing 
concentration of compound (Figure 2.12). However, Congo Red, a known aggregator, dose-
dependently inhibited β-lactamase, but did not inhibit β-lactamase in the presence of 0.1% Triton 
X-100, indicative of aggregation-based inhibition. These results show that the rhodanine-
containing compounds did not inhibit a non-related enzyme, and the assay was validated with a 
known aggregator. Although the compounds may have some inherent specificity problems, such 
as binding to AIF, a protein with a similar substrate, or inhibiting cysteine proteases (possible 
through a 1,4-conjugate addition), none of these mechanisms speak to aggregation. However, the 
lack of β-lactamase inhibition suggests that rhodanine-containing PARG inhibitors are not 
simply aggregators. This theory was further examined in both detergent-containing and BSA-
containing assays. 
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2.3.2 The Activity of Rhodanine-Containing PARG Inhibitors in the Presence of Detergent and 
Bovine Serum Albumin 
Two of the most straightforward assays to evaluate compound aggregation are 1) the 
addition of detergent to the buffer conditions,16,17 which breaks up the aggregate, allowing the 
target enzyme to regain its activity, and 2) the addition of excess bovine serum albumin (BSA) to 
the buffer,18,19 which will compete with the target enzyme for binding to the aggregate, relieving 
inhibition of the target enzyme (Table 2.1). Therefore, these two assays were performed with 
PARG as the target enzyme and evaluated in the radiometric PARG TLC assay. 
 
Shoichet, a pioneer in the field of compound aggregation, has seen that many aggregators 
lose activity in the presence of 0.01% Triton X-100;14 however, some more unique “detergent 
hardy” aggregators require higher amounts of detergent (0.1% Triton X-100) in order to disrupt 
inhibition.17 Therefore, the rhodanine-containing PARG inhibitors, 2.3, 2.6, 2.19, and 2.20, and 
the known aggregator, Congo Red, were incubated in a phosphate-based PARG buffer that 
contained either 0% or 0.1% Triton X-100, and the activity of PARG was analyzed by the 
radiometric PARG TLC assay. Briefly, compounds (50 µM) were incubated with PARG (0.014 
ng/µL) for 10 min. After the addition of synthesized 32P-PAR (3 µL), the solutions were 
incubated at 37 °C for 1 h and were quenched by heating at 90 °C for 2 min. The TLC plate was 
spotted, developed, and visualized as previously described. 
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Figure 2.13. Detergent Effect on Rhodanine-Containing PARG Inhibitors. Compounds 2.3, 2.7, 2.19, and 
2.20, as well as a known aggregator, Congo Red, were incubated in the presence and absence of 0.1% 
Triton X-100, and tested for their ability to inhibit PARG-mediated degradation of 32P-PAR by TLC. a) 
The TLC-based assay shows intact 32P-PAR when the rhodanine-containing PARG inhibitors are 
incubated both with and without 0.1% Triton X-100. However, Congo Red loses its ability to inhibit 
PARG in the presence of detergent, the expected result of an aggregating compound. b) Densitometry of 
32P-PAR was calculated and a significant percentage of 32P-PAR degradation was observed only once 
Congo Red was treated with detergent-containing buffer. Error bars represent SD (n=3) from 3 
independent experiments.   
 
All of the potent rhodanine-containing PARG inhibitors (2.3, 2.6, 2.19, 2.20), inhibited 
PARG at 50 µM both in the presence and absence of 0.1% Triton X-100 (Figure 2.13). These 
results show that compounds 2.3, 2.6, 2.19, and 2.20 are not detergent sensitive, and do not 
display the typical behaviors of compounds that inhibit enzymes through an aggregation-based 
mechanism. Additionally, the loss of inhibition in the presence of detergent was seen when a 
known aggregating compound, Congo Red, was subjected to the same assay conditions, which 
further validates the assay.  
 
The resurgence in activity of the target enzyme in the presence of a non-related protein 
such as BSA is another method to identify an aggregating molecule. Coan et al. observed this 
effect when an aggregate was pre-incubated with 0.1 mg/mL of BSA, followed by addition of the 
target enzyme.18 The target enzyme did not lose its ability to process its substrate, most likely 
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because BSA was already absorbed by the aggregate, leaving an active target enzyme. Therefore, 
Shoichet believes 0.1 mg/mL of BSA is an effective concentration of protein to disrupt the 
aggregate’s mode of action.14 Therefore, rhodanine-containing PARG inhibitors, 2.3, 2.6, 2.19, 
and 2.20, were incubated in phosphate-based PARG buffer in the absence or presence of 0.1 
mg/mL BSA, and the activity of PARG was measured using the radiometric TLC assay. Briefly, 
compound (50 µM) and BSA (0.1 mg/mL) were pre-incubated (10 min). Subsequently, PARG 
(0.014 ng/µL) was added, and the solutions continued to incubate for an additional 10 min. After 
adding 32P-PAR (3 µL), the solutions were incubated at 37 °C for 1 h and were quenched by 
heating at 90 °C for 2 min. The components were separated by TLC, as previously described. 
 
 
Figure 2.14. The Effect of BSA on PARG Inhibition by Active Rhodanine-Containing Compounds. 
Compounds 2.3, 2.7, 2.19, and 2.20 (50 µM), were incubated with and without BSA (0.1 mg/mL), and 
their ability to inhibit PARG’s activity was assessed in the radiometric PARG TLC assay. The assay 
demonstrates that PARG is unable to degrade 32P-PAR when the rhodanine-containing PARG inhibitors 
are incubated in the presence and absence of BSA, which suggests these compounds are not inhibiting in 
an aggregation-based mechanism.  
 
 
All of the PARG inhibitors, 2.3, 2.7, 2.19, and 2.20, inhibited PARG at 50 µM with and 
without BSA (Figure 2.14). These results are indicative of a compound that is not inhibiting 
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PARG through an aggregation-based mechanism. In conclusion, this series of experiments 
suggests that the lack of β-lactamase inhibition, lack of detergent-sensitive PARG inhibition, and 
lack of BSA-sensitive PARG inhibition indicates that the observed PARG inhibition by 2.3, 2.7, 
2.19, and 2.20 is not associated with aggregation. 
 
 
2.4 ADP-HPD Compared to Rhodanine-Containing PARG Inhibitors 
Adenosine diphosphate (hydroxymethyl)pyrrolidinediol (ADP-HPD) is the most potent 
and specific inhibitor of PARG (IC50 = 1 µM for catalytic PARG), although its cell 
impermeability prevents its use in cell culture and in vivo.29-31 Despite its high potency and 
specificity, certain characteristics of ADP-HPD make it unfavorable even for in vitro use. As 
discussed in Chapter 1, ADP-HPD is very difficult to synthesize, and even more costly to 
purchase ($2600/mg). Additionally, it has limited efficacy, because it only partially inhibits 
PARG.31 Even with these inherent problems, ADP-HPD is considered the best PARG inhibitor 
to date, and we sought to compare the rhodanine-containing PARG inhibitors to it in a head-to-
head fashion. Therefore, ADP-HPD was tested side-by-side with 2.6 in the radiometric PARG 
TLC assay (Figure 2.15). Briefly, increasing concentrations of ADP-HPD and 2.6 (0.5-10 µM) 
were incubated with PARG (0.014 ng/µL) for 10 min. After the addition of synthesized 32P-PAR 
(3 µL), the solutions were incubated at 37 °C for either 30 min or 120 min and the components 
were separated by TLC, as previously described.  
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Figure 2.15. Compound 2.6 Compared to Known PARG Inhibitor ADP-HPD in the Radiometric PARG 
TLC Assay. The potency, degree of inhibition, and time of inhibition (30 min and 120 min) of PARG 
(0.014 ng/µL) for ADP-HPD and 2.6 (0.5-10 µM) were compared in the radiometric PARG TLC assay. 
After assessment, ADP-HPD inhibited at lower concentrations than 2.6, however, the overall percent 
inhibition of PARG and efficacy was better in the presence of 2.6. 
 
Although ADP-HPD appeared to inhibit PARG at lower concentrations than 2.6 upon 
incubation in the presence of PARG for 30 min, its capacity to only partially inhibit PARG was 
evident, as characterized by the production of ADP-ribose (spots at the top of the TLC plate) at 5 
and 10 µM ADP-HPD. In contrast, 2.6 showed complete inhibition of PARG at the same 
compound concentrations, over the same 30 min time course. Additionally, PARG was able to 
process PAR into ADP-ribose in the presence of ADP-HPD for 120 min. Whereas, over the same 
time course, 2.6 was still able to inhibit PARG with a slight reduction in potency (10 µM).  
Therefore, it was concluded that although 2.6 did not inhibit PARG at as low of concentrations 
as ADP-HPD, it is able to more fully inhibit PARG over prolonged durations. Coupling these 
characteristics with its ease of synthesis, the rhodanine-containing PARG inhibitors seem to be 
more tractable compounds for in vitro use. Additionally, the effectiveness of ADP-HPD as 
compared to the rhodanine-containing PARG inhibitors in cell lysate will be discussed later in 
this chapter (section 2.6). 
PARG: -    +      +      +       +       +     +       +      +      +       -      +      +       +      +      +        +      +      +     +!
[cmpd] (µM):  0.5     1       5       10   0.5     1       5     10                     0.5     1      5      10      0.5    1      5    10            !!!!!!!! 
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2.5 Kinetics of PARG Inhibition by Rhodanine-Containing Compounds 
We sought to determine the mechanism of enzyme inhibition by the active PARG 
inhibitors. An enzyme’s rate is most conveniently measured in real time using either a 
fluorescent or colorimetric substrate. However, the standard assay that measures PARG’s 
activity is limited by its substrate, 32P-PAR, whose cleavage cannot be measured in real time. 
Therefore, the TLC-based assay was employed in order to determine the kinetics of compound 
inhibition of PARG.31 There are inherent problems in using an endpoint assay to determine 
enzyme kinetics including the ability to take a number of time points over a short duration, and 
the geneal inefficiency of the assay. The radiometric PARG TLC assay was optimized in order to 
determine the number of time points necessary to capture the initial slope of product production, 
ADP-ribose. Briefly, PARG (0.014 ng/µL) was incubated with DMSO (6%), and upon the 
addition of synthesized 32P-PAR (3 µL), the solutions incubated at 37 °C over a designated time 
course (1-30 min). Due to the time it takes to quench a reaction by heating at 90 °C, the most 
accurate method to quench each reaction at the appropriate time was with SDS (0.1%). All 
 
 
Figure 2.16. Kinetic Determination of PARG Activity over 30 min. a) PARG (0.014 ng/µL) was incubated 
with DMSO and two concentrations of 32P-PAR. PARG catalyzed cleavage of 32P-PAR (30 min) was 
monitored through the appearance of ADP-ribose units (spots at the top of the TLC plate) over the time 
course and measured by densitometry. b) Densitometry of ADP-ribose was plotted against time. 32P-PAR 
was completely degraded by 15 min, which caused a plateau in ADP-ribose formation. Additionally, the 
initial slope appeared to be measurable within the first 5 min of the reaction.   
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samples were analyzed in the PARG TLC assay, as previously described. The rate of PARG’s 
activity was measured by examining the appearance of ADP-ribose (the cleavage product) over 
the time course using densitometry. 
 
After assessing PARG’s ability to cleave 32P-PAR over a 30 min time course, the amount 
of ADP-ribose produced seemed to plateau after 15 min of incubation at both concentrations of 
substrate (Figure 2.16). Interestingly, less ADP-ribose was produced when PARG was incubated 
with the higher amount of 32P-PAR (4 µL) as compared to the lower amount of 32P-PAR (3 µL). 
This difference in ADP-ribose produced could be due to insensitivity in the densitometry 
analysis. Examination of the curve from the 30 min time course revealed that the initial velocity 
could be best captured by an increased number of time points in the first 5 min of the assay. 
Therefore, the PARG kinetic assay was repeated with four different amounts of 32P-PAR (1, 2, 4, 
and 8 µL) over a 4 min time course with time points every 30 sec (Figure 2.17).     
         
Figure 2.17. Full Kinetic Determination of PARG Enzymatic Activity over 4 min. In order to calculate Ki, 
the initial slope of product formation must be determined. PARG (0.014 ng/µL) was incubated in the 
presence of DMSO with four amounts of 32P-PAR (substrate). Product formation (ADP-ribose) was 
measured by densitometry, and plotted against time. General trends in slope were captured, where 
increasing amounts of substrate caused increasing amounts of product formed at a quicker rate. However, 
some abnormalities in the slopes prevented V0 calculations. 
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General trends in PARG activity were seen after analysis of ADP-ribose formation at 
four different 32P-PAR concentrations. More ADP-ribose was produced faster with the highest 
amount of substrate (8 µL). Additionally, the lowest amount of ADP-ribose was produced 
slowest with the lowest amount of substrate (1 µL). However, the trend was not as distinct at the 
intermediate concentrations. ADP-ribose production seemed to follow in suit with 4 µL of 32P-
PAR through the first half of the time course, but the amount of ADP-ribose produced in the 
second half of the time course wavered, causing the slope of the line to be distorted. Similar 
vacillations in ADP-ribose production were seen with the 2 µL treatment of 32P-PAR. Even with 
some of these faults, which speak to limitations of endpoint assays, Ki determination was 
attempted using 5 µM, 10 µM, 20 µM, and 40 µM 2.7 with 1, 2, 4, and 8 µL 32P-PAR in the 4 
min time course. 
 
Compound 2.7 was assessed at four concentrations, and unfortunately no useful kinetic 
information could be extracted from the data. When PARG was treated with 5 µM of 2.7, which 
is near the IC50 value of the compound, minimal inhibition was seen and PARG was able to 
process 32P-PAR to ADP-ribose at all substrate concentrations (Figure 2.18 a). However when 
PARG was treated with 10 µM, 20 µM, or 40 µM of 2.7 (Figure 2.18 b, c, d, respectively), there 
was significant inhibition, causing poor signal-to-noise ratio, thus making the data 
uninterpretable. 
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Figure 2.18. Kinetic Determination of 2.7 Mechanism of PARG Inhibition. PARG (0.014 ng/µL) was 
incubated in the presence of 2.7, a) 5 µM, b) 10 µM, c) 20 µM, d) 40 µM. After adding 32P-PAR (1 µL, 2 
µL, 4 µL, 8 µL), the appearance of ADP-ribose was monitored in the TLC-based assay and measured by 
densitometry. After plotting the amount of ADP-ribose produced verses time, the complete inhibition of 
PARG by 2.7 at 10 µM, 20 µM, and 40 µM prevented any kinetic information from being gained from 
the experiment. 
 
These results highlight the need for an improved assay and substrate that will enable a 
more efficient study of PARG and its inhibitors. Dr. Matthew Brichacek is currently working on 
the first synthesis of PAR, which could be labeled with a fluorophore for use in kinetic assays. 
Although we are not able to determine kinetic information of the rhodanine-containing 
compounds for now, we plan to investigate the compounds in cell lysate and cell culture assays, 
and determine KD by SPR. 
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2.6 Efficacy of Rhodanine-Containing PARG Inhibitors in Cellular Lysate  
Rhodanine-containing PARG inhibitors inhibit PARG in vitro, and display specificity 
towards PARG over non-related proteins such as β-lactamase. Additionally, they do not inhibit 
PARG through an aggregation-based mechanism, which was verified by the addition of 
detergent and BSA to the standard PARG assays. However, all of these assays were carried out 
in vitro with purified proteins. Next, the compounds were tested in cell lysate to determine 
whether they are able to inhibit PARG in a complex environment.32-35 First, cell lysate was 
generated from mouse embryonic fibroblasts (MEFs), and was optimized for the amount of cell 
lysate necessary to degrade 32P-PAR over a 60 min time course. Varying amounts of cell lysate 
(1.6, 10, and 35 µg) were incubated with DMSO, and 32P-PAR degradation was monitored over 
60 min using the TLC-based assay.  
               
Figure 2.19. MEF Cell Lysate Degradation of 32P-PAR. Three quanitites of MEF cell lysate (1.6, 10, 35 
µg) were incubated with DMSO and 32P-PAR. Upon analyzing the lysate over a 60 min time course, 
complete 32P-PAR degradation was seen at 60 min, 15 min, and 5 min with 1.6 µg, 10 µg, and 35 µg of 
32P-PAR, respectively. 
 
32P-PAR degradation was seen by PARG in 1.6 µg, 10 µg, and 35 µg of cell lysate 
(Figure 2.19), and the amount of lysate directly related to the rate of 32P-PAR degradation. With 
Time (min):     0    5      15    30    60    0      5    15     30    60    0     5     15    30    60  
Cell Lysate:          1.6 µg 10 µg 35 µg 
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only 1.6 µg of cell lysate, 32P-PAR degradation did not occur completely until the 60 min time 
point, while complete 32P-PAR degradation was seen at 15 min and 5 min with 10 µg and 35 µg 
of cell lysate, respectively. In order to most accurately evaluate each compound’s ability to 
inhibit PARG in cell lysate over a 60 min time course, 1.5 µg of cell lysate was used in future 
assays.  
 
Next, compound 2.7 was examined in cell lysate at three concentrations (Figure 2.20). 
Briefly, compound (5, 10, 25 µM) was incubated with cell lysate (1.5 µg) over a time course of 
60 min (0, 5,15, 30 60 min), and at the appropriate time, the reaction was quenched by the 
addition of SDS (0.1%).34 Upon quenching, the time course was analyzed by TLC, as previously 
described. 
  
   
Figure 2.20. Correlation Between Compound Concentration and 32P-PAR Degradation. a) MEF lysate 
(1.5 µg), treated with increasing concentrations of 2.7 (5, 10, 25 µM), was incubated with 32P-PAR for 0-
60 min. 32P-PAR was degraded similarly when treated with DMSO or 5 µM of 2.7. 10 µM of 2.7 
prevented 32P-PAR degradation for 30 min, while 25 µM of 2.7 prevented 32P-PAR degradation for the 
length of the time course. b) Densitometry of 32P-PAR showed that >80% of 32P-PAR was hydrolyzed in 
the presence of 5 µM of 2.7 at 60 min, and >60% in the presence of 10 µM of 2.7, but 32P-PAR remained 
fully intact when treated with 25 µM of 2.7. 
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Densitometry analysis revealed 5 µM of 2.7 (near the in vitro IC50 value) only slightly 
delayed 32P-PAR degradation at 5 and 15 min, but ultimately did not prevent degradation (Figure 
2.20). When cell lysate was treated with 10 µM of 2.7, the hydrolysis of 32P-PAR was prevented 
at 5 and 15 min, but eventually, 32P-PAR degradation was observed at 30 min (51%) and 60 min 
(64%), albeit not to the same extent as DMSO treated lysate. In contrast, cell lysate that was 
incubated in the presence of 25 µM 2.7 remained intact for the entirety of the time course. 
Therefore, 25 µM was found to be an effective concentration of compound in cellular lysate, and 
all rhodanine-containing compounds were examined at this concentration in lysate.   
  
 
Figure 2.21. Rhodanine-Containing PARG Inhibitor Prevents 32P-PAR Degradation. a) MEF lysate (1.5 
µg) was incubated with DMSO (control), 2.7 (rhodanine-containing PARG inhibitor), 2.21 (inactive 
derivative), and ADP-HPD (PARG inhibitor), and treated with 32P-PAR for 0-60 min. 32P-PAR 
degradation occurred rapidly with vehicle and 2.21, whereas 32P-PAR was intact at 30 min with ADP-
HPD and at 60 min with 2.7. b) Densitometry of 32P-PAR revealed at 60 min >80% of 32P-PAR was 
degraded with 2.21, >50% with ADP-HPD and <10% with 2.7.  
 
 
 
Initially, 2.7 (rhodanine-containing PARG inhibitor), 2.21 (structurally similar, 
rhodanine-containing inactive compound), and ADP-HPD (known PARG inhibitor) were 
compared at 25 µM for their ability to inhibit PARG in cell lysate (Figure 2.21). As expected, 
lysate treated with 2.21 exhibited the same rate of 32P-PAR hydrolysis as lysate incubated with 
DMSO. Additionally, ADP-HPD did delay the degradation of 32P-PAR, although its partial 
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inhibition was evident at 30 min and 60 min, where 26% and 53% of the 32P-PAR was degraded, 
respectively. Again, 32P-PAR remained intact for the entire 60 min time course in lysate treated 
with 2.7. These results demonstrate that compound 2.7 is a more effective PARG inhibitor in cell 
lysate than ADP-HPD. 
 
Similar results were also seen when other rhodanine-containing PARG inhibitors were 
incubated with cell lysate. Compound 2.3, a carboxylic acid derivative, and 2.20, a tetrazole 
derivative (25 µM), delayed the degradation of 32P-PAR over the 60 min time course (Figure 
2.22), albeit not to the same extent as 2.7. These results further confirm that both the carboxylic 
acid and tetrazole derivatives of the rhodanine-containing PARG inhibitors are effective in cell 
lysate. Due to their success in a complex environment, these compounds were moved forward to 
whole cell assays, described in 2.7. 
 
 
Figure 2.22. Carboxylic Acid and Tetrazole-Containing PARG Inhibitors Prevent 32P-PAR Degradation 
in Cell Lysate. MEF lysate (1.5 µg) was incubated with DMSO (vehicle), 2.3 (carboxylic acid-containing 
PARG inhibitor), and 2.20 (tetrazole-containing PARG inhibitor), and treated with 32P-PAR for 0-60 min. 
32P-PAR degradation was delayed at the 30 min and 60 min time points when lysate was treated with 2.3 
and 2.20, as compared to lysate treated with DMSO.  
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2.7 The Effects of Rhodanine-Containing PARG Inhibitors in Cell Culture 
Although it has been hypothesized that small molecule PARG inhibitors could be either 
chemopotentiators or cytoprotective agents, without a compound that is both specific and cell 
permeable, the biochemical, as well as therapeutic study of PARG has been limited. Therefore, 
the effects of the rhodanine-containing PARG inhibitors were examined in MEFs by monitoring 
the accumulation of PAR by Western blot.32,36,37 Dr. Kathryn Partlow assessed active and 
inactive rhodanine-containing compounds for their ability to inhibit PARG in healthy cells and 
after PARP-1 was activated by N-methyl-N’-nitro-N-nitrosoguanidine (MNNG). Additionally, 
she observed the effects of PARG inhibition by the compounds on DNA damage repair. All 
cellular effects were analyzed with compounds 2.19, 2.20, the tetrazole versions of the active 
derivatives, and compound 2.22, the tetrazole version of the inactive derivative, due to their 
increased solubility compared to their carboxylic acid counterparts.  
 
First, PAR accumulation was examined with increasing concentrations of compound 
(2.19, 2.20, 2.22) to determine if there was a direct correlation between concentration of 
compound and amount of PAR build-up observed. Briefly, MEFs were treated with compound 
(10, 25, 50, 100 µM) for 20 h and lysed in the presence of protease inhibitors and 50 µM of 
compound 2.7 to prevent further PARG-catalyzed degradation of PAR in the lysate. The cell 
lysate was separated by SDS-PAGE, blotted against anti-PAR antibody, and imaged using a 
horseradish peroxidase (HRP) secondary antibody. The Western blot revealed there was PAR 
build-up after the whole cells were treated with compound in a dose dependent manner (Figure 
2.23). Compound 2.19 resulted in the most dramatic PAR accumulation, with long-chain PAR 
(MW >250) increasing proportionally with compound concentration treatment (50 µM and 100 
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µM). Additionally, 2.20 had mild PAR build-up with 100 µM treatment. Only minimal PAR 
accumulation was seen with the inactive compound 2.22, and the majority of this increase in 
PAR was shorter chains (MW <150). Because PAR accumulation correlated with compound 
concentration and minimal accumulation was seen with the structurally similar inactive 
compound, the results suggest that PAR build-up is due primarily to PARG inhibition, and not 
because of other secondary effects within the cell. The results of this experiment are fairly 
reproducible with PAR build-up being observed in three separate assays with compounds 2.19 
and 2.20. However, much more variable results were seen with the inactive derivative, 2.22. 
                  
Figure 2.23. Dose-Dependent PAR Accumulation in Mouse Embryonic Fibroblasts. MEFs were treated 
with compounds (10, 25, 50, 100 µM) for 20 h and the lysate was examined for PAR accumulation by 
Western blot. Increased PAR accumulation was observed with increasing concentration of 2.19, and 2.20 
at 100 µM. Compound 2.22, an inactive derivative, had minimal effects. PAR synthesized in vitro was 
used as a control. 
 
As shown in Figure 2.23, rhodanine-containing compounds 2.19 and 2.20 appears to 
cause PAR accumulation in a dose-dependent manner through PARG inhibition in healthy cells. 
In addition, the effects of these compounds in a damaged cell, where PARP-1 is activated and 
PARG’s turnover rate is increased, was investigated. In order to test this affect, cells whose DNA 
was damaged by MNNG were treated with compound, and examined for their ability to affect 
PAR levels. Briefly, MEFs were pre-treated for 4 h with active compounds (2.19, 2.20, 25 µM), 
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and an inactive compound (2.22, 25 µM), as well as vehicle alone (DMSO) as controls. Next, the 
cells were incubated with and without MNNG (500 µM) for 5 min, followed by a short recovery 
(0-10 min) for MNNG-treated cells.  Proteins from cell lysate were separated by SDS-PAGE, 
blotted against anti-PAR, and imaged with HRP, as previously described.  
 
Analysis of the Western blot revealed that PAR accumulation was more rapid when the 
cells were pre-treated with compounds 2.19 and 2.20, as compared to the DMSO control. This 
was best evidenced by the significant increase of PAR after 0 min recovery of MNNG treatment 
in cells treated with compounds 2.19, 2.20, compared to cells treated with DMSO (Figure 2.24). 
This build-up of PAR at 0 min suggests that PARG was inhibited even under cellular stress. 
Additionally, compound treatment with 2.19, and 2.20 at 25 µM (4 h) prevented a build-up of 
PAR without MNNG treatment, which was seen at higher compound treatments (50 and 100 
µM) previously, in Figure 2.23. However, a build-up of PAR was observed with the inactive 
compound, 2.22, both with and without MNNG treatment. This is in contradiction to the results  
 
Figure 2.24. PAR Accumulation in MEFs Pre-treated with Compound Followed by Cellular Damage. 
MEFs were pre-treated with compound (25 µM) or vehicle for 4 h, followed by treatment (5 min) with or 
without MNNG (500 µM). Cells treated with MNNG were allowed to recover for either 0 or 10 min, and 
the cells were lysed. The lysate was separated by SDS-PAGE and blotted against anti-PAR antibody. 
Greater PAR accumulation was seen at the 0 and 10 min time points after MNNG treatment in cells 
treated with the active compounds 2.19 and 2.20 compared to the cells treated with DMSO alone. The 
inactive derivative, 2.22, showed PAR accumulation both with and without MNNG treatment. 
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observed in Figure 2.23 where no significant amount of PAR was accrued at 25 µM compound 
2.22 treatment alone. Overall, these results were difficult to reproduce; however, this effect was 
observed in two separate assessments under the conditions described above. Therefore, the 
results may suggest that compounds 2.19 and 2.20 are effective in a damaged cell with activated 
PARP-1, but there are conflicting results with the inactive derivative, 2.22. 
 
Lastly, Dr. Kathryn Partlow investigated the time dependency of PAR accumulation and 
its relationship with DNA damage repair. MEFs were treated for varying amounts of time with 
active compounds (2.19, 2.20, 50 µM), and an inactive compound (2.22, 50 µM), and analyzed 
by Western blot to determine PAR accumulation using an anti-PAR antibody, as well as histone 
phosphorylation using an anti-γ-H2AX antibody, which identifies double strand DNA breaks.   
Briefly, MEFs were treated with compound (50 µM) for 4, 8, or 24 h. Upon completing the time 
course, the cells were lysed, and the cell lysate was separated by SDS-PAGE. The membrane 
was then blotted against either anti-PAR (for PAR) or anti-γ-H2AX (for double strand DNA 
breaks), and imaged using HRP secondary antibody. Interestingly, significant PAR accumulation 
was observed with 2.19 and 2.20, exclusively after the 24 h treatment (Figure 2.25). 
Additionally, PAR accumulation directly corresponded with decreased DNA damage in the γ-
H2AX blot (Figure 2.25). These results suggest that PAR build-up due to inhibition of PARG 
could promote DNA damage repair, although these results have only been observed once. 
Similar results were also seen with the structurally similar inactive derivative, 2.22, which 
warrant further investigation. 
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Figure 2.25. PAR Accumulation Promotes DNA Damage Repair. MEFs were treated with compound (50 
µM), and the lysate was examined for PAR accumulation (with a PAR antibody) and DNA damage repair 
(using γ-H2AX antibody) by Western blot. The blot revealed that PAR accumulation was time-dependent 
with both 2.19 and 2.20, and corresponded with DNA damage repair.  
 
Overall, these results suggest that the tetrazole versions of the rhodanine-containing 
PARG inhibitors, 2.19 and 2.20, are not only cell permeable but could be effective inhibitors of 
PARG inside the cell. Compounds 2.19 and 2.20 promote PAR accumulation in both a 
concentration- and time-dependent manner. Although a DNA damaging agent could directly 
promote PAR accumulation in a concentration-dependent manner, just as was observed with 
compound, the time dependency seen with 2.19 and 2.20 (i.e. requiring > 20 h) is exclusive to 
these compounds, and suggests that they are not directly causing DNA damage, but are inhibiting 
PARG, which leads to the build-up of PAR. Additionally, Western blot analysis hints that PAR 
accumulation by 2.19 and 2.20 could promote DNA damage repair, although no long term 
benefits of this repair has been investigated.  
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The analysis of these assays does not come without concern, including reproducibility of 
the blots and results observed with the inactive derivative, 2.22. The assay seemed to be sensitive 
to cell passage number, cell growth rate, and cell cycle; however, each of these variables has yet 
to be investigated. Overall, these compounds could help promote the study of the biological 
benefits of PARG inhibition, and to help us gain a better understanding of the biology of PARG 
itself.  
 
2.8 Rhodanine-Containing PARG Inhibitors and Chemopotentiation 
Due to the success of PARP inhibitors in clinical trials as chemopotentiators,38-40 small 
molecule PARG inhibitors could be envisioned to work in a similar manner. PARP inhibitors 
prevent the synthesis of PAR, which has been implicated in DNA repair and been identified as a 
cause of cellular resistance to chemotherapeutics;41 therefore, combination therapy of PARP 
inhibitors and a chemotherapeutic causes an increase in efficacy of the chemotherapeutic. 
Likewise, there is interest in investigating PARG inhibitors and their effects with 
chemopotentiators. A PARG inhibitor could indirectly inhibit PARP-1 by leaving it in a 
PARsylated state, ultimately inhibiting the PAR cycle. This could either lead to increased 
cellular sensitivity for the treatment of cancer in concert with a chemotherapeutic, or cause a 
cytoprotective effect through the promotion of DNA damage repair.  
 
Two chemotherapeutics that are commonly used in combination with PARP inhibitors 
are temozolomide (TMZ),42,43 a DNA alkylator that is an oral derivative of dacarbazine, and 
topotecan,43 a topoisomerase I inhibitor that is a water-soluble derivative of camptothecin. In 
investigating rhodanine-containing PARG inhibitors as possible chemopotentiators, 
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temozolomide and camptothecin were used in conjunction with the compounds. First, the 
toxicity of rhodanine-containing PARG inhibitors 2.7, 2.19, 2.20, 2.21, as well as PARP 
inhibitor PJ34 were assessed in HeLa and MCF-7 cell lines, cervical cancer and breast cancer 
cell lines, respectively, in order to determine how long the cells could be treated with compound 
before observing toxicity. Briefly, cells were pre-plated, and treated with 25 µM or 50 µM of 
compound mixed with RPMI 1640 media for either 24 or 72 h. After this period, cell death was 
analyzed by sulforhodamine B assay (SRB), to determine cell biomass.44 In general, none of the 
compounds tested caused any appreciable amount of cell death at 25 µM or 50 µM after 24 h of 
treatment in either HeLa or MCF-7 cells (Figure 2.26 a, c). However, the treatment of HeLa and 
MCF-7 cells with inactive derivative 2.21 (25 and 50 µM) for 72 h did result in >40% cell death 
at 50 µM and >20% cell death at 25 µM (Figure 2.26 b, d). None of the other compounds 
appeared to be toxic at the longer time point. In order to see a minimal amount of toxicity at the 
longest treatment time, compounds were tested at 25 µM for 72 h in potentiation assays with 
temozolomide and camptothecin. 
 
Next, the amount of camptothecin was optimized to obtain minimal amount of cell death 
over the 72 h period. Interestingly, camptothecin was much more potent in HeLa cells than 
MCF-7 cells. Therefore, HeLa cells were treated with a maximum concentration of 10 nM of 
camptothecin over the 72 h period, while MCF-7 cells were exposed to 60 nM of camptothecin 
over the same time period, which resulted in similar amounts of cell death. TMZ did not require 
optimization because no significant amount of cellular toxicity was observed after 72 h in either  
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Figure 2.26. Compound Toxicity in HeLa and MCF-7 Cell Lines. Compounds were tested at 25 µM and 
50 µM for 24 h and 72 h to determine the highest concentration of compound, with no associated toxicity. 
a) HeLa cells at 24 h, b) HeLa cells at 72 h, c) MCF-7 cells at 24 h, d) MCF-7 cells at 72 h. Compound 
2.21 showed the most toxicity after a 50 µM treatment for 72 h. In general, toxicity was considered to be 
minimal after a 25 µM treatment for 72 h. Error bars represent SD (n=5) of technical replicates within 1 
experiment. 
 
cell line at 1000 µM. Once compound and toxin concentrations were optimized, the potentiation 
assay was attempted.43,45,46 Rhodanine-containing compounds 2.7, 2.19, 2.21, and 2.22, as well 
as PJ34, a PARP inhibitor, were treated in combination with camptothecin and TMZ in HeLa 
and MCF-7 cell lines for 72 h. Briefly, compound (2.7, 2.19, 2.21, 2.22, and PJ34, 25 µM) was 
pre-mixed with media and pre-incubated with pre-plated cells (HeLa and MCF-7) for 15 min. 
Next, toxin (camptothecin, HeLa (0-10 nM) and MCF-7 (0-60 nM), TMZ, HeLa and MCF-7 (0-
1000 µM)) was pre-mixed with media and added to the compound pre-treated cells. The cells 
were incubated for 72 h, and upon completion of the time course, cell death was analyzed by 
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SRB assay.  Some potentiation was seen when PJ34 was treated in combination with both toxins.  
For example, when PJ34 was incubated with 750 µM TMZ in HeLa cells (Figure 2.27 b), there 
was an increase in cell death of almost 20% compared to 750 µM TMZ alone. This same effect 
was even more pronounced when MCF-7 cells were co-treated with PJ34 and camptothecin (10 
nM, Figure 2.27 c) or TMZ (500 µM, Figure 2.27 d). A greater than 30% increase in cell death 
was seen in both cases.  
 
However, the results from cellular treatment with rhodanine-containing PARG inhibitors 
were not as promising.  Despite analyzing compound toxicity at both 24 h and 72 h time points, 
too much initial cell death was seen when cells (both HeLa and MCF-7) were treated with 
inactive compound 2.21. Although to a lesser extent, toxicity was observed when active 
derivative 2.7 was incubated with cells for 72 h. Percent cell death in HeLa cells treated with 
active compounds 2.7 and 2.19 was similar if not greater in combination with camptothecin (5 
nM, Figure 2.27 a) and TMZ (750 µM, Figure 2.27 b), compared to the positive control PJ34. 
However, the non-toxic inactive derivative 2.22 displayed a similar trend in cellular death at the 
same concentrations. In MCF-7 cells, PJ34 showed a much greater potentiation effect than either 
PARG inhibitor, 2.7 or 2.19. Although 2.7 displayed some cellular toxicity on its own, 2.19, 
which was non-toxic, still showed no potentiation effect when treated in tandem with the toxins, 
as compared to camptothecin or TMZ alone (Figure 2.27 c, d). Again, the inactive PARG 
inhibitor 2.22 mirrored the effects of the active PARG inhibitor 2.19. Therefore, rhodanine-
containing PARG inhibitors, 2.7 and 2.19 were unable to potentiate camptothecin and TMZ 
toxicity under these conditions.   
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Figure 2.27. Compound Potentiation of Camptothecin and Temozolomide in HeLa and MCF-7 Cells. 
Cells were pre-treated with compound (25 µM) mixed in media for 15 min followed by addition of either 
camptothecin or temozolomide mixed in media. The cells were co-treated for 72 h and cell death was 
assessed by SRB assay. a) HeLa cells with compound (25 µM) and camptothecin (0-10 nM), b) HeLa 
cells with compound (25 µM) and temozolomide (0-1000 µM), c) MCF-7 cells with compound (25 µM) 
and camptothecin (0-60 nM), d) MCF-7 cells with compound (25 µM) and temozolomide (0-1000 µM). 
Potentiation was seen when cells (HeLa and MCF-7) were pre-treated with PJ34, PARP inhibitor, 
followed by treatment with toxin (camptothecin or temozolomide). However, this same effect was not 
observed with the PARG inhibitors 2.7 or 2.19. Error bars represent SD (n=5) of technical replicates 
within 1 experiment. 
 
Despite these discouraging results, there is still promise that these PARG inhibitors could 
have similar effects as PARP inhibitors in the cell. Currently, Prof. Nicola Curtin of University 
of Newcastle upon Tyne, a pioneer in the discovery of PARP inhibitors as single entity agents in 
BRCA deficient cells lines,47 is testing these compounds in a variety of assays including toxicity 
in BRCA deficient cell lines, and potentiation effects after chemotherapeutic (TMZ) or 
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irradiation treatment. First the compounds (2.3, 2.20, 2.26) were assessed for toxicity against a 
BRCA-2 deficient cell line (V-C8) and its corrected counterpart that has BRCA-2 (V-C8 B2). 
Cells were treated with increasing concentration of compound (1-30 µM) for 24 h, followed by 
seeding for colony formation. After 2 weeks, the colonies were stained with crystal violet and 
counted. A mild effect (increased cell death) was seen with active compounds (2.3, 2.20) in the 
BRCA deficient cell line (V-C8) as compared to the V-C8 B2 cell line (Figure 2.28). This same 
effect was not observed when cells were treated with the inactive compound (2.26).  
 
 
Figure 2.28. Compound Toxicity in BRCA Deficient Cells. Increasing concentration of compound (1-30 
µM) was tested in both BRCA-2 deficient (V-C8) and BRCA-2 corrected (V-C8 B2) cell lines. Cell death 
was calculated using a colony formation assay, which was stained with crystal violet. An increase in cell 
death was observed with both active compounds, a) 2.3, and b) 2.20 in the V-C8 cells as compared to the 
V-C8 B2 cells. c) Compound 2.26, the inactive derivative, did not have an effect in either cell line. d) The 
structure of the inactive derivative, 2.26.  
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Figure 2.29. Compound Potentiation Temozolomide in LoVo Cells. Cells were treated with compound (3 
or 10 µM) and temozolomide (0-1000 µM) in media. A control with PARP inhibitor, AG014699, was 
done within each plate. The cells were co-treated for 5 d and cell death was assessed by SRB assay. a) 
2.3, b) 2.7 c) 2.19, d) 2.20, e) 2.21, f) 2.26. Potentiation was only seen when cells treated with AG014699 
and temozolomide. However, this same effect was not observed with any of the PARG inhibitors. Error 
bars represent SD (n=5) of technical replicates within 1 experiment. 
 
Prof. Curtin also performed some potentiation assays with compound and TMZ in a 
similar fashion as previously described. LoVo cells were treated with either 3 or 10 µM of both 
active and inactive rhodanine-containing compounds (2.3, 2.7, 2.19, 2.20, 2.21, 2.26), as well as 
RBPI-6 alone (3 µM and 10 µM)
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PARP inhibitor, AG014699, and increasing concentrations of TMZ (0-1000 µM) for 5 days. 
Upon completion of the incubation period, cell death was assessed by SRB assay. As seen 
previously, the PARG inhibitors were unable to potentiate TMZ (Figure 2.29 a-f).   
 
Although the active PARG inhibitors were unable potentiate the chemotherapeutic TMZ, 
mild toxicity of PARG inhibitors was observed in BRCA-2 deficient cells that warrant further 
investigation at more concentrations and longer incubation periods. Additionally, potentiation 
assays with irradiation and compound presents another method to assess the effectiveness of the 
compounds.  
 
2.9 Summary 
Using the knowledge that the diphosphate moiety in ADP-HPD, a known PARG 
inhibitor, is necessary for PARG recognition and binding, rhodanine scaffolds were screened in a 
TLC-based assay, and compound 2.1 was identified as an inhibitor of PARG. After assay 
optimization and library synthesis, nine potent PARG inhibitors (2.3, 2.6, 2.7, 2.8, 2.9, 2.10, 
2.11, 2.12, 2.13) were identified as potent PARG inhibitors (IC50 <10 µM). Teterazole 
derivatives of some of these compounds (2.19, 2.20) were synthesized to improve solubility and 
cell permability, and all compounds were assessed in specificity and aggregation tests.  After 
testing each compound’s ability to inhibit the AIF-DNA interaction, as well as investigate their 
ability to inhibit β-lactamase, only compounds 2.3, 2.6, and 2.7 emerged with selectivity. These 
compounds, as well as their tetrazole counterparts, 2.19 and 2.20, do not inhibit PARG through 
an aggregation-based mechanism, as confirmed by a lack of detergent and BSA sensitivity. 
These rhodanine-containing PARG inhibitors were effective in delaying 32P-PAR degradation in 
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cell lysate, as well as causing a build-up of PAR in cell culture as determined by TLC-based 
assay and Western blot, respectively. Although these compounds did not show any potentiation 
effect in combination with either camptothecin or TMZ, PAR build-up may be correlated with 
DNA damage repair.  
 
In the immediate future, these compounds may be suitable replacements of ADP-HPD for 
the biological study of PARG and poly(ADP-ribose) signaling cascades. Despite its costly 
purchase and lengthy synthesis, ADP-HPD is commonly used as controls in cell lysate 
experiments, and additives in Western blot analysis. For example, to study PAR accumulation by 
Western blot, ADP-HPD is typically added to the lysate in order to prevent further PARG-
catalyzed degradation of PAR after cell lysis.48-51 In these assays, ADP-HPD is used at varying 
concentration from 1 µM to 100 µM. Currently, Dr. Kathryn Partlow uses 50 µM of compound 
2.7 as an additive in cell lysate alongside protease inhibitors for the study of PAR accumulation 
by Western blot with much success. Additionally, we have shown that the rhodanine-containing 
PARG inhibitors are more effective PARG inhibitors in lysate than ADP-HPD, and therefore, we 
believe that these compounds could be very useful in lysate studies.  
 
The understanding of the biochemistry of PARG has been enhanced with the use of ADP-
HPD and its derivatives through SPR analysis and photochemical studies. With the aid of these 
ADP-HPD derivatives, important structural information has been discovered such as critical 
acidic residues and a potential binding site. ADP-HPD was also used to define the function of the 
110 kDa PARG isoform in cell lysate.52-54 In a similar fashion, Claire Knezevic has synthesized 
 114 
an azido version of a rhodanine-containing PARG inhibitor to identify important binding 
residues in PARG through photo-crosslinking.  
 
Lastly, ADP-HPD has been utilized to help study the function and necessity of PAR and 
other PARsylated proteins in different environments within the cell. For example, ADP-HPD 
(100 µM) was able to rescue mitotic spindle formation in Xenopus egg extracts, which confirmed 
that PAR was required for spindle formation.55 ADP-HPD was used in similar fashions to study 
tankyrase-1 activity and the Sir2 family of proteins, which are NAD+-dependent 
deacetylases.56,57 Although our rhodanine-containing PARG inhibitors have not been used in 
these scenarios, the community has such a need for more useful PARG inhibitors than ADP-
HPD, and we are currently starting a collaboration with the Mitchison lab to use our compounds 
in the study of spindle formation. Overall, we have discovered a novel class of PARG inhibitors, 
rhodanine-containing PARG inhibitors, that are suitable replacements for ADP-HPD in the study 
of PARG in vitro, and can potentially be used to monitor the build-up of PAR in cell culture, and 
one day, be used to understand the importance of PARG in disease. 
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2.11 Materials and Methods 
General Methods 
Reaction solvents tetrahydrofuran (Fisher, HPLC grade), methylene chloride (Fisher, 
unstabilized HPLC grade), acetonitrile (Fisher, HPLC grade), and methanol (Fisher, low water) 
were dried by percolation through two columns packed with neutral alumina under a positive 
pressure of nitrogen. All other solvents were obtained from Fisher Scientific and were used 
without further purification. All H2O used was either deionized or purified through a MilliQ 
purification system. 
 
Silica gel for chromatography was performed on EMD Biosciences silica gel 60 (230-400 mesh).  
Chromatography was performed on the Teledyne ISCO CombiFlash Rf MPLC chromatography 
system.  Silica gel provided in pre-packaged cartridges.  Thin-layer chromatography plates 
(Merck, 245 nm fluorescent indicator) were visualized by UV and stained with cerium 
ammonium molybdate (CAM), iodine (I2), and ninhydrin.   
 
All NMR experiments were acquired in the Varian-Oxford Instrument Center for Excellence in 
NMR Spectroscopy (VOICE) laboratory at the University of Illinois at Urbana-Champaign.  
NMR experiments were recorded in CDCl3, CD3OD, and (CD3)2SO on Varian Unity 500 MHz 
spectrometers.  Chemical shift, δ (ppm); coupling constant, J (Hz); multiplicity (s = singlet, d = 
doublet, t = triplet, q = quartet, quin = quintet, m = multiplet); and integration are reported.  
High-resolution mass spectral data were recorded on a Micromass Q-T of Ultima hybrid 
quadrupole/time-of-flight ESI mass spectrometer at the University of Illinois at Urbana-
Champaign Mass Spectrometry Laboratory. 
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Mouse embryonic fibroblasts (MEFs) were cultured in Dulbecco’s modified Eagle medium 
(DMEM) containing 4.5 g/L glucose and supplemented with 10% (v/v) fetal bovine serum 
(Gemini Bio-Products, West Sacramento, CA), 1mM sodium pyruvate, 100 U/ml penicillin 
(Cellgro, Manassas, VA), and 100 mg/mL streptomycin (Cellgro, Manassas, VA). HeLa (human 
cervical carcinoma cells) and MCF-7 (human breast cancer cells) were grown in RPMI 1640 
supplemented with 10% (v/v) fetal bovine serum (Gemini Bio-Products, West Sacramento, CA), 
100 U/ml penicillin (Cellgro, Manassas, VA), and 100 mg/mL streptomycin (Cellgro, Manassas, 
VA). All cells were maintained in a humidified atmosphere with 95% air and 5% CO2. 
 
2.11.1 Supplemental Figures 
 
 
Figure S2.1. Rhonaine-Containing Compounds with IC50 values >50 µM. 
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Figure S2.1 Cont’d. Rhonaine-Containing Compounds with IC50 values >50 µM. 
 
2.11.2 Biological Protocols 
Synthesis of 32P-PAR 
32P-β-NAD+ (ARP 0141) was purchased from American Radiolabeled Chemicals, Inc., with a 
specific activity of 800 Ci/mmol, and a concentration of 5 mCi/mL, was stored at -20 °C. Calf 
thymus activated DNA (cas # 91080-16-9) was purchased from Sigma. DNA was diluted in H2O 
and concentration was determined per manufacturer’s instructions and stored at -20 °C.  To a 
2.0-mL tube, PAR synthesis buffer (100 mM Tris-HCl (pH 8.0), 10 mM MgCl2, 8 mM DTT, 
10% v/v glycerol, 1 mM unlabeled β-NAD+, 23 µg of calf thymus activated DNA) was made 
from buffer stocks: 90 µL of 1 M Tris-HCl (pH 8.0), 9 µL of 1 M MgCl2, 90 µL of 100% 
glycerol, 8 µL of 1 M DTT, 18 µL of 50 mM unlabeled β-NAD+, 10 µL of 2.3 µg/µL of calf 
thymus activated DNA. To the solution was added 75 µCi of 32P β-NAD+, and water complete to 
900 µL. Lastly, 100% ethanol (10% v/v, 90 µL) was added dropwise to stimulate the reaction, 
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and the solution heated at 30 °C for 5 min. To the solution was added 20 U of PARP-1 
(Trevigen, catalog # 4668-100-01), and the solution heated at 30 °C for 30 min. Upon 
completion, the reaction was quenched and PAR was precipitated with 100 µL of 3M sodium 
acetate (pH 5.2) and 700 µL of isopropanol. The solution was placed in an ice bath for 30 min, 
and the PAR was pelleted by centrifugation at 14,000xg at 4 °C for 10 min. The pelleted PAR 
was washed with cold 80% (v/v) ethanol in H2O two times with centrifugation each time 
between (14,000xg at 4 °C for 10 min). The pellet was re-suspended in 800 µL of H2O and 
stored at -20 °C. 
 
Determination of 32P-PAR Integrity 
Five amounts of synthesized 32P-PAR (1, 2, 3, 4, or 5 µL) were tested in the presence or absence 
of PARG. First, 10X PARG buffer (Trevigen, cat # 4680-096-02) was diluted with H2O to make 
a 2X PARG buffer. Next, PARG (Trevigen, cat # 4680-096-01) was diluted to 0.025 ng/µL 
(from a 1 µg/mL solution of PARG) in 2X PARG buffer. To each 0.5-mL tube, 0.5 µL of 
DMSO, 32P-PAR made to a volume of 5 µL with H2O, and either 2X PARG buffer (4.5 µL) or 
PARG diluted in 2X PARG buffer (4.5 µL) was added. The solutions incubated at 37 °C for 1 h 
and were quenched by heating at 90 °C for 3 min. Upon cooling, 1.3 µL of each solution was 
spotted two times on a TLC plate. Then, the TLC plate was developed twice in a TLC chamber 
with 100-mL of 70% isopropanol/ 30% of 0.2% aq. NH4+OH-, allowing for the TLC plate to dry 
completely between each run. The dried TLC plate was wrapped in saran wrap, and placed in 
Storage Phosphor Screen (Molecular Dynamics) overnight, and the screen was imaged on a 
Storm Imager (GE Life Sciences, Piscataway, NJ). 
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Radiometric PARG TLC Assay 
Increasing concentrations of compound were tested in the presence of PARG. Compounds were 
prepared from a 10 mM stock solution made in dimethyl sulfoxide (DMSO) to the specified 
concentrations. First, 10X PARG buffer (Trevigen, cat # 4680-096-02) was diluted with H2O to 
make a 2X PARG buffer. Next, PARG (Trevigen, cat # 4680-096-01) was diluted to 0.025 ng/µL 
(from a 1 µg/mL solution of PARG) in 2X PARG buffer. To a 0.5-mL tube, 0.5 µL of 
compound, and PARG diluted in 2X PARG buffer (4.5 µL) were added. Additionally, controls 
with DMSO in the presence and absence of PARG were conducted within each experiment.  The 
solution incubated at RT for 10 min. After the incubation, 32P-PAR (3 µL) was added to each 
solution. Next, the solutions incubated at 37 °C for 2 h and were quenched by heating at 90 °C 
for 3 min. Upon cooling, 1.3 µL of each solution was spotted two times on a TLC plate. Then, 
the TLC plate was developed twice in a TLC chamber with 100-mL of 70% isopropanol/ 30% of 
0.2% aq. NH4+OH-, allowing for the TLC plate to dry completely between each run. The dried 
TLC plate was wrapped in saran wrap, and placed in Storage Phosphor Screen (Molecular 
Dynamics) overnight, and the screen was imaged on a Storm Imager (GE Life Sciences, 
Piscataway, NJ). Intact 32P-PAR was analyzed by densitometry using ImageJ, and the mean 
intensity of each spot was used to calculate percent PARG inhibition as compared to controls. 
The data were plotted as compound concentration verses percent PARG inhibition, and fitted to a 
logistic-dose response curve using Table Curve (SYSTAT Software, Richmond, CA). The data 
were generated in triplicate, and IC50 values are represented as the average of the three separate 
experiments. Data shown is a representative of the triplicate experiments. 
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In the presence of ADP-HPD, the experiment was repeated as explained above; however, PARG 
activity after the addition of 32P-PAR was measured at both 30 min and 2 h. TLC development 
and percent PARG inhibition proceeded, as explained previously.   
 
AIF Gel-shift Assay 
Dr. James Heeres generated linearized pUC19 DNA in mini-prep elution buffer (10 mM Tris, pH 
8.3) as detailed in his thesis.26 Compound or DMSO (control) was pre-incubated with 15-30 µg 
of purified AIF (Δ1-128), depending on propensity to bind DNA, for 30 min at room temperature 
in AIF assay buffer (50 mM Tris, 100 mM NaCl, pH 8.0) at a volume of 20 µL. Next, 60 ng of 
linearized DNA was added to solution to bring the total volume to 25 µL, and the solution 
incubated at room temperature for 15 min. 5 µL of blue/orange loading dye (Promega) was 
added to each sample, and 12.8 µL of each sample was loaded on a 1% agarose gel. The gel was 
electrophoresed for 1 h at 10 W. Gels were stained overnight with SYBR green I (Cambrex) 
(diluted in TAE buffer) and imaged by a BioRad gel imager. Bands were analyzed by 
densitometry using ImageJ. 
 
Caspase-3 Assay 
Caspase-3 was expressed as described in Peterson et al.58 Capase-3 substrate, Ac-DEVD-pNA, 
was synthesized as described in Peterson et al.59 Caspase-3 was diluted to a 1 µM solution in 
standard caspase-3 buffer (50 mM HEPES (pH 7.4), 300 mM NaCl). Compounds were prepared 
from a 10 mM stock solution made in dimethyl sulfoxide (DMSO) to the specified 
concentrations. In a standard clear bottom 384-well plate, appropriately concentrated compound 
(1 µL) was preincubated with caspase-3 buffer (19 µL) at RT for 5 min. Next, 25 µL of caspase-
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3 (1 µM) was added to each well and the plate incubated for 1 h at 37 °C. Controls with DMSO 
and enzyme were conducted within each experiment. After incubation, 5 µL of a 2 mM Ac-
DEVD-pNA (final concentration 200 µM, diluted in caspase-3 buffer) solution was added to 
each well. The plate was immediately read at 405 nm every 30 sec for 1 h in a SpectraMax Plus 
384 plate reader (Molecular Device, Sunny Vale, CA). The data were plotted as absorbance 
verses time, and the slope of each well was used to calculate percent inhibition as compared to 
controls.  
 
β-Lactamase Assay  
β-Lactamase (cas # 9001-74-5) was purchased from Sigma and was diluted to a 5 U/mL solution 
in 50 mM potassium phosphate (pH 7.0) buffer and stored at -20 °C.  Its substrate CENTA (cat # 
219475) was purchased from CalBioChem, diluted to 20 mM in DMSO, aliquotted into 50 µL 
aliquots, and stored at 4 °C.  Compounds were prepared from a 10 mM stock solution made in 
dimethyl sulfoxide (DMSO) to the specified concentrations. In a standard clear bottom 96-well 
plate, compound (2 µL) was preincubated with 38 µL of PARG phosphate buffer (50 mM 
potassium phosphate (dibasic, pH 7.5), 50 mM potassium chloride, 100 µg/mL BSA) at RT for 5 
min. Next, 50 µL of β-Lactamase (0.006 U/mL final concentration) was added to each well and 
the plate incubated for 30 min at 37 °C. Controls with DMSO, enzyme and substrate, as well as 
compound without enzyme and substrate were conducted within each experiment. After 
incubation, 10 µL of a 2 mM substrate (final concentration 200 µM, diluted in PARG phosphate 
buffer) solution was added to the appropriate wells. The plate was immediately read at 405 nm 
every 30 sec for 30 min in a SpectraMax Plus 384 plate reader (Molecular Device, Sunny Vale, 
CA). The data were plotted as absorbance vs. time, and the slope of each well was used to 
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calculate percent inhibition as compared to controls. Additionally, the slope of compound alone 
was observed to verify compound absorbance did not change over time. The data were generated 
in triplicate, and percent inhibition is represented as the average of the three separate 
experiments.  
 
 DTT Addition Into Compounds 
40 µM compound was tested in the presence of dithiothretiol (DTT). Compounds were prepared 
to a 10 mM stock solution made in dimethyl sulfoxide (DMSO). Compound was added to 4 mL 
of 50 mM phosphate buffer (pH 6.8) in a UV transparent plastic cuvette. The absorbance of 
buffer alone and compound in buffer were observed on the SpectraMax Plus 384 plate reader 
(Molecular Device, Sunny Vale, CA) every 10 nm from 300-550 nm, to determine background 
absorbance. Next, DTT (20 mM) was added to the buffered solution with compound, and upon 
mixing, absorbance was monitored every 10 nm from 300-550 nm after 1, 5, 30, and 50 min. The 
data of the time points were plotted as wavelength verses absorbance. Additionally, the 
absorbance of buffer alone and compound in buffer was observed to verify absorbance did not 
change over time. 
 
Radiometric PARG TLC Assay in the Presence of Detergent 
50 µM compound was tested in the presence and absence of 0.1% Triton X-100. First, 
compounds were prepared from a 10 mM stock solution made in dimethyl sulfoxide (DMSO) to 
the specified concentration. A 1.8X phosphate-based PARG buffer (90 mM potassium phosphate 
(dibasic, pH 7.5), 90 mM potassium chloride, and 18 mM BME) was made, and to an aliquot of 
buffer was added Triton X-100 for a concentration of 0.18%. Next, PARG (Trevigen, cat # 4680-
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096-01) was diluted to 0.025 ng/µL (from a 1 µg/mL solution of PARG) in 1.8X PARG buffer 
with and without Triton X-100. To a 0.5-mL tube, 0.5 µL of compound, and PARG diluted in 
1.8X PARG buffer with or without Triton X-100  (4.5 µL) was added. Additionally, controls 
with DMSO in the presence and absence of PARG were conducted within each experiment.  The 
solution incubated at RT for 10 min. After the incubation, 32P-PAR (3 µL) was added to each 
solution. Next, the solutions incubated at 37 °C for 1 h and were quenched by heating at 90 °C 
for 2 min. Upon cooling, 1.3 µL of each solution was spotted two times on a TLC plate. Then, 
the TLC plate was developed twice in a TLC chamber with 100-mL of 70% isopropanol/ 30% of 
0.2% aq. NH4+OH-, allowing for the TLC plate to dry completely between each run. After 
drying, the TLC was wrapped in saran wrap, and placed in Storage Phosphor Screen (Molecular 
Dynamics) overnight, and the screen was imaged on a Storm Imager (GE Life Sciences, 
Piscataway, NJ). Intact 32P-PAR was analyzed by densitometry using ImageJ, and the mean 
intensity of each spot was used to calculate percent 32P-PAR degradation as compared to 
controls. The data were generated in triplicate, and percent 32P-PAR degradation is represented 
as the average of the three separate experiments. 
 
Radiometric PARG TLC Assay in the Presence of Bovine Serum Albumin 
50 µM compound was tested in the presence and absence of 0.1 mg/mL bovine serum albumin 
(BSA). First, compounds were prepared from a 10 mM stock solution made in dimethyl 
sulfoxide (DMSO) to the specified concentration. Additionally, BSA (Fraction V, Research 
Products International Corp., Mt. Prospect, IL) dilution was prepared from an 8 mg/mL stock 
solution made in H2O to the specified concentration. Lastly, a 2.3X phosphate-based PARG 
buffer (115 mM potassium phosphate, (dibasic, pH 7.5) 115 mM potassium chloride, and 23 mM 
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BME) was made. PARG (Trevigen, cat # 4680-096-01) was diluted to 0.0325 ng/µL (from a 1 
µg/mL solution of PARG) in 2.3X PARG buffer. In a 0.5-mL tube, 0.5 µL of compound was 
pre-treated with either 1.0 µL BSA (0.1 mg/mL final concentration) or 1.0 µL H2O at RT for 10 
min. After the incubation, PARG diluted in 2.3X PARG buffer (3.5 µL) was added to each tube. 
Additionally, controls with DMSO in the presence and absence of PARG were conducted within 
each experiment.  The solution incubated again at RT for 10 min. Then, 32P-PAR (3 µL) was 
added to each solution. The solutions incubated at 37 °C for 1 h and were quenched by heating at 
90 °C for 3 min. Upon cooling, 1.3 µL of each solution was spotted two times on a TLC plate. 
Then, the TLC plate was developed twice in a TLC chamber with 100-mL of 70% isopropanol/ 
30% of 0.2% aq. NH4+OH-, allowing for the TLC plate to dry completely between each run. 
After drying, the TLC was wrapped in saran wrap, and placed in Storage Phosphor Screen 
(Molecular Dynamics) overnight, and the screen was imaged on a Storm Imager (GE Life 
Sciences, Piscataway, NJ). Intact 32P-PAR was analyzed by densitometry using ImageJ, and the 
mean intensity of each spot was used to calculate percent 32P-PAR degradation as compared to 
controls. The data were generated in triplicate, and percent 32P-PAR degradation is represented 
as the average of the three separate experiments. 
 
Compound Kinetics of PARG Inhibition 
Compound was tested in the presence of PARG with varying amounts of 32P-PAR. Compounds 
were prepared from a 10 mM stock solution made in dimethyl sulfoxide (DMSO) to the specified 
concentrations. First, 10X PARG buffer (Trevigen, cat # 4680-096-02) was diluted with H2O to 
make a 2X PARG buffer. Next, PARG (Trevigen, cat # 4680-096-01) was diluted to 0.025 ng/µL 
(from a 1 µg/mL solution of PARG) in 2X PARG buffer. To a 0.5-mL tube, 0.5 µL of compound 
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(5, 10, 20, 40 µM or DMSO), and PARG diluted in 2X PARG buffer (4.5 µL) were added. Next, 
32P-PAR (1, 2, 4, or 8 µL) made to a volume of 10 µL with H2O were added to each solution. 
32P-PAR degradation was monitored over a time course from when the 32P-PAR was added. The 
solutions incubated at 37 °C for the appropriate amount of time (0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, or 4 
min) and were quenched with 2 µL of 1% SDS (0.1% final concentration). Upon completing the 
time course, 1.3 µL of each solution was spotted two times on a TLC plate. Then, the TLC plate 
was developed twice in a TLC chamber with 100-mL of 70% isopropanol/ 30% of 0.2% aq. 
NH4+OH-, allowing for the TLC plate to dry completely between each run. The dried TLC plate 
was wrapped in saran wrap, and placed in Storage Phosphor Screen (Molecular Dynamics) 
overnight, and the screen was imaged on a Storm Imager (GE Life Sciences, Piscataway, NJ). 
ADP-ribose production was analyzed by densitometry using ImageJ, and the mean intensity of 
each spot was used to monitor ADP-ribose production over time. The data were plotted as ADP-
ribose production verses time (min).  
 
Cellular Extract for Compound in Cell Lysate Experiments 
Mouse embryonic fibroblasts (2,000,000 cells) that were grown overnight in a 10 cm tissue 
culture treated dish were lysed with 1X Trevigen PARG buffer (Trevigen, cat # 4680-096-02) 
supplemented with 0.5 mM PMSF and protease inhibitor cocktail set III (1:100, CalBioChem, 
San Diego, CA), which was added at a concentration recommended by the manufacturer. Whole-
cell lysate was generated after centrifugation at 14000xg for 10 min at 4 °C. Supernatant was 
collected and stored at -80 °C until use. 
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Protein concentration of cell lysate was determined using the Pierce bicinchoninic acid (BCA) 
Assay Kit (Rockford, IL), with BSA as a standard. 
 
Compound Analysis in Cell Lysate 
Compound was tested for the inhibition of PARG in cell lysate. Compounds were prepared from 
a 10 mM stock solution made in dimethyl sulfoxide (DMSO) to the specified concentrations. 
First, 10X PARG buffer (Trevigen, cat # 4680-096-02) was diluted with H2O to make a 1X 
PARG buffer. To a 0.5-mL tube, 0.5 µL of compound (25 µM), cell lysate (1.5 µg), and 1X 
PARG buffer (2.5 µL) were added, and incubated at RT for 10 min. Additionally, controls with 
DMSO in the presence of cell lysate were conducted within each experiment. 32P-PAR 
degradation was monitored over a 60 min time course from when the 32P-PAR (3 µL) was added. 
The solutions incubated at 37 °C for the appropriate amount of time (0, 5, 15, 30, 60 min) and 
were quenched with 1 µL of 1% SDS (0.1% final concentration). Upon completing the time 
course, 1.3 µL of each solution was spotted two times on a TLC plate. Then, the TLC plate was 
developed twice in a TLC chamber with 100-mL of 70% isopropanol/ 30% of 0.2% aq. 
NH4+OH-, allowing for the TLC plate to dry completely between each run. The dried TLC plate 
was wrapped in saran wrap, and placed in Storage Phosphor Screen (Molecular Dynamics) 
overnight, and the screen was imaged on a Storm Imager (GE Life Sciences, Piscataway, NJ). 
Intact 32P-PAR was analyzed by densitometry using ImageJ, and the mean intensity of each spot 
was used to calculate percent 32P-PAR degradation as compared to controls. The data were 
plotted as time verses percent PAR degradation.  
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Compound Treatment and Cell Extracts for Western Blot Analysis 
Mouse embryonic fibroblasts were plated in a 6-well tissue culture treated plate and grown to 
90% confluency. Compounds were prepared from a 10 mM stock solution made in dimethyl 
sulfoxide (DMSO) to the specified concentrations, and the N-methyl-N'-nitro-N-nitrosoguanidine 
(MNNG) stock was made at 500 mM in DMSO (1000X). Cells were treated with compound (10, 
25, 50, or 100 µM) for the specified time (4, 8, 20, or 24 h). If the cells were treated in 
conjunction with MNNG, cells were pre-treated with compound (25 µM) for 4 h, followed by a 5 
min treatment with MNNG (500 µM). After removing MNNG by washing 3 times with complete 
media, compound was re-added and the cells were allowed to recover from treatment for the 
specified time (0, or 10 min). Additionally, controls with DMSO (1% final concentration) in the 
presence and absence of MNNG were conducted within each experiment.   
Cells were collected by centrifugation and lysed in RIPA lysis buffer (50 mM Tris (pH 7.4), 150 
mM sodium chloride, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS) supplemented 
with 50 µM 2.7, 1 mM PMSF, 1 mM EDTA, phosphatase inhibitor cocktail 2 (1:100, Sigma, St. 
Louis, MO), and protease inhibitor cocktail set III (1:100, CalBioChem, San Diego, CA), which 
were added as recommended by the manufacturer. Lysate was incubated on ice for 30 min prior 
to centrifugation at 16000xg for 5 min at 4 °C to remove the insoluble fraction. Supernatant was 
collected and stored at -20 °C until use. 
 
Protein concentration of cell lysate was determined using the Pierce bicinchoninic acid (BCA) 
Assay Kit (Rockford, IL), with BSA as a standard. 
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Western Blot Analysis 
60 µg of cell lysate (normalized for each sample) was separated by SDS-PAGE (4-20% gel, Bio-
Rad TGX) for 1 h at 120V. Additionally, PAR (3 µL) was run alongside as a control and the 
Precision Plus Protein Kaleidoscope ladder as a standard. The contents of the gel were 
transferred to a PVDF membrane (Bio-Rad) for 2 h at 45V. The blot was divided between 75 and 
50 kD to allow simultaneous staining of PAR (above 75 kD) and γ-H2AX (below 50 kD). After 
blocking (1% non-fat milk and 1% BSA for 1 h for anti-PAR, or 5% BSA containing 50 mM 
NaF for 1 h for γ-H2AX), the blot was probed with primary antibody (1:500 of 1 mg/mL stock of 
anti-PAR (Clone 10H, Tulip Biolabs, West Point, PA) or 1:1000 of 1 mg/mL stock of anti-
phopho-H2AX (Clone JBW301, Millipore, Bulerica, MA). Both primary antibodies were 
detected with horseradish peroxidase (HRP) anti-mouse secondary antibody (1:20,000, 
ThermoScientific, Rockford, IL).  Detection of the secondary antibody was performed using 
SuperSignal West Pico Chemiluminescent Substrate Kit (Rockford, IL). Images were obtained 
by exposure to autoradiography film (Denville Scientific, Metuchen, NJ) and visualized on the 
Futura 200K film processor (Fisher Industries, Geneva, IL). 
 
Cell Growth Inhibition Assay 
Compound toxicity was assessed using the sulforhodamine B assay. HeLa (5,000 cells/well) or 
MCF-7 (5,000 cells/well) cells were plated in a 96 well plate and allowed to adhere overnight. 
Compounds were prepared from a 10 mM stock solution made in dimethyl sulfoxide (DMSO) to 
the specified concentrations. Cells were treated with compound (25 or 50 µM) that had been pre-
mixed in RPMI media to a total volume of 200 µL per well. Additionally, both live and dead cell 
controls were done within each plate. The plates were incubated for the appropriate amount of 
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time (24 or 72 h) at 37 °C in a 5% CO2 incubator. Cells were fixed with 100 µL of 10% (w/w) 
aqueous trichloroacetic acid (TCA), and cellular biomass was stained using 0.057% SRB that 
was solubilized in 10 mM tris base solution. Absorbance was read at 510 nm on a SpectraMax 
Plus 384 plate reader (Molecular Device, Sunny Vale, CA), and the data were plotted as 
compound concentration verses percent cell death, as compared to controls. Each experiment 
was done in singlicate with 5 technical replicates done within each plate.  
 
Compound Potentiation Assays 
Compound potentiation was assessed using the sulforhodamine B assay. HeLa (5,000 cells/well) 
or MCF-7 (5,000 cells/well) cells were plated in a 96 well plate and allowed to adhere overnight. 
Compounds were prepared from a 10 mM stock solution made in dimethyl sulfoxide (DMSO) to 
the specified concentrations. Toxins, temozolomide was prepared from a 200 mM stock in 
DMSO, and camptothecin, a 20 µM stock in DMSO. Cells were treated with compound (25 µM) 
that had been pre-mixed in RPMI media to a total volume of 100 µL per well. The plates 
incubated with compound for 15 min at RT, followed by treatment with either temozolomide 
(250-1000 µM) or camptothecin (HeLa: 0.5-10 nM, MCF-7: 10-60 nM) that had been pre-mixed 
in RPMI media to a total volume of 100 µL per well. Additionally, both live and dead cell 
controls, as well as, toxin alone, and compound alone controls were done within each plate. The 
plates were incubated for 72 h at 37 °C in a 5% CO2 incubator. Cells were fixed with 100 µL of 
10% (w/w) aqueous trichloroacetic acid (TCA), and cellular biomass was stained using 0.057% 
SRB that was solubilized in 10 mM tris base solution. Absorbance was read at 510 nm on a 
SpectraMax Plus 384 plate reader (Molecular Device, Sunny Vale, CA), and the data were 
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plotted as toxin concentration verses percent cell death, as compared to controls. Each 
experiment was done in singlicate with 5 technical replicates done within each plate.  
 
2.11.3 Synthetic Procedures and Compound Characterization 
General Procedure for Rhodanine-Containing Compound Synthesis: 
Alkylation of Isatin 
 In a 25 mL round-bottomed flask, a solution of isatin (1 mmol) and potassium carbonate (2 
mmol) were stirred in acetonitrile (10 mL) at room temperature for 30 min. In a second 25 ml 
round-bottomed flask, a solution of benzylhalide (1 mmol) and potassium iodide (0.1 mmol) 
were stirred in acetonitrile (10 mL) at room temperature for 10 min. Upon completion, the 
solution of benzylhalide/potassium iodide was added dropwise to the stirring solution of 
isatin/potassium carbonate over 10 min. The solution continued to stir at room temperature 
overnight. Upon completion (12 h), the solution was concentrated in vacuo. The resulting solids 
were resuspended in 100 mL of dichloromethane, and filtered to remove any insoluble 
particulates. The solution was concentrated in vacuo to obtain a solid, which was purified 
through trituration by sonication with MeOH (2 mL x 3). Any residual MeOH was concentrated 
to dryness to afford the desired alkylated isatin. 
Condensation of Rhodanine and Isatin 
In a 20 mL relux condenser vial, a solution of alkylated isatin (1 mmol), N-acetic or N-propionic 
acid rhodanine (1 mmol), and sodium acetate (10 mmol) were stirred in acetic acid (4 mL) under 
reflux overnight. Upon completion, the solids were filtered, washed with H2O (30 mL), and dried 
under high vacuum to afford the isatin functionalized rhonanine without any further purification.  
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(E)-3-(5-(5-chloro-1-(2,6-dichlorobenzyl)-2-oxoindolin-3-ylidene)-4-oxo-2-thioxothiazolidin-
3-yl)propanoic acid, 2.3 
1H NMR ((CD3)2SO) δ 8.92 (s, 1H), 7.56 (m, 3H), 7.42 (t, 1H, J = 7.5 Hz), 7.00 (d, 1H, J = 8.5 
Hz), 5.26 (s, 2H), 4.26 (d, 2H, J = 8 Hz), 2.64 (t, 2H, J = 8 Hz) 
 13C NMR ((CD3)2SO) δ 197.3, 172.5, 167.2, 166.8, 143.8, 136.0, 135.2, 132.7, 131.5, 130.4, 
127.6, 127.5, 122.6, 121.3, 111.9, 41.3, 40.9, 31.4  
HRMS (ESI): m/z calculated for C21H14Cl3N2O4S2 (M+H+) 526.9461, found 526.9470 
 
 
(E)-3-(5-(5-bromo-1-(2,6-dichlorobenzyl)-2-oxoindolin-3-ylidene)-4-oxo-2-
thioxothiazolidin-3-yl)propanoic acid, 2.6 
1H NMR ((CD3)2SO) δ 9.03 (s, 1H), 7.65 (br s, 1H), 7.51 (d, 2H, J = 8 Hz), 7.40 (t, 1H, J = 8.5 
Hz), 6.92 (d, 1H, J = 9 Hz), 5.23 (s, 2H), 4.24 (t, 2H, J = 7.5 Hz), 2.63 (t, 2H, J = 7.5 Hz) 
13C NMR ((CD3)2SO) δ 197.3, 172.4, 167.2, 166.7, 144.2, 136.0, 135.5, 135.2, 131.5, 130.4, 
130.3, 129.8, 122.5, 121.7, 115.2, 112.4, 41.3, 39.7, 31.5,  
HRMS (ESI): m/z calculated for C21H14BrCl2N2O4S2 (M+H+)  570.8955, found 570.8956 
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(E)-3-(5-(5-bromo-1-(2-chloro-6-fluorobenzyl)-2-oxoindolin-3-ylidene)-4-oxo-2-
thioxothiazolidin-3-yl)propanoic acid, 2.7 
1H NMR ((CD3)2SO) δ 9.00 (d, 1H, J = 2.0 Hz), 7.66 (dd, 1H, J = 2.1 Hz, J = 8.5 Hz), 7.41 (dt, 
1H, J = 6.0 Hz, J = 8.1 Hz), 7.36 (d, 1H, J = 7.7 Hz), 7.24 (t, 1H, J = 8.6 Hz), 6.98 (d, 1H, J = 
8.5 Hz), 5.13 (s, 2H), 4.24 (t, 2H, J = 7.8 Hz), 2.62 (t, 2H, J = 7.8 Hz ) 
13C NMR ((CD3)2SO) δ 196.5, 171.7, 166.5, 165.9, 161.3 (d, J = 249.6), 143.4, 134.9, 134.5, 
134.2 (d, J = 5.3), 131.0 (d, J = 9.9), 129.7, 125.9 (d, J = 3.0), 121.8, 120.9, 120.4 (d, J = 16.3), 
114.9 (d, J = 22.4), 114.5, 111.5, 40.1, 40.0, 39.9, 39.8, 39.8, 39.7, 39.6, 39.5, 39.3, 39.2, 39.0, 
36.5 (d, J = 3.0), 30.76 
HRMS (ESI): m/z calculated for C21H14BrClFN2O4S2 (M+H+) 554.9251, found 554.9227 
 
 
(E)-4-(5-(5-bromo-1-(2-chloro-6-fluorobenzyl)-2-oxoindolin-3-ylidene)-4-oxo-2-
thioxothiazolidin-3-yl)butanoic acid, 2.8  
HRMS (ESI): m/z calculated for C22H16BrClFN2O4S2  (M+H+) 568.9407, found 568.9416 
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(E)-5-(5-(5-bromo-1-(2-chloro-6-fluorobenzyl)-2-oxoindolin-3-ylidene)-4-oxo-2-
thioxothiazolidin-3-yl)pentanoic acid, 2.9 
1H NMR ((CD3)2SO) δ 9.04 (s, 1H), 7.68 (d, 1H, J = 8.4Hz), 7.41 (dd, 1H, J = 7.9Hz, J = 14.2 
Hz), 7.36 (d, 1H, J = 7.9 Hz), 7.24 (t, 1H, J = 9.0 Hz), 7.00 (d, 1H, J = 8.4 Hz), 5.14 (s, 2H), 4.03 
(t, 2H, J = 7.1 Hz), 2.24 (t, 2H, J = 7.1 Hz), 1.66 (td, 2H, J = 7.4 Hz, J = 14.4 Hz), 1.54 (td, 2H, J 
= 7.0 Hz, J = 14.2 Hz) 
HRMS (ESI): m/z calculated for C23H18BrClFN2O4S2 (M+H+) 582.0564, found 582.9570 
 
 
(E)-4-(5-(5-chloro-1-(2-chloro-6-fluorobenzyl)-2-oxoindolin-3-ylidene)-4-oxo-2-
thioxothiazolidin-3-yl)butanoic acid, 2.10 
1H NMR ((CD3)2SO) δ 8.89 (s, 1H), 7.55 (s, 1H), 7.41 (dt, 1H, J = 6.1 Hz, J = 8.1 Hz) 7.36, (d, 
1H, J = 7.9 Hz), 7.24 (t, 1H, J = 9.2 Hz), 7.05 (s, 1H), 5.15 (s, 2H), 4.09 (t, 2H, J = 6.9 Hz), 2.32 
(t, 2H, J = 7.4 Hz), 1.88 (quin, 2H, J = 7.0 Hz) 
13C NMR ((CD3)2SO) δ 197.0, 173.8, 166.9, 166.0, 161.3 (d, J = 249.7), 142.9, 134.8, 134.3 (d, J 
= 5.3), 131.9, 131.0 (d, J = 10.0), 126.9, 126.8, 126.0 (d, J = 2.8), 121.7, 120.6, 120.4 (d, J = 
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16.3), 114.9 (d, J = 22.4), 110.9, 43.6, 40.0, 39.8, 39.8, 39.7, 39.5, 39.3, 39.2, 39.0, 36.5 (d, J = 
1.8, 1H), 30.9, 22.02 
HRMS (ESI): m/z calculated for C22H16Cl2FN2O4S2 (M+H+) 524.9913, found 524.9924 
 
 
(E)-4-(5-(1-(2-chloro-6-fluorobenzyl)-5-iodo-2-oxoindolin-3-ylidene)-4-oxo-2-
thioxothiazolidin-3-yl)butanoic acid, 2.11 
1H NMR ((CD3)2SO) δ 9.18 (s, 1H), 7.79 (s, 1H), 7.41 (dt, 1H, J = 6.1 Hz, J = 8.1 Hz), 7.35 (d, 
1H, J = 8.0 Hz), 7.24 (t, 1H, J = 9.2 Hz), 6.86 (d, 1H, J = 8.3 Hz), 5.12 (s, 1H), 4.09 (t, 2H, J = 
6.9 Hz), 2.32 (t, 2H, J = 7.3 Hz), 1.88 ( quin, 2H, J = 7.1 Hz) 
13C NMR ((CD3)2SO) δ 197.0, 173.8, 166.9, 166.0, 161.3 (d, J = 249.7), 142.9, 134.8, 134.3 (d, J 
= 5.3), 131.9, 131.0 (d, J = 10.0), 126.9, 126.8, 126.0 (d, J = 2.8), 121.7, 120.6, 120.4 (d, J = 
16.3), 114.9 (d, J = 22.4), 110.9, 43.6, 40.0, 39.8, 39.8, 39.7, 39.5, 39.3, 39.2, 39.0, 36.5 (d, J = 
1.8, 1H), 30.9, 22.02 
HRMS (ESI): m/z calculated for C22H16IClFN2O4S2 (M+H+) 616.9269, found 616.9256 
 
 
N
S
N
OO
S
Cl
I
F
O
HO
 139 
 
(E)-5-(5-(1-(2,6-difluorobenzyl)-5-iodo-2-oxoindolin-3-ylidene)-4-oxo-2-thioxothiazolidin-3-
yl)pentanoic acid, 2.12 
1H NMR ((CD3)2SO) δ 12.03 (s, 1H), 9.23 (d, 1H, J = 1.5 Hz), 7.85 (dd, 1H, J = 8.5, 1.5 Hz), 
7.44 (quin, 1H, J = 6.5 Hz), 7.12 (t, 1H, J = 8 Hz), 6.96 (d, 1H, J = 8.5 Hz), 5.09 (s, 2H), 4.06 (t, 
2H, J = 7 Hz), 2.26 (t, 2H, J = 7 Hz), 1.68 (quin, 2H, J = 6.5 Hz), 1.56 (quin, 2H, J = 7 Hz) 
13C NMR ((CD3)2SO) δ 197.6, 174.9, 167.5, 166.4, 161.6 (dd, J = 247, 6 Hz), 144.3, 141.3, 
136.1, 134.9, 131.6 (t, J = 11 Hz), 122.4, 122.1, 112.7, 112.5 (t, J = 6 Hz), 111.4 (t, J = 18 Hz), 
86.7, 44.6, 33.9, 33.2, 26.7, 22.4  
HRMS (ESI): m/z calculated for C23H18IF2N2O4S2 (M+H+) 614.9721, found 614.9719 
 
 
(E)-4-(5-(5-chloro-1-(2,6-dichlorobenzyl)-2-oxoindolin-3-ylidene)-4-oxo-2-thioxothiazolidin-
3-yl)butanoic acid, 2.13 
1H NMR ((CD3)2SO) δ 8.89 (s, 1H), 7.51 (d, 3H, J = 8.1 Hz), 7.39 (t, 1H, J = 8.1 Hz), 6.97 (s, 
1H), 5.23 (s, 2H), 4.08 (t, 2H, J = 7.0 Hz), 2.32 (t, 2H, J = 7.5 Hz), 1.88 (m, 2H) 
HRMS (ESI): m/z calculated for C22H16Cl3N2O4S2 (M+H+) 540.9617, found 540.9608 
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CHAPTER 3. 
THE DEVELOPMENT OF SMALL MOLECULE INHIBITORS OF APOPTOSIS 
INDUCING FACTOR 
Some information in this chapter has been published by: Chan, L. L., Lidstone, E. A., Finch, K. 
E., Heeres, J. T., Hergenrother, P. J., Cunningham, B. T. A Method for Identifying Small-
Molecule Aggregator Using Photonic Crystal Biosensor Microplates. J Assoc Lab Autom 2009, 
14, 348.   
 
3.1 Targeting the AIF-DNA Interaction as a Drug Target 
Apoptosis inducing factor (AIF), a protein involved in PARP-mediated, caspase-
independent cell death, binds to DNA and causes stage I chromatin condensation. This method of 
cell death is facilitated by the activation of poly(ADP-ribose) polymerase-1 (PARP-1), which 
synthesizes poly(ADP-ribose) (PAR), and through a mechanism that is not fully elucidated, PAR 
causes the release of AIF. This mechanism of cell death is thought to play a major role in 
neuronal cell death in many neurodegenerative diseases such as Parkinson’s disease (PD), and 
Huntington’s disease, along with more acute forms of cell death such as ischemia and stroke. 
Therefore, the disruption of the AIF-DNA interaction has emerged as a potential therapeutic 
target for many neurological disease states. 
 
3.1.1 Biochemistry and Cell Biology of AIF 
AIF is synthesized as a 67 kDa flavoprotein precursor that is converted to mature (57 
kDa) AIF upon mitochondrial import and the removal of the N-terminal mitochondrial 
localization sequence (MLS).1 AIF is comprised of three main domains: a FAD-binding domain, 
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a putative NADH-binding domain, and a C-terminal domain, which contains important DNA-
binding residues (Figure 3.1). AIF has sequence similarity to several bacterial hydrogen peroxide 
scavengers, which suggests it has an oxidoreductase activity in the mitochondria that requires 
flavin adenine dinucleotide (FAD) as a co-factor.1 However, AIF has a separate apoptogenic 
function, once it translocates from the mitochondria to nucleus that does not require FAD.2 
 
 
Figure 3.1. Structure of AIF. AIF is 67 kDa protein comprised of a FAD-binding domain, which is 
required for its oxidoreductase activity, a NADH-binding domain, and a C-terminus domain, which 
contains important DNA binding residues. AIF also has a N-terminal MLS that upon cleavage (to a 57 
kDa protein), translocates through the cytosol to the nucleus via its two NLS’s. MLS: mitochondrial 
localization sequence; NLS: nuclear localization sequence. 
 
 
 The majority of AIF resides in the inner mitochondrial membrane space; however, upon 
insult, AIF is translocated to the nucleus where it binds DNA. Although the exact mechanism of 
AIF’s release from the mitochondria to the nucleus is unknown, it is thought that PARP-1 
activation plays a major role (Figure 3.2).3 Upon massive DNA damage, overactivation of 
PARP-1 causes the accumulation of branched, long chain PAR.  Cytosolic PAR then translocates 
to the surface of the mitochondrion where it releases AIF by an unknown mechanism.4 After its 
release, AIF proceeds through the cytoplasm and enters the nucleus via its nuclear localization 
sequence (NLS). Once in the nucleus, its surface exposed positively charged amino acids forms 
electrostatic interactions with DNA. AIF preferentially binds to single stranded DNA and then in 
a cooperative fashion, invades double stranded DNA.5 At this point, AIF recruits other co-
hAIF, 67 kDa 
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factors, such as cyclophilin A, to cause stage I chromatin condensation and large-scale DNA 
fragmentation (~50 kb).1,6  
 
However, the release of AIF is not limited to PARP-1 mediated mechanisms; the pro-
apoptotic factor Bax has been shown to mediate mitochondrial depolarization as well as the 
release of AIF.7,8 AIF itself is thought to be cleaved from the inner mitochondrial space by 
calpain I, as calpain knockouts prevent AIF release into the cytosol and ultimately prevent 
chromatin condensation in neuronal cells.8,9  
 
 
Figure 3.2. AIF Translocation to the Nucleus. After DNA is damaged, PARP-1 is activated and PAR  is 
synthesized. Next, cytosolic PAR causes the release of AIF through a mechanism that has not been fully 
elucidated. This event results in the translocation of AIF to the nucleus, where it binds to DNA causing 
stage I chromatin condensation and cell death. 
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Recent evidence disputes the necessity of calpain I involvement in the cleavage of AIF 
from the mitochondria. In fact, under conditions where calpain I was not activated, AIF still 
translocated to the nucleus and chromatin condensation was observed.10 Subsequently, a second 
pool of loosely bound AIF was discovered that is located on the cytosolic side of the outer 
mitochondria membrane that translocates to the nucleus upon PARP-1 activation in the brain.11 
Because this second pool of AIF does not have to be cleaved by calpain I, it is hypothesized that 
the outer mitochondrial AIF can be directly released by PAR. Although the exact mechanism of 
AIF release is not understood, there seems to be two separate pools of AIF that have two separate 
mechanisms of release. Despite its originating location, upon release, AIF translocates to the 
nucleus causing chromatin condensation and cell death. 
 
To date, there are no small-molecule inhibitors of AIF, but there are antagonists to its 
apoptogenic activity.  The release of AIF from the mitochondria is prevented by Bcl-2 
upregulation, and its activity is sequestered in the cytosol by a heat shock protein, Hsp70.2,12 The 
upregulation of the anti-apoptotic factor Bcl-2 prevents AIF from leaving the mitochondria; 
however, Bcl-2 has no cytoprotective effects once AIF is in the cytosol.2 The only known 
inhibitor of AIF, thus far, is Hsp70.  Its upregulation antagonizes AIF in the cytoplasm 
preventing it from entering the nucleus and saving the cell from death.12  
 
3.1.2 AIF as a Pharmacological Target for Neurodegenerative Diseases 
The AIF-DNA interaction is a viable target for neurodegenerative disease because of its 
role in PARP-1 mediated caspase-independent cell death, a mechanism of death implicated in 
many neurodegenerative diseases.  The study of AIF has proved difficult because its genetic 
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ablation is embryonic lethal (E9) preventing the examination of AIF knockout (KO) mice.13 
Therefore, other methods were utilized to analyze the specific role of AIF, which include PARP-
1-/- models,4 AIF-specific neutralizing antibodies,2 the partial knockdown of AIF on the genomic 
level in the Harelquin (Hq) mutant mouse,14 and shRNA mediated knockdown of AIF.15 The Hq 
mutation is caused by a proviral insertion into intron 1 of the Aif gene of the X chromosome of 
the Hq mouse causing an 80 % reduction in the RNA and protein levels of AIF.14  
 
The role of PARP-1 in caspase-independent cell death has been investigated in 
immortalized mouse embryonic PARP-1-/- fibroblasts, along with fibroblasts derived from their 
wild-type littermates. Cells were treated for 15 min with 0.5 mM N-methyl-N’-nitro-N-
nitrosoguanidine (MNNG), a DNA-alkylating agent that activates PARP-1 and causes caspase-
independent cell death. After 24 h, cell death was assessed by flow cytometry.4 As expected, cell 
death was observed with wild-type cells (~90%), but the PARP-1-/- fibroblasts were resistant to 
the effects of MNNG (~5%). Accordingly, NAD+ was rapidly depleted in the MNNG treated 
wild-type fibroblasts, while the PARP-1-/- fibroblasts retained NAD+ levels by ~60%, 24 h after 
MNNG treatment. Next, the translocation of AIF in PARP-1-/- fibroblasts was observed by 
microscopy and Western blot, respectively.4 AIF release from the mitochondria was blocked and 
nuclear condensation was prevented in the PARP-1-/- fibroblasts, along with wild-type fibroblasts 
that were treated with a PARP inhibitor, 3,4-dihydro-5-[4-(1-piperidinyl)butoxy]-1(2H)-
isoquinolinone (DPQ). These results suggest that PARP-1 activation triggers AIF translocation to 
the nucleus, and the loss of PARP-1 prevents cell death associated with AIF.  
 
 145 
The cellular effects of AIF were more directly delineated though AIF neutralization, and 
knockout models in glutamate/N-methyl-D-aspartic acid (NMDA) excitoxicity models. The 
NMDA receptor is activated by either its natural substrate (glutamate) or an amino acid 
derivative (NMDA). The overstimulation of the NMDA receptor causes the build-up of calcium, 
which results in ROS production. Next, the ROS causes DNA damage, which activates PARP-1; 
therefore, NMDA excitoxicity is an in vitro method to evaluate PARP-mediated cell death. 
Wang et al. observed AIF translocation, dissipation of the mitochondrial membrane potential, 
exposure of phosphatidylserine on the outer surface of the membrane, and chromatin 
condensation when cortical neurons were exposed to NMDA (500 µM).16 This neurotoxic effect 
was abolished with the treatment of an AIF neutralizing antibody. Thus, these results correlate 
AIF translocation with PARP-1 activation in caspase-independent neuronal death. Additionally, 
the Hq mouse mutation, which is characterized by an 80% down regulation of AIF,14 showed 
protection against glutamate-induced (100 µM, 1 h) excitotoxicity,17 resistance to NMDA (100 
µM, 5 min) treatment, as well as well as protection from PAR toxicity, as compared to wild-type 
cortical neurons.3 The results from both the neutralization and the partial knockout models 
suggest that cytoprotective effects and improved cellular survival can be attributed to lower 
levels of AIF. 
 
Additionally, the apoptogenic effects of AIF were analyzed using the neurotoxin 1-
methyl-4-phenylpyridinium (MPP+). MPP+ is the active metabolite of 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP), which causes parkinsonian like symptoms by inhibiting 
complex I in the electron transport chain resulting in the build-up of free radicals, which 
ultimately leads to neuronal death. AIF was knocked down in a midbrain-derived dopaminergic 
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cell line, MN9D, through shRNA.15 The MN9D cells with reduced expression of AIF showed 
both a decrease in condensed nuclei and an increase in cell viability compared to that of the 
control cells after being treated for 24 h with MPP+.15 These results again confirm that AIF is 
necessary for cell death in multiple neurotoxic models and presents itself as a potential 
pharmacological target for the prevention of neuronal death.   
 
Although the aforementioned studies demonstrate AIF is critical for cell death, they do 
not demonstrate how AIF orchestrates the cell’s demise. Therefore, Ye et al. altered AIF’s ability 
to bind DNA by mutating the positively charged, surface exposed amino acid residues on AIF 
that were thought to be critical for DNA binding. Thus 11 different AIF mutants were made.1 
Although all the AIF-GFP fusion constructs translocated to the nucleus 48 h after transfection, 
some of the mutants’ ability to associate with DNA was reduced or obliterated. In fact, two 
mutants (m255: K255A, R265A; m510: K510A, K518A), with mutations on the unique D3 
domain of AIF, completely lacked the ability to bind DNA, induce chromatin condensation, and 
cause cell death. Of the 11 mutants, seven of them exhibited cell death at 48 h similar to or 
greater than that of the wild-type AIF-GFP fusion protein.1 These results demonstrate that the 
apoptogenic activity of AIF is not due to its ability to be released from the mitochondria or 
translocate to the nucleus, but is dependent upon its ability to bind DNA. Additionally, these 
points of mutation potentially provide places of interest for a small molecule to disrupt AIF’s 
ability to bind DNA. 
 
We hypothesized that a small molecule that could specifically disrupt the AIF-DNA 
interaction could have therapeutic benefits for the treatment of PD and other neurodegenerative 
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diseases. Thus far, there are no small molecule inhibitors of AIF. Ideally, a small molecule 
would interact directly with AIF preventing it from binding DNA, thus prohibiting chromatin 
condensation and caspase-independent cell death. As described in the Chapter 1, for other 
proteins involved in caspase-independent cell death (such as PARP-1), very potent 
pharmacological inhibitors have been identified. However, the inhibition of the AIF-DNA 
interaction could serve as a unique target in this cascading pathway. The research discussed in 
this chapter will focus on the development, synthesis, and analysis of small-molecule inhibitors 
of AIF.  
 
3.2 Screen for Disruptors of the AIF-DNA Interaction 
A gel-based assay was designed and optimized by Dr. James Heeres in order to identify 
inhibitors of the AIF-DNA interaction.18 Briefly, ten compounds per well (200 µM per 
compound) were incubated with AIF (Δ1-128, 18 µg) for 30 min at room temperature.  Next, 16 
µg of linearized pUC19 DNA was added and incubated further for 15 min.  After adding loading 
dye, the samples were electrophoresed for 1 h in a 1% agarose gel. Detection of DNA was 
performed by SYBR green, staining overnight after running the gel.18 A hit compound was easily 
identified because DNA with AIF bound had less mobility in the agarose than free DNA. 
Therefore, an in-house library (~22,000 compounds) was screened, and hit compounds were 
identified and deconvoluted.18 Of the 16 hit compounds, 12 compounds were commercially 
available and were re-ordered and tested. The 12 compounds were tested for dose-dependent 
inhibition of the AIF-DNA interaction at 8 concentrations (0.002, 0.02, 0.2, 2, 20, 100, 200, and 
400 µM) and 5 compounds (3.1, 3.2, 3.3, 3.4, and 3.5) showed potent inhibition (Figure 3.3). 
Next, these 5 compounds were tested for general toxicity in HL-60 cells as assessed by the MTS 
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assay for cell viability, and 3.1 and 3.3 did not possess cellular toxicity. Upon determination of 
full effective concentration (EC50) values, compound 3.3 was identified as a lead compound. 
Additionally, compound 3.5 was investigated further despite its initial toxicity seen in HL-60 
cells. As such, this work will focus on the efforts to determine a structure-activity relationship 
through derivative synthesis and insights into the mechanism of disruption. 
 
Figure 3.3. Five Potent Inhibitors of the AIF-DNA Interaction. An in-house library was screened for 
inhibitors of the AIF-DNA interaction.  Twelve hit compounds, which were commercially available, were 
retested at 8 concentrations (0.002, 0.02, 0.2, 2, 20, 100, 200, 400 µM) with AIF(Δ1-128). After a 30 min 
pre-incubation period at RT, 60 ng of pUC19 DNA was added and the solution incubated further for 15 
min. The mixture was separated via electrophoresis in a 1% agarose gel, and stained overnight with 
SYBR Green I. Of the 12 compounds tested, five compounds (3.1, 3.2, 3.3, 3.4, and 3.5) inhibited the 
AIF-DNA interaction at 400 µM or less.  
 
3.3 Library and In Vitro Data of Compound 3.3 
Because 3.3 showed little toxicity towards the leukemia cell line, 3.3 was initially 
investigated as a molecule that could specifically disrupt the AIF-DNA interaction. In order to 
O
OH
O
OH
O
OHHO
HO
O
3.1
HN
H
N OS
O
O
O2N
O
3.2
N
H
N
OCl
Cl
OH
OH
OH
3.3
N
NH
H
ON
O
Cl
3.4
NN
O
N OH
I
I
3.5
 149 
gain a better understanding of how the compound was disrupting binding, many derivatives of 
3.3 were synthesized and were evaluated in the gel-shift assay, in hopes of developing a structure 
activity relationship and determining the mode of action.  
 
3.3.1 Synthesis of Library 
Because little was known about the structure-activity relationship (SAR) of 3.3 and its 
mechanism of inhibition of AIF, the initial evaluation of the compound yielded sites for 
derivatization including the benzyaldehyde ring, the arylhydrazide ring, and the N-acyl 
hydrazone linker of the molecule. First, 3.3 was re-synthesized through condensation of 
benzylhydrazide 3.6 and benzaldehyde 3.7 under reflux (Scheme 3.1). The crude product was re-
crystallization to yield the desired compound, 3.3. 
 
 
Scheme 3.1. Synthesis of 3.3. 3.3 was identified in the high-throughput screen and was re-synthesized via 
condensation of hydrazide 3.6 and benzaldehyde 3.7. 
 
Furthermore, derivatives of 3.3 were synthesized either through conventional refluxing or 
under microwave heating conditions. By condensing hydrazide with excess aldehyde, 18 N-acyl 
hydrazones were prepared 3.3 a - r (Scheme 3.2, Figure 3.4, Table S3.1).19 Of the 18 derivatives 
synthesized, 8 compounds contained the trihydroxy moiety, while the other 10 compounds 
displayed other benzyl moieties including dihydroxy, methoxy, and methyl groups. As for the 
hydrazide moiety, 5 compounds contained the 2,4-dichlorobenzylhydrazide (3.6) that was in the 
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lead compound, while the other 13 compounds contained other halogens, hydroxy, amino, nitro, 
and methyl groups. However, all 18 compounds were similar in shape, size, and molecular 
weight, plus they all contained the same N-acyl hydrazone linker. 
 
 
Scheme 3.2. Synthesis of 3.3 Derivatives, 3.3 a-r.  18 derivatives of 3.3 were synthesized with 
modifications to both the hydrazide and benzaldehyde portions of the molecule. 
 
 
Figure 3.4. 18 Derivatives of 3.3, 3.3 a-r.  
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Therefore, a single compound was synthesized to probe the importance of the N-acyl 
hydrazone linker. Instead of condensing benzaldehyde 3.7 with a corresponding hydrazide, 3.7 
was condensed with hydrazine 3.8 to provide hydrazone 3.9 (Scheme 3.3). Additionally, the 
reduction of the N-acyl hydrazone and the hydrazone bond in 3.3 and 3.9, respectively, proved to 
be problematic under reducing conditions using sodium cyanoborohydride and hydrogenation 
conditions using Pd/C (10 mol%).  Neither formed the desired product, potentially due to 
coordination of the metal ions with the trihydroxy moiety. Therefore, the reduction of the imine 
bond was abandoned.  
 
 
Scheme 3.3. Synthesis of 3.9. 3.9 was synthesized in order to examine the importance of the N-acyl 
hydrazone linker. 
 
Lastly, efforts were made to synthesize larger, more complex molecules in order to find 
more potent derivatives. Due to the fact that AIF binds DNA in a cooperative manner, the 
potency of the small molecule could be dependent upon its ability to bind within a large binding 
area on AIF. Accordingly, larger compounds have the propensity to bind with stronger affinity to 
protein targets that contain larger binding sites.20 To test this hypothesis, the Sonogashira 
reaction was employed to derivatize the aromatic ring of the hydrazide. As previously discussed, 
the palladium catalyzed cross-coupling reaction had to be performed before benzaldehyde 3.7 
was installed within the molecule in order for the condensation to proceed due to metal 
coordination. Therefore, alkyne 3.10 was cross-coupled to 4-iodoester 3.11 under Sonogashira 
conditions (Scheme 3.4).21 Nucleophilic attack on ester 3.12 by hydrazine afforded 3.13, after 
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purification by column chromatography.  Hydrazide 3.13 was coupled to aldehyde 3.7 using 
methods previously described to yield N-acyl hydrazone 3.14.   
 
 
Scheme 3.4. Synthesis of Alkynyl Derivative 3.14 via Sonogashira Cross-Coupling Reaction. 3.14, the 
largest derivative, was synthesized in order to assess the size of the AIF binding area. 
 
3.3.2 Biochemical Evaluation of Compound 3.3 and Its Derivatives 
Upon synthesis, Dr. James Heeres tested the compounds by gel electrophoresis in the 
method previously described to assess each compound’s ability to disrupt the AIF-DNA 
interaction.  In all cases, compounds constructed from the benzaldehyde building block 3.7 
showed inhibition with the exception of the product from the Sonogashira reaction, 3.14, which 
displayed reduced activity. Interestingly, aldehyde 3.7 itself showed modest inhibition in the 
assay. Therefore, the structure-activity relationship for 3.3 and its derivatives revealed that the 
trihydroxy moiety was necessary for inhibition. Additionally, 3.3 f inhibited the AIF-DNA 
interaction despite only containing a 2,5-dihydoxybenzaldehyde. Regardless of the variety of 
hydrazide groups coupled to benzaldehyde 3.7, no correlation between activity and the 
hydrazides were observed. All compounds coupled to 3.7 had similar inhibition profiles.   
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As discussed in chapter 1, a flat SAR and similar IC50 values can be indicative of an 
aggregating compound.22 Therefore, Dr. James Heeres investigated whether 3.3 and its active 
derivatives were inhibiting the AIF-DNA interaction through the non-specific mechanism of 
compound aggregation. As discussed previously, no one experiment is definitive in determining 
compound aggregation, and therefore, many experiments were employed in order to declare that 
these compounds were promiscuous inhibitors. These experiments included the addition of a 
surfactant (such as Tween 20) or a non-related protein (such as bovine serum albumin, BSA) into 
the buffer conditions, and the evaluation of the compound in a non-related enzymatic assay (such 
as chymotrypsin).   
 
As Dr. James Heeres undertook these experiments, the hypothesis of a non-specific 
mechanism of inhibition by 3.3 was strongly supported by the disruption of binding at high 
concentration of Tween 20 (Figure 3.5 a), compound sensitivity to increasing amounts of BSA 
(Figure 3.5 b), and compound inhibition of chymotrypsin (Figure 3.5 c). Although 3.3 did not 
display loss of activity in the presence of Tween 20 until very high concentrations (between 0.5 
and 1%), compound sensitivity to BSA was noted within the rage typically seen with 
aggregators. In both experiments, the addition of Tween 20 or BSA did not affect DNA’s ability 
to migrate down the gel or AIF’s ability to bind DNA. Lastly, 3.3 inhibited chymotrypsin in a 
dose-dependent manner. Interestingly, 3.3 inhibited chymotrypsin (109 µM) within 2-fold of its 
IC50 value for AIF (47 µM), a result that supports the notions that 3.3 was a non-specific 
inhibitor of AIF.  
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Figure 3.5. Promiscuity Data of 3.3. a) A decrease in 3.3’s inhibition of the AIF-DNA interaction is 
noted when tested in the presence of increasing concentrations of Tween 20. AIF(Δ1-128) was pre-
incubated with 200 µM of 3.3 and buffer containing the detergent Tween 20 (0, 0.01, 0.05, 0.1 0.5, 1, 5%) 
for 30 min at RT. 60 ng of pUC19 DNA was added to the solution and incubated for 15 min. After adding 
loading dye, the solution was separated by electrophoresis for 1 h in a 1% agarose gel, and stained with 
SYBR green I overnight. b) The ability of 3.3 to inhibit the AIF-DNA interaction was abrogated in the 
presence of increasing concentrations of BSA. The assay was run as previously described except with 
buffer containing BSA (0, 0.04, 0.08, 0.2, 0.4, 0.8, 1.2, 1.6, 2 mg/mL). c) Compound 3.3 inhibits 
chymotrypsin, a non-related enzyme, in a dose-dependent manner. Increasing concentrations of 3.3 were 
pre-incubated with chymotrypsin (20 ng/mL) for 30 min at RT. Substrate was added (final concentration 
200 µM) and absorbance was read at 405 nm for 15 min. D: DNA alone with 1% DMSO; A: DNA plus 
AIF with 1% DMSO. 
 
 
Therefore, 3.3 and its derivatives were abandoned as data suggests these compounds form 
aggregates that non-specifically inhibit AIF.  Additionally, compounds containing the trihydroxy 
motif have appeared to inhibit a variety of targets in in vitro assays including MurC, and 
MurD.23,24 Subsequently, trihydrozybenzaldehyde 3.7 has been isolated from the A. leptopus tea, 
and has been shown to inhibit cyclooxygenase (COX-1 and COX-2).25 Because of their 
aggregating properties, these compounds were used as proof-of-concept that a novel technology, 
0 
0.2 
0.4 
0.6 
0.8 
1 
1.2 
1.4 
0 1 2 3 4 5 6 7 8 9 10
 
11
 
12
 
13
 
14
 
15
 
nm
ol
 p
N
A 
pr
od
uc
ed
 
Time (min) 
0 uM 
1.25 uM 
2.5 uM 
5 uM 
12.5 uM 
25 uM 
50 uM 
100 uM 
200 !"#
a) b) 
c) 
D      A      0    0.01  0.05  0.1   0.5    1      5 
200 µM 3.3  + % Tween 20 
D     A     0  0.04  0.08 0.2  0.4  0.8 1.2   1.6   2 
200 µM 3.3  +  BSA (mg/mL) 
 155 
photonic crystal biosensors, is able to identify large compound aggregates on the biosensor 
surface.26 Therefore, this technology provides yet another method to quickly eliminate a lead 
compound based on a non-specific mechanism of inhibition. 
 
3.4 Synthesis and In Vitro Data of Compound 3.5 
Although initial toxicity to HL-60 cells were seen with 3.5, derivatives of this compound 
were synthesized in order to increase potency, determine a structure-activity relationship (SAR), 
resolve the mechanism of inhibition, and identify a derivative that is non-toxic to human cells. 
 
3.4.1 Synthesis of Library 
After assessing the ability of 3.5 to inhibit the AIF-DNA interaction in the presence 
Tween 20 and BSA, Dr. James Heeres was able to conclude that 3.5 was not a promiscuous 
inhibitor of AIF because neither detergent nor BSA attenuated its activity. Therefore, 3.5 was re-
synthesized along with a library of its derivatives in order to systematically gain insight into the 
SAR; derivitizations included modifications to the aldehyde, the amine, and the imine bond. 
 
A short synthetic route was devised to synthesize 3.5 and its derivatives; however, the 
desired furazan ring (3.16 a) had to first be synthesized.  Furazan ring 3.16 a was made in a one-
pot, two-step synthesis starting with ethyl acetoacetate (Scheme 3.5, 3.15 a).27 The methyl group 
on 3.16 a was modified to ethyl, and propyl groups (3.16 b, c, respectively), in order to probe the 
importance of the methyl group and to see if larger alkyl chains could be tolerated. 
 156 
 
Scheme 3.5. Synthesis of 3.16 a-c. Furazan 3.16 a was synthesized in order to re-synthesize the lead 
compound, 3.5. Additionally derivatives (3.16 b-c) were made to examine the length of the alkyl chain. 
 
Next, 3.16 a was condensed with commercially available 3,5-diiodosalicylaldehyde (3.17) under 
microwave heating conditions to afford 3.5 (Scheme 3.6). 
 
 
Scheme 3.6. Synthesis of 3.5. 3.5 was identified in a high-throughput screen and was re-synthesized via 
condensation of furazan 3.16 a and benzaldehyde 3.17. 
 
 
In order to develop a more comprehensive SAR, the aldehyde portion of the molecule was 
derivatized. The 3 furazan rings, 3.16 a-c, were condensed with 17 different aldehydes to afford 
27 structurally unique imines, 3.5 a-aa (Scheme 3.7, Figure 3.6, Table S3.2). The 17 aldehydes 
were decorated with halogens, hydroxyls, and amines. 
 
 
Scheme 3.7. Synthesis of 3.5 Derivatives, 3.5 a-aa.  27 derivatives of 3.5 were synthesized with 
modifications focusing on the benzaldehyde portions of the molecule. 
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Figure 3.6. 27 Derivatives of 3.5, 3.5 a-aa. 
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Next, various amines were used while salicylaldehyde 3.17 was left unmodified. Therefore, four 
anilines (Scheme 3.8) and five primary amines (Scheme 3.9) were coupled to salicylaldehyde 
3.17 as previously described to afford imines 3.18 a - d and 3.19 a - e (Figure 3.7, Table S3.2). 
 
Scheme 3.8. Synthesis of 3.5 Derivatives, 3.18 a-d.  Four derivatives of 3.5 were synthesized by coupling 
anilines to benzaldehyde 3.17. 
 
 
Scheme 3.9. Synthesis of 3.5 Derivatives, 3.19 a-ae.  Five derivatives of 3.5 were synthesized by 
condensing primary amines with benzaldehyde 3.17. 
 
 
 
Figure 3.7. Nine Derivative of 3.5, 3.18 a-d and 3.19 a-d. 
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After making major changes to the amine portion of the ring (3.18 a-d, 3.19 a-e) and the 
aldehyde portion of the ring (3.5 a-aa), more systematic derivatives were synthesized in order to 
determine the necessity of the two aryl iodines, the hydroxyl group, and the imine on 3.5. One 
derivative was prepared to examine the effect of having a single iodo group in the para-position 
on benzealdehyde, but the corresponding starting aldehyde was not commercially available. 
Therefore, benzoic acid 3.20 was converted to the Weinreb amide (3.21) where it was reduced to 
aldehyde 3.22 using DIBAL-H.28,29 The resulting aldehyde, 3.22, was coupled to furazan 3.16 a 
to afford imine 3.23 (Scheme 3.10, Table S3.2).   
 
 
 
Scheme 3.10. Synthesis of 3.23. 3.23 was synthesized in order to examine how the iodo groups in the 3- 
and 5-positions on benzaldehyde 3.17 affect activity. 
 
Next, a compound with a singe halogen in the 3-position on salicylaldehyde was 
synthesized. Although 3-iodosalicylaldehyde was the most logical derivative to make based on 
the activity of 3.5, limitations in the substrate scope for directed ortho metalations prevented 3-
iodosalicylaldehyde from being easily constructed. Therefore, 3-chlorosalicylaldehyde was 
synthesized in order to evaluate the necessity of halogens in the 5-position. Phenol 3.24 was 
subjected to directed ortho metalation conditions to yield aldehyde 3.26, which was then coupled 
to furazan 3.16 a to provide imine 3.27 (Scheme 3.11, Table S3.2).30,31 
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Scheme 3.11. Synthesis of 3.27. 3.27 was synthesized through a directed ortho metalation to yield 3.26 
followed by condensation with 3.16 a in order to systematically remove the 5-positioned chloro group 
and evaluate how its removal affects the activity of 3.27.  
 
 
Next, the necessity of the hydroxyl group was probed through the synthesis of the methoxy 
benzyaldehyde (3.28). The hydroxyl group of aldehyde 3.17 was methylated using methyl iodide 
to afford 3.28,32 which was coupled with 4-iodoaniline (3.29) under standard conditions to yield 
imine 3.30 (Scheme 3.12, Table S3.2).  
 
 
 
Scheme 3.12. Synthesis of 3.30. 3.30 was synthesized in order to assess the necessity of the 2-positioned 
hydroxyl group.  
 
A systematic derivative was prepared to examine whether the activity of 3.5 was dependent upon 
a labile imine bond. Therefore, the imine bond of compound 3.5 was reduced to form the 
secondary amine (3.31) through a reductive amination using sodium cyanoborohydride (Scheme 
3.13).33 
 
Scheme 3.13. Synthesis of 3.31. The imine bond of 3.5 was reduced to yield 3.31 to determine how this 
modification affects activity.  
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Additionally, the linker was modified further by coupling hydroxylamine 3.32 to salicylaldehyde 
3.33 to afford oxime 3.34 (Scheme 3.14). Oximes, in general, are more stable than imines, and 
therefore, this derivative also explores whether the activity of 3.5 is based upon the reversible 
hydrolysis of the imine bond. 
 
Scheme 3.14. Synthesis of 3.34. Oxime 3.34 was synthesized to improve linker stability. 
 
  
Lastly, a set of derivatives was synthesized in order to compare the size and electronics of 
installed groups with the iodides of 3.5. First, a compound was synthesized in which methyl 
groups occupied the 3 and 5 positions on salicylaldehyde. Because methyl groups are smaller 
than the halogens on the previously assessed 3,5-dichloro-, and diiodosalicylaldehydes, the 
dimethyl derivative could show if there is a relationship between compound activity and size. 
Therefore, 3,5-dimethylsalicylaldehyde (3.36) was easily synthesized by subjecting 2,4-
dimethylphenol (3.35) to formaldehyde, magnesium chloride, and triethylamine.34,35 Next, 3.36 
was coupled to aniline (3.37) to produce imine 3.38 (Figure 3.15, Table S3.2).  
 
 
 
Scheme 3.15. Synthesis of 3.38. 3.38 was synthesized to further probe the size of groups that can be put in 
the 3- and 5-positions on the benzaldehyde ring without losing activity. 
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The last derivative synthesized included an electron withdrawing group, similar to that of the 
iodo groups on 3.5, in order to determine if it is simply the electronic capabilities of the iodo 
groups that are promoting inhibition. Therefore, commercially available 4-cyanobenzaldehyde 
(3.39) was coupled to furazan 3.16 a to afford imine 3.40 (Scheme 3.16, Table S3.2) 
 
 
Scheme 3.16. Synthesis of 3.40. In order to explore the affect of electron withdrawing groups on activity, 
3.40 was synthesized. 
 
3.4.2 Biochemical Evaluation of Compound 3.5 and Its Derivatives 
In conjunction with Dr. James Heeres, all the previously synthesized compounds were 
assessed in the gel-shift assay as previously described. Briefly, increasing concentrations of 
compounds (0.5-200 µM) were incubated with AIF (Δ1-128, 15-30 µg) for 30 min at room 
temperature. Next, 60 ng of linearized pUC19 DNA was added and incubated for an additional 
15 min.  After adding loading dye, the samples were electrophoresed for 1 h in a 1% agarose gel. 
Detection of DNA was performed by SYBR green I post staining overnight.18 The first 28 
compounds, 3.5, and 3.5 a – aa, gave initial insights into the SAR. All three furazan rings (3.16 a 
– c) were well tolerated; however, compounds lacking halogens in the 3- and 5-positions on 
salicylaldehyde loss complete activity. Interestingly, varying degrees of inhibition were seen 
with compounds containing the dichlorosalicylaldehyde motif; however, in general, they were 
less potent than compounds containing diiodosalicylaldehyde, 3.17 (Figure 3.8, Figure S3.1).  
Despite synthesizing compounds coupled to anilines, 3.18 a – d, and primary amines, 3.19 a – e, 
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neither class of imines affected activity; in fact, all nine compounds displayed varying but 
similar degrees of inhibition (Figure 3.8, Figure S3.1).   
 
Figure 3.8. Imine-Containing Compound Inhibition of the AIF-DNA Interaction. Three libraries of 
compounds were synthesized including a variety of benzaldehydes, primary amines, and anilines, in order 
to develop a SAR. After testing the compounds in the gel-shift assay, it was seen that any imine-based 
compound containing 3,5-diiodosalicylaldehyde was well tolerated. Compounds containing the 3,5-
dichlorosalicylaldehyde moiety were also able to inhibit the AIF-DNA interaction, with decreased 
potency.   
 
 
Even though many systematic derivatives to the diiodosalicylaldehyde 3.17 portion of the 
molecule and the imine linker were synthesized, it became evident that even the loss of a single 
halogen (3.27, 3.23) would cause great reduction in activity. However, the hydroxyl group was 
found to be dispensable (see section 3.4.3) although the methoxy containing compound, 3.30, 
showed no activity. Additionally, it was concluded that neither size nor electronic effects altered 
inhibition because neither 3.38 nor 3.40 inhibited the AIF-DNA interaction. Lastly, the imine 
bond was deemed necessary because its reduction, which afforded amine 3.31, completely 
ablated activity, as did its replacement with an oxime in compound 3.34. Due to the known 
reversibility of imine bonds, further studies were performed to investigate the stability of these 
compounds. 
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3.4.3 Aldehyde Modification of AIF 
In order to assess the stability of the compounds, 3.5 was subjected to the AIF buffer for 
9 h. Upon extraction, compound integrity was analyzed by NMR. Despite most of the imine 
being intact, peaks corresponding to diiodosalicylaldehyde 3.17 were identified in a 1 to 10 ratio 
(Figure 3.9).  
             
Figure 3.9. NMR spectrum of 3.5 stability. A 10 mM stock of 3.5 was made in DMSO and diluted to 200 
µM in AIF buffer for a total volume of 275 mL with 0.2% DMSO. The solution was stirred for 9 h, 
extracted with EtOAc, and analyzed by NMR in CDCl3. Peaks corresponding to 3.17 appeared in a 1:10 
ratio of 3.5 to 3.17. 
 
Therefore, commercially available 3,5-dihalogensalicylaldehydes (3.17, 3.33, 3.41, 3.42, 3.43) 
were analyzed by gel shift assay to assess their ability to disrupt the AIF-DNA interaction. 
Interestingly, the aldehydes inhibited the AIF-DNA interaction with similar efficiency as their 
corresponding imine, with 3.17 being the most potent inhibitor (Figure 3.10, Figure S3.2). 
 
Figure 3.10. 3,5-Dihalogensalicylaldehyde Inhibition of the AIF-DNA Interaction. Five salicylaldehydes 
were tested in the gel-shift assay for their ability to inhibit the AIF-DNA interaction. 3.17 was able to 
potently inhibit AIF, which interestingly corresponds to the potency seen with 3.5 in the same assay.  
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Aldehydes are known to covalently modify proteins by forming an imine bond with the 
NH2 group on lysines, causing the protein to be inactivated. Although this interaction is non-
specific, not all aldehydes show reactivity; in fact, MacFarland et al. concluded that an 
aldehyde’s propensity to modify a protein was increased by the addition electron withdrawing 
groups on an aryl aldehyde.36 Therefore, commercially available aryl aldehydes with strong 
electron withdrawing groups, such as nitro groups (3.45, 3.46), along with a synthesized 
aldehyde containing a cyano group (3.46, Scheme S3.1) were analyzed in the gel-shift assay for 
their ability to disrupt the AIF-DNA interaction. However, none of the compounds inhibited AIF 
(Figure 3.11, Figure S3.2). 
 
Figure 3.11. Reactivity of Salicylaldehydes that Contain Electron Withdrawing Groups. Three 
salicylaldehydes that contain electron withdrawing groups were analyzed for their ability to disrupt the 
AIF-DNA interaction. The compounds were tested in the gel-shift assay, and interestingly, none of the 
compounds had an inhibitory effect. 
 
Knowing it was not merely the electron withdrawing nature of the aldehyde that dictated 
the inhibition of the AIF-DNA interaction, a variety of commercially available aldehydes were 
tested in the gel-shift assay. The aldehydes included substituents in the 3, 5- position on the 
salicylaldehyde (3.47), a substituent in the 3-position on the salicylaldehyde (3.48), 
salicylaldehyde (3.49), anisaldehyde (3.50), and an aldehyde with chloro groups in the 3, 4 
positions (3.51), whose corresponding imine (3.5 k) is known to be inactive. Upon testing the 
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aldehydes in the gel-shift assay, none of the 5 aldehydes showed any inhibition (Figure 3.12, 
Figure S3.2). 
 
Figure 3.12. Reactivity of Aldehydes. Five commercially available aldehydes that contain a variety of 
substituents were analyzed for their ability to disrupt the AIF-DNA interaction. The compounds were 
tested in the gel-shift assay, and none of the compounds had an inhibitory effect. 
 
 
Based on the knowledge that 3.17 was the most potent inhibitor of the AIF-DNA 
interaction, a series of 3 benzaldehydes plus 1 ketone, all with iodo groups at 3 and 5 positions, 
were synthesized in order to probe the necessity of the hydroxyl group (3.28; 3.52, Scheme S3.2; 
3.53, Scheme S3.3), and the aldehyde (3.54, Scheme S3.4). Surprisingly, 3.53 was an effective 
inhibitor of AIF, but none of the other derivatives had any success (Figure 3.13, Figure S3.2).   
 
Figure 3.13. Reactivity of Four Diiodo-Containing Compounds. Three diiodo-containing aldehydes and 1 
diioddo-containing ketone were tested in the gel-shift assay to test their ability to disrupt the AIF-DNA 
interaction. Although three of the compounds were inactive, 3.53 was a very potent inhibitor of the 
interaction.  
 
Although a strong SAR was not observed, it could be concluded that aldehyde 3.17 most 
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inhibited AIF as well, albeit not as efficiently. It also seemed as if the hydroxyl group on 3.17 
was dispensable because 3.53 was still active in the assay. Overall, these results indicate that 3.5 
potently inhibits the AIF-DNA interaction; however, the aldehyde portion of the molecule 
dictates inhibition, potentially due to hydrolysis of the imine bond. This is further supported by 
the results that show that the SAR of the aldehydes do not differ from the SAR of their 
corresponding imines. Specifically for the aldehydes, the SAR revealed that halogens in the 3- 
and 5-positions are critical for activity, and potency decreases as the halogens decrease in size. 
Additionally, the hydroxyl group is not necessary for inhibition, although adding larger groups in 
the 2-positions can ablate activity.   
 
To verify that the aldehyde (3.17) from the transient imine (3.5) was indeed modifying 
AIF as hypothesized, AIF was incubated with imine 3.5 (200 µM) under reductive conditions 
(NaCNBH3) for 30 min. The samples were submitted to Dr. Peter Yau at the Protein Sciences 
Facility and analyzed through trichloroacetic acid (TCA) precipitation of the protein followed by 
electrospray ionization mass spectrometry (ESI-MS). As predicted, a mass shift was observed by 
ESI-MS corresponding to an AIF-3.17 adduct (Figure 3.14), confirming that the hydrolysis of 
3.5 resulted in aldehyde 3.17, which was the active species. The exact same adducts were seen 
when aldehyde 3.17 itself was incubated with AIF in the same reduced environment (Figure 
3.14).  
 168 
 
 
Figure 3.14. Aldehyde Modification of AIF. AIF(Δ1-128, 200 µM) was incubated with a) DMSO (1%), b) 
imine 3.5 (200 µM), or c) aldehyde 3.17 (200 µM) for 30 min in the presence of reductant NaCNBH3 (1 
mg/mL) in AIF buffer. The samples were precipitated by TCA and analyzed by ESI-MS. The DMSO 
treated sample showed a peak corresponding to the weight of AIF alone. However, samples treated with 
either 3.5 or 3.17 showed similar mass-adducts corresponding to protein modification by 3.17. 
 
Similar results were also observed when other active aldehydes, 3.41, and 3.33, were 
incubated with AIF in reduced conditions and analyzed by ESI-MS (Figure 3.14). However, 
covalently modified AIF peaks were not observed when inactive aldehyde 3.51 was incubated 
under the same conditions (Figure 3.15). Dr. James Heeres also showed that the active aldehydes 
were able to modify other non-related proteins, such as myoglobin and lysozyme.18 Although we 
suspect lysine residues to be the target, unfortunately, the exact amino acids that were modified 
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by the aldehydes were never able to be identified.  
 
 
Figure 3.15. Aldehyde Modification of AIF. AIF(Δ1-128) was incubated with a) 3.33, b) 3.41, or c) 3.51 
for 30 min in the presence of reductant NaCNBH3 (1 mg/mL) in AIF buffer. The samples were 
precipitated by TCA and analyzed by ESI-MS. Samples treated with either active aldehyde, 3.33 or 3.41, 
showed mass-adducts indicative to AIF being modified by the corresponding aldehyde. However, the 
sample treated with the inactive aldehyde, 3.51 did not show new mass-adducts. 
 
 
It was concluded that 3.5 was not actively inhibiting AIF, but rather its component 3.17 
was modifying AIF, preventing it from binding to DNA. This conclusion is supported by the fact 
that when the imine was reduced to an amine (3.31), thus preventing compound hydrolysis and 
the production of aldehyde 3.17, the compound no longer had inhibitory activity. Additionally, 
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covalent adducts were observed by ESI-MS under conditions similar to the assay. Therefore, 
3.17 could potentially be used to modify proteins through modification via lysine residues. 
 
Currently, there are many methods being studied to facilitate specific protein labeling 
strategies in aqueous medium. Limitations in organic chemistry have made cross-couplings 
difficult with proteins. However, advances in the field have proven that proteins can be modified 
through cross-coupling reactions using iridium,36 rhodium,37 copper,38,39 and palladium40-42 
catalysts with great chemoselectivity. Most of these methods have proven efficient in modifying 
proteins with fluorescent dyes for imaging, or azides for activity profiling. However, the use of 
specific catalysts can be very cumbersome. In a similar fashion, reactive aldehydes such as 
pyridoxal 5’-phosphate (PLP) have been used to non-specifically label proteins in reduced 
environments.43 Dr. James Heeres conducted competition studies between PLP and 3.17 with a 
model enzyme, and showed that although both compounds were very reactive, 3.17 had a greater 
number of modifications after 1 min of incubation than PLP under the same conditions.18 
Therefore, 3.17 could potentially present a novel compound for effective and efficient protein 
labeling that could be more reactive than PLP. An advantage of using a reactive aldehyde such as 
3.17 for protein modification is that the resulting linkage would be a secondary amine, which 
allows the protein to retain a positive charge on the lysine. This is in contrast to other 
modification methods such as NHS-esters, which form amides with the lysines and cause a 
neutralization of the charge. Furthermore, the synthesis of fluorescently-labeled or biotin-labeled 
derivatives of 3.17 could provide more facile methods for protein imaging or activity profiling. 
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3.5 Summary 
A screen of 22,000 compounds was conducted in a gel-shift assay to identify inhibitors of 
the AIF-DNA interaction. Of the initial five hits that were identified to inhibit AIF in a dose-
dependent manner, two compounds were investigated further. First, derivatives of 3.3 were 
synthesized, and SAR analysis revealed that 2,3,4-trihydroxybenzaldehyde was both necessary 
and sufficient for inhibition. After assessing 3.3’s ability to inhibit AIF in the presence of 
detergent and BSA, as well as inhibit chymotrypsin, it was concluded that 3.3 was an aggregator, 
and efforts to identify novel AIF-DNA inhibitors were shifted to compound 3.5. However, 3.3 
and its derivatives were used to validate that a new technology, photonic crystal biosensors, 
could be used to identify compound aggregates in a similar manner as SPR.  
 
After determining 3.5 was not inhibiting AIF through an aggregation-based mechanism, 
derivatives of 3.5 were synthesized, and SAR analysis revealed that the transient imine bond was 
necessary for inhibition. After testing the reversibility of the imine bond and 3,5-
diiodosalicylaldehyde alone in the gel-shift assay, it was apparent that 3,5-diiodosalicylaldehyde 
was sufficient to prevent AIF binding to DNA. Through mass-spectrometry analysis, new 
aldehyde-AIF adducts were observed, and it was concluded that the highly reactive aldehyde was 
able to modify proteins. This compound was used to explore a novel, facile labeling technique of 
lysine-containing proteins that could be used in the future. 
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3.7 Materials and Methods 
General Methods 
Reaction solvents tetrahydrofuran (Fisher, HPLC grade), methylene chloride (Fisher, 
unstabilized HPLC grade), acetonitrile (Fisher, HPLC grade), and methanol (Fisher, low water) 
were dried by percolation through two columns packed with neutral alumina under a positive 
pressure of nitrogen. All other solvents were obtained from Fisher Scientific and were used 
without further purification. All H2O used was either deionized or purified through a MilliQ 
purification system. 
 
Silica gel for chromatography was performed on EMD Biosciences silica gel 60 (230-400 mesh).  
Chromatography was performed on the Teledyne ISCO CombiFlash Rf MPLC chromatography 
system.  Silica gel provided in pre-packaged cartridges.  Thin-layer chromatography plates 
(Merck, 245 nm fluorescent indicator) were visualized by UV and stained with cerium 
ammonium molybdate (CAM), iodine (I2), and ninhydrin.   
 
Reactions performed under microwave heating conditions were performed in a CEM DiscoverTM 
Series Microwave.  Internal reaction temperatures are reported based on infrared sensing.  
Reaction times are specified as hold times at final temperatures. 
 
All NMR experiments were acquired in the Varian-Oxford Instrument Center for Excellence in 
NMR Spectroscopy (VOICE) laboratory at the University of Illinois at Urbana-Champaign.  
NMR experiments were recorded in CDCl3, CD3OD, and (CD3)2SO on Varian Unity 500 MHz 
spectrometers.  Chemical shift, δ (ppm); coupling constant, J (Hz); multiplicity (s = singlet, d = 
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doublet, t = triplet, q = quartet, quin = quintet, m = multiplet); and integration are reported.  
High-resolution mass spectral data were recorded on a Micromass Q-T of Ultima hybrid 
quadrupole/time-of-flight ESI mass spectrometer at the University of Illinois at Urbana-
Champaign Mass Spectrometry Laboratory. 
 
3.7.1 Supplemental Figures and Schemes 
 Supplemental Figures 
 
 
Figure S3.1. Imine Inhibition of AIF-DNA Interaction. Increasing concentrations of imine (5, 10, 25, 50, 
100, 150, 200 µM) were pre-incubated with AIF(Δ1-128) for 30 min at RT. 60 ng of pUC19 DNA was 
added and the solution incubated further for 15 min. The mixture was separated via electrophoresis in a 
1% agarose gel, and stained overnight with SYBR Green I. It was seen that compounds containing 
aldehyde 3.17 were potent inhibitors of the AIF-DNA interaction, when coupled to furazans (3.5), 
primary amines (3.19 b), and anilines (3.18 a). Also, imines that were afforded by amines coupled to 3,5-
dichlorosalicylaldehydes (3.5 y) also inhibited the AIF-DNA interaction, but with less potency. D: DNA 
(1% DMSO), A: DNA + AIF (1% DMSO). 
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Figure S3.2. Aldehyde Inhibition of AIF-DNA Interaction. Increasing concentrations of aldehyde (5, 10, 
25, 50, 100, 150, 200 µM) were pre-incubated with AIF(Δ1-128) for 30 min at RT. 60 ng of pUC19 DNA 
was added and the solution incubated further for 15 min. The mixture was separated via electrophoresis in 
a 1% agarose gel, and stained overnight with SYBR Green I. Results from the gel shift assay revealed that 
3.5-dihalogensalicylaldehydes inhibited the AIF-DNA interaction, but potency decreased as the halogens 
decreased in size. Electron withdrawing groups did not have an effect in potency, and neither did simply 
having substituents in the 3, and 5 positions on the benzaldehyde ring. Lastly, it was seen that the 
hydroxyl group on 3.17 was dispensable but other larger groups in the 2-position were not well tolerated. 
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Supplemental Schemes 
 
Scheme S3.1. Synthesis of 2-Iodo-5-nitrilesalicylaldehyde, 3.46.  
 
 
Scheme S3.2. Synthesis of 3,5-diiodo-2-(prop-2-yn-1-yloxy)benzaldehyde, 3.52.  
 
 
 
 
Scheme S3.3. Synthesis of 3,5-diiodobenzaldehyde, 3.53.  
 
 
 
 
Scheme S3.4. Synthesis of 1-(2-hydroxy-3,5-diiodophenyl)ethanone, 3.54. 
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3.7.2 Biological Protocols 
AIF gel-shift assay 
Dr. James Heeres generated linearized pUC19 DNA in mini-prep elution buffer (10 mM Tris, pH 
8.3) as detailed in his thesis.18 Compound or DMSO (control) was preincubated with 15-30 µg of 
purified AIF (Δ1-128), depending on propensity to bind DNA, for 30 min at room temperature in 
AIF assay buffer (50 mM Tris, 100 mM NaCl, pH 8.0) at a volume of 20 µL. Next, 60 ng of 
linearized DNA was added to solution to bring the total volume to 25 µL, and the solution 
incubated at room temperature for 15 min. 5 µL of Blue/orange loading dye (Promega) was 
added to each sample, and 12.8 µL of each sample was loaded on a 1% agarose gel. The gel was 
electrophoresed for 1 h at 10 W. Gels were stained overnight with SYBR green I (Cambrex) 
(diluted in TAE buffer) and imaged by a BioRad gel imager. Bands were analyzed by 
densitometry using ImageJ. 
Mass spectrometry analysis 
AIF(Δ1-128, 200 µM) was incubated with DMSO (1%) or compound (200 µM) for 30 min in 
AIF buffer at 25 °C to a volume of 25 µL. The reducing agent, NaCNBH3 (1 mg/mL) was added, 
and the solution continued to incubate for 10 min at 25 °C. The samples were submitted and 
analyzed by Dr. Peter Yau at the Protein Sciences Facility at UIUC. The samples were 
precipitated by TCA and analyzed by ESI-MS using a Water Q-ToF API-US mass spectrometer.  
Compound stability assay 
A 10 mM stock of 3.5 was made in DMSO (25.0 mg in 5.49 mL). In a 500 mL round-bottomed 
flask, the 10 mM DMSO stock of 3.5 was diluted to 200 µM with 269.01 mL of AIF assay buffer 
(50 mM Tris, 100 mM NaCl, pH 8.0). The solution stirred at room temperature for 9 h, followed 
by compound extraction from the aqueous solution using EtOAc. The organic layer was washed 
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with H2O, dried (MgSO4), and concentrated in vacou. The resulting compound was analyzed by 
NMR in CDCl3.  
 
 
3.7.3 Synthetic Procedures and Compound Characterization 
 
 
General procedure for compound 3.3 and its derivatives: 
 
Compounds 3.3, and 3.3 a – j: In a 50 mL round-bottomed flask, a solution of hydrazide A (X 
mmol), aldehyde B (Y mmol), and hydrochloric acid (5 mol%) in ethanol (3-mL) was heated 
under reflux for 4 hours and cooled to room temperature. 
Compounds 3.3 k – r:  In a 10 mL microwave vessel, a solution of hydrazide A (X mmol), 
aldehyde B (Y mmol), and hydrochloric acid (5 mol%) in ethanol (3 mL) was heated via the 
CEM discover microwave at 110 °C for 5 min at a power of 300 Watts.   
 
Work-Up: 
A: precipitated/recrystallization: Upon completion, the crude material was recrystallized in 
ethanol/H2O (50/50).  The mixture was filtered and the crystals were washed with cold H2O to 
afford the N-acyl hydrazone. 
N
H
NH2
O
H
O
N
H
N
OHCl (5 mol%)
EtOH, µwave
8-95%
R
R R
R
 181 
B: Column chromatography: Upon completion, the reaction solution was concentrated in vacou.  
The crude material was purified by chromatography (Hexane/ ethyl acetate, see chart) to provide 
the N-acyl hydrazone. 
Table S3.1. Derivatives of Compound 3.3. 
Compound  mmol A mmol B Work-up  
Amount 
(mg) Percent yield 
3.3 0.244 0.366 A 56.3 68% 
3.3 a 0.232 0.348 B (60/40) 77.3 37% 
3.3 b 0.329 0.493 B (60/40) 42.1 42% 
3.3 c 0.224 0.366 B (50/50) 16.1 21% 
3.3 d 0.200 0.300 B (70/30) 49.0 84% 
3.3 e 0.244 0.366 A 31.4 42% 
3.3 f 0.200 0.300 A 17.4 27% 
3.3 g 0.200 0.300 A 6.1 8% 
3.3 h 0.333 0.500 A 63.9 67% 
3.3 i 0.300 0.450 A 40.7 45% 
3.3 j 0.200 0.300 A 28.4 52% 
3.3 k 0.200 0.300 A 55.2 77% 
3.3 l 0.329 0.493 A 77.2 82% 
3.3 m 0.301 0.451 A 68.2 75% 
3.3 n 0.276 0.414 A 62.3 71% 
3.3 o 0.333 0.499 A 53.3 59% 
3.3 p 0.333 0.449 A 42.6 47% 
3.3 q 0.333 0.500 A 85.7 95% 
3.3 r 0.316 0.474 A 54.7 59% 
  
2,4-Dichloro-benzoic acid (2,3,4-trihydroxy-benzylidene)-hydrazide, 3.3 
1H NMR ((CD3)2SO) δ (1 rotamer A: 0.5 rotamer B) 12.00 (s, 1H, rotamer A), 11.97 (s, 0.5H, 
rotamer B), 11.10 (s, 1H, rotamer A), 9.52 (s, 1H, rotatmer A), 9.45 (s, 0.5H, rotamer B), 9.44 (s, 
0.5H, rotamerB), 8.49 (s, 1H, rotamer A), 8.39 (s, 0.5H, rotamer B), 8.28 (s, 0.5H, rotamer B), 
8.11 (s, 0.5H, rotamer B), 7.76 (d, J= 2.0 Hz, 0.8H, rotamer A), 7.75 (d, J= 2.0 Hz, 0.4H, 
rotamer B), 7.64 (s, 0.4H, rotamer B), 7.62 (s, 0.6H, rotamer A), 7.60 (d, J= 2.0 Hz, 0.6H, 
rotamer A), 7.54 (d, J= 2.0 Hz, 0.5, rotamer A), 7.53 (d, J= 2.0 Hz, 0.4H, rotamer A), 7.51 (s, 
0.4H, rotamer A), 6.79 (d, J= 8.5 Hz, 1H, rotamer A), 6.62 (d, J= 8.5 Hz, 0.5H, rotamer B), 6.37 
(d, J= 8.5 Hz, 1H, rotamer A), 6.30 (d, J= 8.5 Hz, 0.5H, rotamer B)  
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HRMS (ESI): m/z calculated for C14H10N2O4Cl2 (M+H+) 341.0018, found 341.0096 
 
3-Bromo-benzoic acid (3-methoxy-benzylidene)-hydrazide, 3.3 a 
1H NMR ((CD3)2SO) δ 11.92 (s, 1H), 8.40 (s, 1H), 7.84 (d, J= 8.3 Hz, 2H) 7.74 (d, J= 8.3 Hz, 
2H), 7.37 (t, J= 7.3 Hz, 1H), 7.27 (d, J= 7.0 Hz, 2H), 7.00 (m, J= 7.0 Hz, 1H), 3.79 (s, 3H) 
HRMS (ESI): m/z calculated for C15H13N2O4Br (M+H+) 333.0160, found 333.0239 
 
3-Hydroxy-benzoic acid (3,4-dichloro-benzylidene)-hydrazide, 3.3 b 
1H NMR ((CD3)2SO) δ 11.96 (s, 1H), 9.77 (s, 1H), 8.39 (s, 1H), 7.94 (s, IH), 7.71 (s, 2H), 7.30 
(d, J= 6.4 Hz, 2H), 7.28 (d, J=6.5 Hz, 1H), 6.97 (m, 1H) 
 
2,4-Dichloro-benzoic acid (3-hydroxy-benzylidene)-hydrazide, 3.3 c 
1H NMR ((CD3)2SO) δ (1 rotamer A: 0.7 rotamer B) 11.99 (s, 1H, rotamer A), 11.98 (s, 0.7 H, 
rotamer B), 9.65 (s, 1H, rotamer A), 9.55 (s, 0.7H, rotamer B), 8.14 (s, 1H, rotamer A), 7.95 (s, 
0.7H, rotamer b), 7.76 (d, J= 2 Hz, 1H, rotamer A), 7.72 (d, J= 1.8 Hz, 0.7H rotamer B), 7.62 (s, 
0.3H, rotamer B) 7.60 (s, 0.5H, rotamer A) 7.56 (d, J= 2 Hz, 0.6H, rotamer A) 7.54 (d, J= 2 Hz, 
0.3H, rotamer B), 7.52 (d, J= 1.8 Hz, 0.2H, rotamer B) 7.50 (d, J= 1.9 Hz, 0.5H, rotamer A) 7.48 
(s, 0.5H, rotamer A) 7.46 (s, 0.2H, rotamer A) 7.24 (t, J= 7.9 Hz, 1H rotamer A), 7.17 (m, J= Hz, 
1H, rotamer A), 7.14 (t, J= 7.8 Hz, 0.7H, rotamer B), 7.07 (m, 0.8H, rotamer B) 6.82 (m, 2H, 
rotamer A) 6.74 (m, 1.5H, rotamer B)   
 
2,4-Dichloro-benzoic acid benzylidene-hydrazide, 3.3 d 
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1H NMR ((CD3)2SO) δ (1 rotamer A: 0.7 rotamer B) 12.02 (s, 0.5H, rotamer B), 11.98 (s, 1H, 
rotamer A), 8.24 (s, 1H, rotamer A), 8.04 (s, 0.7H, rotamer B), 7.76 (d, J= 2.1 Hz, 0.7H, rotamer 
B), 7.73-7.70 (m, 2.6, rotamer B), 7.62 (s, 0.3H, rotamer B), 7.60 (s, 0.6H, rotamer A), 7.55 (dd, 
J= 8.0, 2.1 Hz, 1H, rotamer A), 7.52 (dd, J= 8.1, 2.1 Hz, rotamer B), 7.47-7.43 (m, 2.4, rotamer 
A and B), 7.43 (d, J= 2.0 Hz, 1H, rotamer A), 7.38-7.33 (m, 4H, rotamer A)  
HRMS (ESI): m/z calculated for C14H10N2OCl2 (M+H+) 293.0170, found 293.0248 
 
2,4-Dichloro-benzoic acid (4-methyl-benzylidene)-hydrazide, 3.3 e 
1H NMR ((CD3)2SO) δ (1 rotamer A: 0.3 rotamer B), 8.15 (s, 1H, rotamer A), 7.95 (s, 0.3H, 
rotamer B), 7.70 (d, J= 8.1 Hz, 2H, rotamer A), 7.63 (d, J= 1.9 Hz, 1H, rotamer A), 7.58 (s, 1H, 
rotamer A), 7.56 (s, 1H, rotamer B), 7.49 (d, J= 1.9 Hz, 1H, rotamer A), 7.47 (d, J= 1.9 Hz, 
0.3H, rotamer B), 7.43 (d, J= 1.9 Hz, 1H, rotamer B), 7.31 (d, J= 8.1 Hz, 0.7H, rotamer B), 7.26 
(d, J= 8.1 Hz, 2H, rotamer A), 7.15 (d, J= 8.1 Hz, 0.6H, rotamer B), 2.38 (s, 3H, rotamer A), 
2.31 (s, 0.9H, rotamer B)  
HRMS (ESI): m/z calculated for C15H12N2O2Cl2 (M+H+) 307.0327, found 307.0405 
 
2,4-Dichloro-benzoic acid (2,5-dihydroxy-benzylidene)-hydrazide, 3.3 f 
1H NMR ((CD3)2SO) δ (1 rotamer A: 0.6 rotamer B) 12.02 (s, 1H, rotamer A), 12.01 (s, 0.5H, 
rotamer B), 10.05 (s, 1H, rotamer A), 9.21 (s, 0.6H, rotamer B), 8.98 (s, 1H, rotamer A), 8.87 (s, 
0.6H, rotamer B), 8.39 (s, 1H, rotamer A), 8.22 (s, 0.6, rotamer B), 7.76 (dd, J= 2.0, 0.4 Hz, 
0.8H, rotamer A), 7.72 (dd, J= 1.9, 0.4 Hz, 0.4H, rotamer B), 7.63 (d, J= 0.4 Hz, 0.3H, rotamer 
B), 7.61 (d, J= 0.4 Hz, 0.6H, rotamer A), 7.55 (d, J= 2.0 Hz, 0.6H, rotamer A), 7.54 (d, J= 2.0 
Hz, 0.3H, rotamer B), 7.53 (d, J= 1.9 Hz, 0.1 H, rotamer B), 7.51 (d, J= 1.9 Hz, 0.4H, rotamer 
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A), 7.49 (d, J= 0.4 Hz, 0.4H, rotamer A), 7.47 (d, J= 0.4 Hz, 0.1H, rotamer B), 7.00 (dd, J= 2.1, 
0.4 Hz, 1H, rotamer A), 6.72 (m, 1.8H, rotamer B), 6.61 (s, 2H, rotamer A)  
HRMS (ESI): m/z calculated for C14H11N2O3Cl2 (M+H+) 325.0068, found 325.0147 
 
2,4-Dichloro-benzoic acid (3,4,5-trimethoxy-benzylidene)-hydrazide, 3.3 g 
1H NMR ((CD3)2SO) δ (1 rotamer A: 0.5 rotamer B) 8.16 (s, 1H, rotamer A), 7.92 (s, 0.5H, 
rotamer B), 7.77 (d, J= 1.8 Hz, 0.8H, rotamer A), 7.73 (d, J= 1.8 Hz, 0.4H, rotamer B), 7.61 (s, 
0.3H, rotamer B), 7.59 (s, 0.7H, rotamer B), 7.56 (d, J= 1.8 Hz, 0.6H, rotamer A), 7.54 (d, J= 1.8 
Hz, 0.3H, rotamer B), 7.51 (d, J= 1.8 Hz, 0.4H, rotamer A), 7.49 (s, 0.3H, rotamer B), 3.82 (s, 
6H, rotamer A), 3.69 (s, 3H, rotamer A), 3.66 (s, 3H, rotamer B), 3.62 (s, 1.5H, rotamer B) 
HRMS (ESI): m/z calculated for C17H16N2O4Cl2 (M+H+) 383.0487, found 383.0565 
 
4-Methyl-benzoic acid (2,3,4-trihydroxy-benzylidene)-hydrazide, 3.3 h 
1H NMR ((CD3)2SO) δ 11.87 (s, 1H), 11.57 (s, 1H), 9.43 (s, 1H), 8.47 (s, 1H), 8.43 (s, 1H), 7.82 
(d, J= 8.2 Hz, 2H), 7.32 (d, J= 8.2 Hz, 2H), 6.75 (d, J= 8.2 Hz, 1H), 6.37 (d, J= 8.2 Hz, 1H), 2.36 
(s, 3H)  
HRMS (ESI): m/z calculated for C15H14N2O4 (M+H+) 287.0954, found 287.1032 
 
3,4-Diamino-benzoic acid (2,3,4-trihydroxy-benzylidene)-hydrazide, 3.3 i 
1H NMR ((CD3)2SO) δ (1 rotamer A: 0.4 rotamer B) 11.98 (s, 0.4H, rotamer B), 11.82 (s, 1H, 
rotamer A), 11.63 (s, 0.4H, rotamer B), 11.49 (s, 1H, rotamer A), 9.49 (s, 0.3H, rotamer B), 9.43 
(s, 0.4H, rotamer B), 9.33 (s, 1H, rotamer A), 8.53 (s, 0.3H, rotamer B), 8.47 (s, 1H, rotamer A), 
8.41 (s, 1H, rotamer A), 8.35 (s, 1H, rotamer A), 7.84 (d, J= 8.4 Hz, 0.4H, rotamer B), 7.38 (d, 
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J= 8.4 Hz, 0.4H, rotamer B), 7.11 (d, J= 1.6 Hz, 1H rotamer A), 7.05 (dd, J= 8.0, 1.6 Hz, 1H, 
rotamer A), 6.77 (d, J= 8.6 Hz, 0.4H, rotamer B), 6.68 (d, J= 8.2 Hz, 1H, rotamer A), 6.51 (d, J= 
8.2 Hz, 1H, rotamer A), 6.48, (d, J= 8.7 Hz, 0.4 Hz, rotamer B), 6.38 (d, J= 8.7 Hz, 0.4H, 
rotamer B), 6.35 (d, J=8.6  Hz, 1H, rotamer A), 5.13 (s, 2H, rotamer A), 4.71 (s, 2H, rotamer A) 
HRMS (ESI): m/z calculated for C14H14N2O4 (M+H+) 303.1015, found 303.1093 
 
Benzoic acid (2,3,4-trihydroxy-benzylidene)-hydrazide, 3.3 j 
1H NMR ((CD3)2SO) δ 11.95 (s, 1H), 11.52 (s, 1H), 9.47 (s, 1H), 8.50 (s, 1H), 8.44 (s, 1H), 7.89 
(2H), 7.89 (d, J= 7.4 Hz, 2H), 7.59 (m, 1H), 7.52 (m, 2H), 6.76 (d, J= 8.5 Hz, 1H), 6.37 (d, J= 
8.5 Hz, 1H)  
HRMS (ESI): m/z calculated for C14H12N2O4 (M+H+) 273.0797, found 273.0875 
 
4-Bromo-benzoic acid (2,3,4-trihydroxy-benzylidene)-hydrazide, 3.3 k 
1H NMR ((CD3)2SO) δ 12.02 (s, 1H), 11.43 (s, 1H), 9.5 (s, 1H), 8.51 (s, 1H), 8.44 (s, 1H), 7.86 
(d, J= 8.9 Hz, 2H), 7.75 (d, J= 8.9 Hz, 2H), 6.78 (d, J= 8.5 Hz, 1H), 6.38 (d, J= 8.5 Hz, 1H) 
HRMS (ESI): m/z calculated for C14H11N2O4Br (M+H+) 350.9902, found 350.9980 
 
3-Hydroxy-benzoic acid (2,3,4-trihydroxy-benzylidene)-hydrazide, 3.3 l 
1H NMR ((CD3)2SO) δ 11.87 (s, 1H), 11.55 (s, 1H), 9.78 (s, 1H), 9.46 (s, 1H), 8.49 (s, 1H), 8.43 
(s, 1H), 7.30 (m, 3H), 6.96 (m, 1H), 6.75 (d, J= 8.2 Hz, 1H), 6.37 (d, J= 8.3 Hz, 1H)  
HRMS (ESI): m/z calculated for C14H12N2O5 (M+H+) 289.0746, found 289.0824 
 
4-Methoxy-benzoic acid (2,3,4-trihydroxy-benzylidene)-hydrazide, 3.3 m 
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1H NMR ((CD3)2SO) δ 11.83 (s, 1H), 11.60 (s, 1H), 9.44 (s, 1H), 8.48 (s, 1H), 8.42 (s, 1H), 7.90 
(d, J= 8.8 Hz, 2H), 7.05 (d, J= 8.8 Hz, 2H), 6.75 (d, J= 8.8 Hz, 1H), 6.37 (d, J= 8.8 Hz, 1H), 3.82 
(s, 3H)  
HRMS (ESI): m/z calculated for C15H14N2O5 (M+H+) 303.0903, found 303.0981 
 
2-Nitro-benzoic acid (2,3,4-trihydroxy-benzylidene)-hydrazide, 3.3 n  
1H NMR ((CD3)2SO) δ (1 rotamer A: 0.8 rotamer B), 12.13 (s, 1H, rotamer A), 11.90 (s, 1H, 
rotamer A), 9.54 (s, 1H, rotamer A), 9.50 (s, 0.8H, rotamer B), 9.15 (s, 0.8H, rotamer B), 8.52 (s, 
1H, rotamer A), 8.39 (s, 0.8H, rotamer B), 8.28 (s, 1H, rotamer A), 8.17 (m, 1H, rotamer A), 
8.11 (s, 1H, rotamer A), 7.86 (m, 2H, rotamer A), 7.78 (s, 0.8H, rotamer B), 7.76 (s, 0.8H, 
rotamer B), 7.74 (m, 1.7, rotamer B), 7.64 (m. .8H, rotamer B), 6.81 (d, J= 8.3 Hz, 1H, rotamer 
A), 6.54 (d, J= 8.3 Hz, 0.8H, rotamer B), 6.38 (d, J= 8.3 Hz, 1H, rotamer A), 6.25 (d, J= 8.3 Hz, 
0.8H, rotamer B),  
 
4-Methyl-benzoic acid (2,4-dihydroxy-benzylidene)-hydrazide, 3.3 o 
1H NMR ((CD3)2SO) δ 11.83 (s, 1H), 11.50 (s, 1H), 9.45 (s, 1H), 8.47 (s, 1H), 7.81 (d, J= 8.5 
Hz, 2H), 7.32 (d, J= 8.6 Hz, 2H), 7.27 (d, J = 8.7 Hz, 1H), 6.34 (m, 1H), 6.29 (m, 1H) 
 
4-Methyl-benzoic acid (3,4-dihydroxy-benzylidene)-hydrazide, 3.3 p 
1H NMR (CD3OD) δ 8.15 (s, 1H), 7.80 (d, J = 8.1 Hz, 2H), 7.36 (d, J = 1.9 Hz, 1H), 7.31 (d, J = 
8.1 Hz, 2H), 7.04 (dd, J = 8.1, 1.9 Hz, 1H), 6.79 (d, J = 8.1 Hz, 1H), 2.40 (s, 3H) 
 
2,3-dihydroxybenzylidene)-4-methylbenzohydrazide, 3.3 q 
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1H NMR (CD3OD) δ 8.46 (s, 1H), 7.83 (d, J= 8.2 Hz, 2H), 7.34 (d, J= 8.2 Hz, 2H), 6.86-6.91 
(m, 2H), 6.78 (t, J= 6.8 Hz, 1H), 2.42 (s, 3H) 
 
4-Methyl-[1,2,3]thiadiazole-5-carboxylic acid (2,3,4-trihydroxy-benzylidene)-hydrazide, 3.3 
r  
1H NMR (CD3OD) δ (1 rotamer A: 0.6 rotamer B) 8.42 (s, 1H, rotamer A), 8.31 (s, 0.6H, 
rotamer B), 7.28 (d, J= 8.7 Hz, 1H, rotamer A), 6.78 (d, J= 8.7 Hz, 0.6H, rotamer B), 6.59 (d, J= 
8.7 Hz, 1H, rotamer A), 6.44 (d, 8.7 J= Hz, 0.6H, rotamer B), 3.01 (s, 3H, rotamer A), 2.91 (s, 
1.8H, rotamer B)  
HRMS (ESI): m/z calculated for C11H10N4O4S (M+H+) 295.0423, found 295.0501 
 
 
4-(Benzyl-hydrazonomethyl)-benzene-1,2,3-triol, 3.9 
A solution of hydrazine 3.8 (50 mg, 0.256 mmol) and aldehyde 3.7 (59.2 mg, 0.384) in ethanol 
(1 mL) was heated under reflux for 1 hr.  The solution was concentrated in vacou and 
crystallized out of ethyl acetate.  Filtration provided hydrazone 3.9. 
1H NMR (CD3OD) δ 8.59 (s, 1H), 7.51 (m, 2H), 7.44 (m, 3H), 7.01 (d, J= 9.4 Hz, 1H), 6.47 (d, 
J= 9.4 Hz, 1H), 4.51 (s, 2H)  
 
N
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4-Phenylethynyl-benzoic acid ethyl ester, 3.12 
To a round-bottomed flask was added alkyne 3.10 (0.596 mL, 5.43 mmol), ethyl-4-iodobenzoate 
3.11 (0.604 mL, 3.62 mmol), CuI (48.3 mg, 7 mol%), Pd(PPh3)4 (418.3 mg, 10 mol%), 10 mL 
DIPA, and 5 mL of toluene. The resulting mixture was stirred at room temperature overnight.  
After completion of the reaction, the mixture was diluted with CH2Cl2, filtered through celite, 
and concentrated in vacou. The resulting crude residue was purified by silica gel flash column 
chromatography (gradient: 0% to 10% ethyl acetate in hexane) to yield alkynyl ester 3.12 (0.891 
g, 98%). 
 
 
4-Phenylethynyl-benzoic acid hydrazide, 3.13 
In a 10 mL microwave vessel, a solution of alkynyl ester 3.12 (500 mg, 2.0 mmol) and hydrazine 
monohydrate (0.970 mL, 20.0 mmol) in toluene (2 mL) and ethanol (1 mL) was heated via the 
CEM discover microwave at 110 °C for 90 min at a power of 300 Watts.  Upon completion, the 
desired product crystallized. The crystals were filtered and washed with H2O to yield hydrazide 
3.12 (134.9 mg, 29% yield). 
O
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I
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1H NMR (CDCl3) δ 7.74 (m, 1H), 7.72 (m, 1H), 7.60 (m, 1H), 7.59 (m, 1H), 7.53 (m, 2H), 7.39 
(s, 1H), 7.36 (m, 3H), 4.11 (s, 2H) 
 
 
4-Phenylethynyl-benzoic acid N’-(2,3,4-trihydroxy-phenyl)-hydrazide, 3.14 
Hydrazide 3.13 was condensed with benzaldehyde 3.7 as described in general methods and 
worked-up using method A.  Yielded N-acyl hydrazone 3.14 (37.0 mg, 47%). 
1H NMR (CD3OD) δ 8.37 (s, 1H), 7.94 (d, J= 8.1 Hz, 2H), 7.66 (d, J= 8.1 Hz, 2H), 7.55 (m, 2H), 
7.40 (m, 3H), 6.76 (d, J= 8.1 Hz, 1H), 6.43 (d, J= Hz, 1H) 
 
 
3-alkyl-4-aminofurazan, 3.16 a - c 
Compounds were synthesized as detailed by Sheremetev, characterization of compounds 
matched that as published by authors.27 a, n = 0 (8.1g, 11%); b, n = 1 (1.1g, 26%); c, n = 2 
(0.71g, 18%) 
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General procedure for 3.5 and its derivatives: 
In a 10 mL microwave vessel, a solution of aldehyde A (X mmol), amine B (Y mmol), and 
trifluoroacetic acid (20 mol%) in dry acetonitrile (2-mL) was heated in the microwave at 150 °C 
for 20 min at a power of 200 Watts.   
 
Work-up methods: 
A: precipitated/re-crystallization: Upon completion, the crude material was re-crystallized out of 
100% acetonitrile.  Filtration afforded the imine. 
B: silica plug only:  Upon completion, the solution was concentrated in vacou.  The crude 
material was purified through a silica plug (Hexane/ethyl acetate 80/20).  The eluent was 
concentrated in vacuo to provide the imine. 
C: high-vacuum only: After running through a silica plug as described above, the impure product 
was placed on high vacuum overnight to afford the imine. 
D: heat/high-vacuum: After running through a silica plug as described above, the impure product 
was placed on high vacuum while in an 80°C oil bath overnight to afford imine. 
E: Column chromatography: Upon completion, the solution was concentrated in vacou.  The 
crude material was purified by chromatography (Hexane/ethyl acetate see chart) to provide the 
imine. 
Table S3.2. Derivatives of Compound 3.5. 
Compound mmol A mmol B Work-up Amount 
(mg) 
Percent yield 
3.5 0.605 0.505 A 64.7 47% 
3.5 a 0.164 0.327 B 25 75% 
3.5 b 0.262 1.04 B 52.2 73% 
3.5 c 0.246 0.984 B   
3.5 d 0.161 0.645 B 51.9 82% 
3.5 e 0.249 0.995 B 30.4 43% 
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Table S3.2 (cont.) 
Compound mmol A mmol B Work-up Amount 
(mg) 
Percent yield 
3.5 f 0.301 1.5 A 36.2 49% 
3.5 g 0.259 1.29 B 71 68% 
3.5 h 0.362 1.45 E (70/30) 57 74% 
3.5 i 0.416 1.66 C 29.6 35% 
3.5 j 0.29 1.16 B 65.8 90% 
3.5 k 0.286 1.14 D 38.4 52% 
3.5 l 0.32 1.28 D 6.8 9% 
3.5 m 0.467 1.87 D 6.7 8% 
3.5 n 0.344 1.38 C 29.2 38% 
3.5 o 0.255 1.02 D 23.2 33% 
3.5 p 0.299 1.2 D 8.9 12% 
3.5 q 0.134 0.535 A 5.4 9% 
3.5 r 0.409 1.64 C 57 64% 
3.5 s 0.246 0.492 C 23.7 48% 
3.5 t 0.262 0.786 D 51.9 70% 
3.5 u 0.249 0.746 D 55.8 76% 
3.5 v 0.467 1.87 C 6.3 7% 
3.5 w 0.286 0.858 E (80/20) 42 54% 
3.5 x 0.124 0.536 A 38.3 59% 
3.5 y 0.262 1.05 E (80/20) 62.5 79% 
3.5 z 0.409 1.23 C 68.6 73% 
3.5 aa 0.249 0.747 D 47.7 62% 
3.18 a 0.134 0.535 A 7 12% 
3.18 b 0.134 0.535 A 39.4 51% 
3.18 c 0.134 0.401 A 72.5 66% 
3.18 d 0.201 0.602 A 70.3 77% 
3.19 a 0.134 0.401 A 7.5 12% 
3.19 b 0.201 0.602 E (80/20) 78.5 91% 
3.19 c 0.201 0.602 A 48.1 47% 
3.19 d 0.201 0.802 A 61.7 59% 
3.19 e 0.201 0.602 A   
3.23 0.323 0.97 E (70/30) 9.6 9% 
3.27 0.213 0.64 D 23.4 46% 
3.30 0.115 0.344 E (90/10) 8.9 13% 
3.38 0.499 1.5 C 98.8 89% 
3.40 0.381 1.14 D 6.6 8% 
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2,4-Diiodo-6-[(4-methyl-furazan-3-ylimino)-methyl]-phenol, 3.5 
1H NMR (CDCl3) δ 13.09 (s, 1H) 9.01 (s, 1H), 8.22 (d, J= 2.1 Hz, 1H), 7.77 (d, J= 2.1 Hz, 1H), 
2.47 (s, 3H)  
13C NMR (CDCl3) δ 168.6, 160.5, 158.3, 151.8, 148.6, 142.2, 120.1, 87.5, 81.3, 7.9 
 
 
2-[(4-Methyl-furazan-3-ylimino)-methyl]-phenol, 3.5 a 
1H NMR (CDCl3) δ 12.08 (s,1H), 9.14 (s, 1H), 7.49 (m, 2H), 7.03 (m, 2H)  
13C NMR (CDCl3) δ 170.8, 162.1, 159.2, 148.6, 135.0, 134.1, 120.1, 118.5, 117.9, 7.9 
 
2,4-Dichloro-6-[(4-methyl-furazan-3-ylimino)-methyl]-phenol, 3.5 b 
1H NMR (CDCl3) δ 12.76 (s, 1H), 9.13 (s, 1H), 7.59 (d, J= 2.5 Hz, 1H), 7.42 (d, J= 2.5 Hz), 2.48 
(s, 3.0)  
13C NMR (CDCl3) δ 160.0, 158.4, 156.4, 148.6, 135.3, 131.3, 124.8, 123.6, 119.6, 7.8 
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Benzylidene-(4-methyl-furazan-3-yl)-amine, 3.5 c 
1H NMR (CDCl3) δ 8.97 (s, 1H), 7.96 (m, 2H), 7.52 (m, 3H), 2.44 (s, 3H) 
 
2,4-Dibromo-3-methoxy-6-[(4-methyl-furazan-3-ylimino)-methyl]-phenol, 3.5 d 
1H NMR (CDCl3) δ 13.15 (s, 1H), 9.08 (s, 1H), 7.68 (s, 1H), 3.00 (s, 3H), 2.47 (s, 3H)  
13C NMR (CDCl3) δ 168.3, 160.1, 159.8, 158.4, 148.5, 136.3, 116.7, 108.2, 108.0, 61.2, 7.9 
 
4-Bromo-2-[(4-methyl-furazan-3-ylimino)-methyl]-phenol, 3.5 e 
1H NMR (CDCl3) δ 12.06 (s, 1H), 9.09 (s, 1H), 7.60 (d, J= 2.3 Hz, 1H), 7.58 (dd, J= 9.0, 2.3 Hz, 
1H), 6.97 (d, J= 9.0 Hz, 1H), 2.47 (s, 3H)  
13C NMR (CDCl3) δ 169.6, 161.0, 158.9, 148.5, 145.4, 138.4, 136.8, 119.9, 119.8, 111.6, 7.9 
 
2-Ethoxy-6-[(4-methyl-furazan-3-ylimino)-methyl]-phenol, 3.5 f 
1H NMR (CDCl3) δ 12.43 (s, 1H), 9.18 (s, 1H), 7.09 (d, J= 7.6 Hz, 2H), 6.94 (d, J= 7.9 Hz, 1H), 
4.16 (q, J= 7.1 Hz, 2.0), 2.44 (s, 3H), 1.52 (t, J= 7.1 Hz, 3H)  
13C NMR (CDCl3) δ 170.8, 159.0, 152.4, 148.7, 148.0, 125.1, 119.7, 118.6, 118.2, 64.0, 15.0, 7.8  
 
5-Diethylamino-2-[(4-methyl-furazan-3-ylimino)-methyl]-phenol, 3.5 g 
1H NMR (CDCl3) δ 12.71 (s, 1H), 8.89 (s, 1H), 7.21 (d, J= 9.4 Hz, 1H), 6.31 (dd J= 2.8 Hz, 1H) 
6.16 (d, J= 2.7 Hz, 1H), 3.43 (q, J= 7.2 Hz, 4H), 2.40 (s, 3H), 1.23 (t, J= 7.2 Hz, 6H)  
13C NMR (CDCl3) δ 167.4, 164.7, 159.7, 153.7, 148.6, 136.7, 108.9, 106.1, 97.4, 45.0, 12.8, 7.9 
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3-[(4-methyl-furazan-3-ylimino)-methyl]-benzene-1,2-diol, 3.5 h 
1H NMR (CDCl3) δ 12.23 (s, 1H), 9.12 (s, 1H), 7.14 (d, J= 7.8 Hz, 1H), 7.06 (d, J= 7.8 Hz, 1H), 
6.91 (t, J= 7.8 Hz, 1H), 5.75 (s, 1H) 2.46 (s, 3H)  
13C NMR (CDCl3) δ 170.9, 159.0, 149.0, 148.5, 145.2, 124.0, 120.5, 120.4, 118.2, 7.9 
 
(4-Methyl-benzylidene)-(4-methyl-furazan-3-yl)-amine, 3.5 i 
1H NMR (CDCl3) δ 8.93 (s, 1H), 7.85 (d, J= 7.9 Hz, 2H), 7.31 (d, J= 7.9 Hz, 2H), 2.44 (s, 3H), 
2.43 (s, 3H)  
13C NMR (CDCl3) δ 165.7, 160.7, 149.2, 137.8, 134.7, 133.9, 131.3, 131.0, 129.0, 7.9 
 
1-[(4-Methyl-furazan-3-ylimino)-methyl]-naphthalen-2-ol, 3.5 j 
1H NMR (CDCl3) δ 14.22 (s, 1H), 10.01 (s, 1H), 8.18 (d, J= 8.5 Hz, 1H), 7.94 (d, J= 9.1 Hz, 
1H), 7.79 (d, J= 7.8 Hz, 1H), 7.60 (t, J= 7.7 Hz, 1H), 7.44 (t, J= 7.7 Hz, 1H), 7.19 (d, J= 9.1 Hz, 
1H), 2.45 (s, 3H)  
13C NMR (CDCl3) δ 165.9, 165.3, 159.0, 148.4, 138.2, 133.0, 129.7, 129.1, 128.1, 124.7, 119.8, 
119.7, 109.7, 7.9 
 
(3,4-Dichloro-benzylidene)-(4-methyl-furazan-3-yl)-amine, 3.5 k 
1H NMR (CDCl3) δ 8.92 (s, 1H), 8.08 (d, J= 1.9 Hz, 1H), 7.76 (dd, J= 8.3, 1.9 Hz, 1H), 7.60 (d, 
J= 8.3 Hz, 1H), 2.44 (s, 3H)  
13C NMR (CDCl3) δ 165.7, 160.8, 149.2, 137.8, 134.7, 133.9, 131.3, 131.0, 129.0, 7.9 
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(4-Methyl-furazan-3-yl)-naphthalen-2-ylmethylene-amine, 3.5 l 
1H NMR (CDCl3) δ 9.14 (s, 1H), 8.28 (s, 1H), 8.20 (dd, J= 8.8, 1.7 Hz, 1H), 7.95 (m, 3H), 7.61 
(m, 2H) 2.49 (s, 3H)  
13C NMR (CDCl3) δ 168.3, 161.4, 149.2, 136.0, 133.9, 132.7, 129.4, 129.2, 128.8, 128.2, 127.2, 
123.7, 8.0 
 
(4-Methyl-furazan-3-yl)-pyridin-3-ylmethylene-amino, 3.5 m 
1H NMR (CDCl3) δ 9.11 (d, J= 1.9 Hz, 1H), 9.06 (s, 1H), 8.82 (dd, J= 4.5, 1.9 Hz, 1H), 8.34 (dt, 
J= 1.9, 7.9 Hz, 1H), 7.49 (m, 1H) 
 
(1H-Indol-3-ylm ethylene)-(4-methyl-furazan-3-yl)-amine, 3.5 n 
1H NMR (CDCl3) δ 9.151 (s, 1H), 8.74 (s, 1H), 8.49 (m, 1H), 7.77 (d, J= 3.0 Hz, 1H), 7.46 (m, 
1H), 7.35 (m, 2H), 2.48 (s, 3H)  
13C NMR (CDCl3) δ 162.2, 161.9, 149.4, 142.6, 137.1, 134.0, 125.0, 124.7, 123.0, 116.4, 111.8, 
8.0 
 
(4-Methyl-furazan-3-yl)-(3,4,5-trimethoxy-benzylidene)-amine, 3.5 o 
1H NMR (CDCl3) δ 8.85 (s, 1H), 7.19 (s, 2H), 3.94, (s, 9H), 2.44 (s, 3H)  
13C NMR (CDCl3) δ 167.8, 161.3, 153.7, 149.0, 142.9, 130.2, 107.0, 61.3, 56.5, 8.1 
 
2-[(4-Methyl-furazan-3-ylimino)-methyl]-4-nitro-phenol, 3.5 p 
1H NMR (CDCl3) δ 12.87 (s, 1H), 9.26 (s, 1H), 8.50 (d, J= 2.8 Hz, 1H) 8.38 (dd, J= 9.3, 2.8 Hz, 
1H) 7.18 (d, J= 9.3 Hz, 1H), 2.50 (s, 3H)  
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13C NMR (CDCl3) δ 169.3, 166.7, 158.4, 148.4, 140.8, 130.5, 130.0, 119.0, 117.6, 7.9 
 
2-[(4-Ethyl-furazan-3-ylimino)-methyl]-4,6-diiodo-phenol, 3.5 q 
1H NMR (CDCl3) δ 13.09 (s, 1H), 9.03 (s, 1H), 8.23 (d, J= 2.1 Hz, 1H), 7.77 (d, J= 2.1 Hz, 1H), 
2.87 (q, J= 7.6 Hz, 2H), 1.40 (t, J= 7.6 Hz, 3H)  
13C NMR (CDCl3) δ 168.5, 160.5, 157.9, 153.2, 151.7, 142.2, 120.1, 87.4, 81.3, 16.7, 12.0 
 
2-[(4-Ethyl-furazan-3-ylimino)-methyl]-phenol, 3.5 r 
1H NMR (CDCl3) δ 12.10 (s, 1H), 9.15 (s, 1H), 7.48 (m, 2H), 7.01 (m, 2H), 2.86 (q, J= 7.5 Hz, 
2H) 1.40 (t, J= 7.5 Hz, 3H)  
13C NMR (CDCl3) δ 170.7, 162.1, 158.8, 153.1, 135.9, 134.1, 120.1, 118.5, 117.9, 16.7, 11.9 
 
Benzylidene-(4-ethyl-furazan-3-yl)-amine, 3.5 s 
1H NMR (CDCl3) δ 8.97 (s, 1H), 7.98 (m, 2H), 7.54 (m, 3H), 2.86 (q, J= 7.5 Hz, 2H), 1.38 (t, J= 
7.5 Hz, 3H) 
 
2,4-Dichloro-6-[(4-ethyl-furazan-3-ylimino)-methyl]-phenol, 3.5 t 
1H NMR (CDCl3) δ 12.77 (s, 1H), 9.13 (s, 1H), 7.58 (d, J= 2.5 Hz, 1H), 7.41 (d, J= 2.5 Hz, 1H), 
2.86 (q, J= 7.3 Hz, 2H), 1.40 (t, J= 7.3 Hz, 3H)  
13C NMR (CDCl3) δ 168.9, 157.9, 156.3, 153.2, 135.2, 131.3, 124.7, 123.6, 119.6, 16.7, 12.0 
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4-Bromo-2-[(4-ethyl-furazan-3-ylimino)-methyl]-phenol, 3.5 u 
1H NMR (CDCl3) δ 12.08 (s, 1H), 9.07 (s, 1H), 7.58 (d, J= 2.5 Hz, 1H), 7.55 (dd, J= 8.8, 2.5 Hz, 
1H), 6.95 (d, J= 8.8 Hz, 1H), 2.85 (q, J= 7.6 Hz, 2H), 1.38 (t, J= 7.6 Hz, 3H)  
13C NMR (CDCl3) δ 169.4, 161.0, 158.4, 153.1, 138.4, 135.8, 119.9, 119.8, 111.6, 16.7, 11.9 
 
(4-Ethyl-furazan-3-yl)-pyridin-3-ylmethylene-amine, 3.5 v 
1H NMR (CDCl3) δ 9.11 (d, J= 2.1 Hz, 1H), 9.06 (s, 1H), 8.81 (dd, J= 4.8, 18 1H), 8.33 (dt, J= 
8.1, 1.8 Hz, 1H), 7.48 (m, 1H),  
 
(3,4-Dichloro-benzylidene)-(4-ethyl-furazan-3-yl)-amine, 3.5 w 
1H NMR (CDCl3) δ 8.92 (s, 1H), 8.08 (d, J= 1.9 Hz, 1H), 7.77 (dd, J= 8.2, 1.9 Hz, 1H), 7.60 (d, 
J= 8.2 Hz, 1H), 2.86 (q, J= 7.7 Hz, 2H), 1.38 (t, J= 7.7 Hz, 3H)  
13C NMR (CDCl3) δ 165.5, 160.4, 153.7, 137.8, 134.7, 133.9, 131.3, 131.0, 129.0, 16.8, 12.0 
 
2,4-Diiodo-6-[(4-propyl-furazan-3-ylimino)-methyl]-phenol, 3.5 x 
1H NMR (CDCl3) δ 9.02 (s, 1H), 8.22 (d, J= 1.9 Hz, 1H), 7.77 (d, J= 1.9 Hz, 1H), 2.81 (t, J= 7.7 
Hz, 2H), 1.83 (quin, J= 7.7 Hz, 2H) 1.04 (t, J= 7.7 Hz, 3H)  
13C NMR (CDCl3) δ 168.5, 160.5, 158.1, 151.9, 142.2, 120.1, 87.4, 83.3, 24.7, 21.0, 13.9 
 
2,4-Dichloro-6-[(4-propyl-furazan-3-ylimino)-methyl]-phenol, 3.5 y 
1H NMR (CDCl3) δ 12.75 (s, 1H), 9.13 (s, 1H), 7.58 (d, J= 3.0 Hz, 1H), 7.41 (d, J= 3.0 Hz, 1H), 
2.82 (J= 7.7 Hz, 2H), 1.82 (quin, J= 7.7 Hz, 2H), 1.05 (t, J= 7.7 Hz, 3H)  
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13C NMR (CDCl3) δ 168.9, 158.1, 156.3, 152.0, 135.2, 131.3, 124.8, 123.6, 119.7, 24.7, 21.0, 
13.9 
 
2-[(4-Propyl-furazan-3-ylimino)-methyl]-phenol, 3.5 z 
1H NMR (CDCl3) δ 12.12 (s, 1H), 9.15 (s, 1H), 7.48 (m, 2H), 7.03 (m, 2H), 2.81 (q, J= 7.7 Hz, 
2H), 1.82 (quin, J= 7.7 Hz, 2H), 1.03 (t, J= 7.7 Hz, 3H)  
13C NMR (CDCl3) δ 170.7, 162.1, 158.9, 152.0, 135.9, 134.1, 120.1, 118.5, 117.9, 24.7, 21.0, 
13.9 
 
4-Bromo-2-[(4-propyl-furazan-3-ylimino)-methyl]-phenol, 3.5 aa 
1H NMR (CDCl3) δ 12.11 (s, 1H), 9.09 (s, 1H), 7.60 (d, J= 2.5 Hz, 1H) 7.57 (dd, J= 8.9, 2.5 Hz, 
1H), 6.97 (d, J= 8.9 1H) 2.81 (t, J= 7.5 Hz, 2H), 1.82 (quin, J= 7.6 Hz, 2H), 1.03 (t, J= 7.6 Hz, 
3H)  
13C NMR (CDCl3) δ 169.3, 161.0, 158.6, 151.9, 138.4, 135.8, 119.9, 119.9, 111.6, 24.8, 21.0, 
12.9 
 
 
2,4-Diiodo-6-petyliminoemthyl-phenol, 3.18 a 
1H NMR (CDCl3) δ 8.47 (s, 1H), 8.11 (d, J= 1.9 Hz, 1H) 7.68 (d, J= 1.9 Hz, 1H), 7.45 (t, J= 8.0 
Hz, 2H), 7.35 (t, J= 7.5 Hz, 1H), 7.30 (d, J= 8.1 Hz, 2H)  
NH2
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CH3CN
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N OH
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R
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13C NMR (CDCl3) δ 160.7, 159.9, 149.3, 146.7, 140.7, 129.9, 128.1, 121.4, 120.8, 87.7, 80.0 
 
2,4-Diiodo-6-[(2-iodo-phenylimnio)-methyl]-phenol, 3.18 b 
1H NMR (CDCl3) δ 8.35 (s, 1H), 8.14 (d, J= 2.1 Hz, 1H) 7.95 (dd, J= 8.0, 1.4 Hz, 1H) 7.70 (d, 
J= 2.1 Hz, 1H), 7.44 (ddd, J= 7.9, 1.4 Hz, 1H), 7.17 (dd, J= 8.0, 1.4 Hz, 1H), 7.04 (ddd, J= 8.0, 
1.4 Hz, 1H)  
13C NMR (CDCl3) δ 160.9, 160.0, 149.8, 149.0, 141.1, 139.9, 129.8, 129.2, 120.8, 118.7, 96.6, 
87.4, 80.4 
 
2-[(2,4-Dibromo-phenylimino)-methyl]-4,6-diiodo-phenol, 3.18 c 
1H NMR (CDCl3) δ 8.42 (s, 1H) 8.15 (d, J= 2.1 Hz, 1H) 7.85 (d, J= 2.1 Hz, 1H), 7.70 (d, J= 2.1 
Hz, 1H) 7.52 (dd, J= 8.6, 2.1 Hz, 1H), 7.11 (d, J= 8.6 Hz, 1H)  
13C NMR (CDCl3) δ 161.1, 160.2, 150.1, 144.8, 141.1, 136.1, 131.9, 121.6, 121.6, 121.3, 120.7, 
120.2, 89.5, 80.5 
 
2,4-Diiodo-6-(pyridin-2yliminomethyl)-phenol, 3.18 d 
1H NMR (CDCl3) δ 9.31 (s, 1H), 8.52 (dd, J= 5.0, 2.0 Hz, 1H), 8.13 (d, J= 2.0 Hz, 1H) 7.82 (td, 
J= 7.7, 2.0 Hz, 1H) 7.76 (d, J= 2.0 Hz, 1H), 7.32 (d, J= 7.8 Hz, 1H), 7.27 (m, 1H)  
13C NMR (CDCl3) δ 162.0, 161.8, 155.7, 150.0, 149.4, 141.8, 139.0, 123.6, 120.7, 120.4, 88.1, 
80.0 
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2-[(Furan-2-ylmethylimino)-methyl]-4,6-diiodo-phenol, 3.19 a 
1H NMR (CDCl3) δ 8.16 (s, 1H), 8.05 (d, J= 2.1 Hz, 1H), 7.53 (d, J= 2.0 Hz, 1H), 7.41 (dd, J= 
0.9, 2.0 Hz, 1H), 6.37 (m, 1H), 6.31 (m, 1H), 4.80 (s, 2H)  
 
2-(tert-Butylimino-methyl)-4,6-diido-phenol, 3.19 b 
1H NMR (CDCl3) δ 8.05 (d, J= 2.4 Hz, 1H), 8.02 (d, J= 6.8 Hz, 1H), 7.47 (d, J= 2.4 Hz, 1H), 
1.41 (s, 1H)  
13C NMR (CDCl3) δ 167.0, 158.7, 149.7, 140.7, 117.6, 93.3, 75.5, 56.9, 29.6 
 
2-(Benzothiazol-2yliminomethyl)-4,6-diiodo-phenol, 3.19 c 
1H NMR (CDCl3) δ 9.21 (s, 1H), 8.20 (d, J= 1.9 Hz, 1H), 8.00 (m, 1H), 7.88 (m, 1H), 7.82 (d, J= 
2.0 Hz, 1H), 7.54 (m, 1H), 7.43 (m, 1H)  
 
2-[(4-Bromo-1H-pyrazaol-3-ylimino)-methyl]-4,6-diiodo-phenol, 3.19 d 
1H NMR (CD3OD) δ 9.01 (s, 1H), 8.13 (d, J= 2.1 Hz, 1H), 7.87 (d, J= 2.1 Hz, 1H), 7.79 (s, 1H) 
 
2,4-Diiodo-6-[(5-methyl-[1,3,4]thiadiazol-2-ylimino)-methyl]-phenol, 3.19 e 
1H NMR (CDCl3) δ 9.04 (s, 1H), 8.21 (d, J= 2.1 Hz, 1H), 7.77 (d, J= 2.1 Hz, 1H), 2.81 (s, 3H) 
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4-Iodo-N-methoxy-N-methyl-benzamide, 3.21 
In a 100 mL round-bottomed flask charged with nitrogen, a solution of 4-iodobenzoic acid 3.20 
(500 mg, 2.02 mmol) and diisopropylethylamine (0.35 mL, 2.02 mmol) in dichloromethane (25 
mL) at -20 °C was added N, O-dimethylhydroxylamine•HCl (394.1 mg, 4.04 mmol), 
diisopropylethylamine (0.76 mL, 4.44 mmol), and benazotriazol-1-yloxy 
tripyrrolidiniophosphonium hexfluorophosphate (PyBOP, 1051 mg, 2.02 mmol).  The solution 
was stirred for 30 minutes at -20 °C and then at room temperature for 6 hours. After dilution with 
dichloromethane (50 mL), the reaction was washed with 3N HCl (4 x 20 mL), saturated aqueous 
NaHCO3 (20 mL), and brine.  The organic phase was dried (MgSO4) and concentrated in vacuo. 
The crude product was purified by chromatography (50% ethyl acetate in hexane) to provide 
hydroxy-amide 3.21 (437.0 mg, 74%).  
1H NMR (CDCl3) δ 7.64 (d, J= 8.4 Hz, 2H), 7.32 (d, J= 8.5 Hz, 2H), 3.41 (s, 3H), 3.23 (s, 3H) 
 
 
4-Iodobenzaldehyde, 3.22 
A 100 mL round-bottomed flask was charged with nitrogen. To a solution of amide 3.21 (464.3 
mg, 1.6 mmol) in dry THF (20 mL) at -78 °C was added diisobutyl aluminum hydride in hexanes 
(DIBAL-H, 1.0M, 4.8 mL, 4.8 mmol) dropwise.  The solution was stirred for 1 h and was 
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O
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warmed to room temperature.  After dilution with 5 % HCl in ethanol (10 mL), the solution was 
washed with brine, ether:CH2Cl2 (1:1 mixture, 50 mL).  The organic phase was dried (MgSO4) 
and concentrated in vacou.  The crude product was purified by chromatography (20% ethyl 
acetate in hexane) to yield aldehyde 3.22 (93.7, 25%).   
1H NMR (CDCl3) δ 9.29 (s, 1H), 7.88 (d, J= 8.5 Hz, 2H), 7.56 (d, J= 8.5 Hz, 2H) 
 
 
5-Iodo-2-[(4-methyl-furazan-3-ylimino)-methyl]-phenol,  3.23 
1H NMR (CDCl3) δ 8.92 (s, 1H), 7.87 (d, J= 8.2 Hz, 2H), 7.68 (d, J= 8.2 Hz, 2H), 2.44 (s, 1H)  
 
 
3-chlorosalicylaldehyde, 3.26 
3.25 (117.4 mg, 17%) was synthesized as detailed by Kauch.  Characterization of compound 
matched that as published by authors.30 3.26 (33.4 mg, 30%) was synthesized as detailed by 
Kauch.  Characterization of compound matched that as published by authors.31  
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2-Chloro-6-[(4-methyl-furazan-3-ylimino)-methyl]-phenol, 3.27 
1H NMR (CDCl3) δ 12.81 (s, 1H), 9.18 (s, 1H), 7.60 (dd, J= 1.5, 7.8 Hz, 1H), 7.43 (dd, J= 1.5, 
7.9 Hz, 1H), 6.99 (t, J= 7.9 Hz, 1H), 2.46 (s, 3H)  
13C NMR (CDCl3) δ 170.1, 158.6, 157.6, 148.6, 135.8, 132.5, 122.5, 120.4, 119.4, 7.9 
 
 
3,5-diiodo-2-methoxybenzaldehyde, 3.28 
In a 10-mL microwave vessel, a solution of 3,5-diiodosalicylaldehyde 3.17 (100 mg, 0.267 
mmol), iodomethane (0.0333 mL, 0.535 mmol), and potassium carbonate (73.9 mg, 0.535 mmol) 
in acetone (5-mL) was heated via microwave for 20 min at 100 °C and 200 W.  The solution was 
concentrated in vacuo.  The crude product was purified by chromatography (20% ethyl acetate in 
hexane) to provide 3,5-diiodo-2-methoxybenzaldehyde, 3.28 (44.5 mg, 43%).  
1H NMR (CDCl3) δ 10.20 (s, 1H), 8.33 (s, 1H), 8.09 (s, 1H), 3.94 (s, 3H) 
 
(3,5-Diiodo-2-methoxy-benzylidene)-(4-methyl-furazan-3-yl)-amine, 3.30 
1H NMR (CDCl3) δ 8.53 (d, J= 2.3 Hz, 1H), 8.50 (s, 1H), 8.24 (d, J= 2.3 Hz, 1H), 7.92 (dd, J= 
7.7, 1.3 Hz, 1H), 7.40 (td, J= 7.8, 1.4 Hz, 1H), 6.98 (m, 2H), 3.89 (s, 3H)  
13C NMR (CDCl3) δ 160.5, 155.4, 152.8, 150.1, 139.4, 137.7, 131.8, 129.6, 127.8, 118.5, 94.8, 
93.7, 89.9, 63.5 
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2,4-Diiodo-6-[(4-methl-furazan-3-ylamino)-methyl]-phenol, 3.31 
Imine 3.5 (75 mg, 0.162 mmol) was dissolved in MeOH (5 mL) and treated with NaCNBH3 
(12.4 mg, 0.198 mmol). The pH was adJusted to 3 using HCl and stirred for 4 hours.  The 
solution was concentrated in vacou.  The residue was dissolved in 10-mL of saturated aqueous 
Na2CO3, and extracted with ethyl acetate (3x 10 mL). The combined organic solution was 
washed with H2O (20 mL), and brine (20 mL), and dried over MgSO4.  The crude material was 
purified by chromatography (40% ethyl acetate in hexane) to provide amine 3.31 (4.3 mg, 6% 
yield).  
1H NMR (CD3OD) δ 7.90 (d, J= 2.0 Hz, 1H), 7.52 (d, J= 2.0 Hz, 1H), 4.38 (s, 2H), 2.25 (s, 3H) 
 
 
3,5-Dichloro-2-hydroxy-benzaldehyde O-benzyl-oxime, 3.34 
In a 10 mL microwave vessel, a solution of hydroxyl amine 3.32 (50 mg, 0.313 mmol), aldehdye 
3.33 (179.5 mg, 0.940 mmol), and trifluoroacetic acid (20 mol%, 0.0048 mL) in ethanol (2-mL) 
was heated via microwave at 150°C for 20 minutes at a power of 200 Watts. Upon completion, 
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the solution was concentrated in vacou and purified by chromatography (10% ethyl acetate in 
hexane) to yield oxime 3.34. 
1H NMR (CDCl3) δ 10.39 (s, 1H), 8.12 (s, 1H), 7.40-7.35 (m, 5H), 7.34 (d, J= 2.4 Hz, 1H), 7.05 
(d, J= 2.4 Hz, 1H), 5.18 (s, 2H) 
 
 
3,5-dimethylsalicylaldehyde, 3.36 
A dry 50-mL, three-necked round-bottomed flask equipped with a stir bar, reflux condenser and 
rubber septa was purged with nitrogen gas.  A solution of phenol 3.35 (0.245 mL, 2.05 mmol), 
anhydrous magnesium chloride beads (292.8 mg, 3.07 mmol), and dry triethylamine (1.07 mL, 
7.67 mmmol) was stirred in dry acetonitrile (25-mL) for 10 minutes.  Dry paraformaldehyde 
(415.5 mg, 6.75 mmol) was added and the reaction was stirred under reflux for 3 hours.  The 
solution was cooled to room temperature and 5% aqueous HCl (15-mL) was added, followed by 
stirring for 30 minutes.  The aqueous solution was extracted with diethyl ether (4x15-mL), and 
the combined organic solution was washed with brine (2x15-mL) and dried over MgSO4.  After 
filtration, the solution was concentrated in vacou.  The crude material was purified by 
chromatography (15% diethyl ether in hexane) to afford the salicylaldehyde 3.36 (224.4 mg, 
73% yield).  
1H NMR (CDCl3) δ 11.09 (s, 1H), 9.80 (s, 1H), 7.19 (s, 1H), 7.14 (s, 1H), 2.29 (s, 3H), 2.23 (s, 
3H)  
13C NMR (CDCl3) δ 196.8, 158.1, 139.2, 131.1, 128.7, 126.7, 119.9, 20.4, 15.1 
OH
H H
O
CH3CN
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2,4-Dimethyl-6-[(4-methyl-furazan-3-ylimino)-methyl]-phenol, 3.38 
1H NMR (CDCl3) δ 13.39 (s, 1H), 8.58 (s, 1H), 7.44 (m, 2H), 7.30 (m, 3H), 7.11 (s, 1H), 7.05 (s, 
1H), 2.34 (s, 3H), 2.33 (s, 3H)  
13C NMR (CDCl3) δ 163.0, 157.5, 148.9, 135.5, 130.1, 129.6, 127.8, 126.9, 126.1, 121.4, 118.3, 
20.6, 15.7 
 
4-[(4-Methyl-furazan-3-ylimino)-methyl]-benzonitrile, 3.40 
1H NMR (CDCl3) δ 9.05 (s, 1H), 8.09 (d, J= 8.2 Hz, 2H), 7.83 (d, J= 8.2 Hz, 2H), 2.47 (s, 3H) 
13C NMR (CDCl3) δ 166.3, 160.7, 149.2, 138.4, 132.9, 130.2, 118.2, 116.5, 7.9 
 
 
4-Hydroxy-3-iodobenzonitrile, S3.2 
In a dried 250-mL, round-bottomed flask equipped with a stir bar, phenol S3.1 (1.0 g, 8.39 
mmol) was dissolved concentrated ammonium hydroxide. (45 mL). In a separate 50-mL, round-
bottomed flask, potassium iodide (6.9 g, 41.95 mmol) and iodine (2.1 g, 8.39 mmol) was 
dissolved in 10 mL of H2O. The aqueous solution was added quickly to phenol S3.1 solution. 
The solution stirred for 18 h, and upon stirring, a white precipitate was formed and filtered by 
gravity filtration. The solution was concentrated in vacou to afford a yellow solid. The crude 
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material was purified by ISCO MPLC (gradient: 40% to 80% dichloromethane in hexane) to 
afford phenol S3.2 (white solid, 403.2 mg, 20% yield).  
1H NMR (CDCl3) δ 7.97 (d, 1H, J=1.7 Hz), 7.55 (dd, 1H, J=1.7 Hz, J=8.5 Hz), 7.05 (d, 1H, 
J=8.5 Hz) 
 
 
3-Iodo-5-nitrilesalicylaldehyde, 3.46 
A dry 40-mL reflux vial, equipped with a stirring bar was purged with nitrogen gas. Anhydrous 
magnesium chloride beads (58.3 mg, 0.612 mmol), and dry triethyl amine (154.9 mg, 1.53 
mmol) were added to a solution of phenol S3.2, which had been dissolved in dry acetonitrile (4 
mL). This solution stirred at room temperature for 10 min. Next, dry paraformaldehyde (82.7 
mg, 2.75 mmol) was added and the reaction stirred under reflux for 18 h. The solution was 
cooled to room temperature and added 5% aqueous HCl (15-mL) followed by stirring for 30 
minutes. The aqueous solution was extracted with dichloromethane (3x10 mL), washed with 
brine (10 mL) and dried (Na2SO4). After filtration, the solution was concentrated in vacou.  The 
crude material was purified by ISCO MPLC (gradient: 85% to 100% dichloromethane in hexane) 
to afford the salicylaldehyde 3.46 (white solid, 18.8 mg, 17% yield).  
1H NMR (CDCl3) δ 12.30 (s, 1H), 9.81 (s, 1H), 8.24 (d, 1H, J=2.0 Hz), 7.93 (d, 1H, J=2.0 Hz) 
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3,5-Diiodo-N-methoxy-N-methylbenzamide, S3.4 
A dried 100-mL, round-bottomed flask equipped with a stirring bar was purged with nitrogen 
gas. Benzoic acid S3.3 (250 mg, 0.669 mmol) was dissolved in dry dichloromethane (8 mL) in a 
nitrogen atmosphere. Next diisopropylethylamine (DIPEA, 0.114 mL, 0.669 mmol) was added, 
and the stirring solution was cooled to -78 °C. Upon cooling, to the solution was added N, O-
dimethyl hydroxyl amine HCl (130.5 mg, 1.34 mmol), DIPEA (.252 mL, 1.47 mmol), and 
PyBOP (348.1 mg, 0.669 mmol). The reaction continued to stir under nitrogen at -78 °C for 6 h. 
Upon completion, the solution was diluted with 25 mL of dichloromethane, and the organic 
solution was washed with 3N HCl (2x25 mL), saturated aqueous NaHCO3 (20 mL), and brine 
(20 mL). The organic layer was dried over Na2SO4, decanted, and concentrated in vacou to 
afford a purple oil. The crude material was purified by ISCO MPLC (gradient: 0% to 30% ethyl 
acetate in hexane) to afford amide S3.4 (86.1 mg, 31% yield).  
1H NMR (CDCl3) δ 8.12 (t, 1H, J=1.4 Hz), 7.95 (d, 2H, J=1.4 Hz), 3.55 (s, 3H), 3.33 (s, 3H) 
 
 
3,5-Diiodobenzaldehyde, 3.53 
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A dried 100-mL, round-bottomed flask equipped with a stirring bar was purged with nitrogen 
gas. Amide S3.4 (80.0 mg, 0.192 mmol) was dissolved in dry THF (5 mL) in a nitrogen 
atmosphere, and the stirring solution was cooled to -78 °C. Upon cooling, to the solution was 
added diisobutyl aluminum hydride (1M in Hexanes, 0.576 mL, 0.576 mmol), dropwise. The 
reaction continued to stir under nitrogen at -78 °C for 3 h. Upon completion, the solution was 
quenched with methanol (at -78 °C). 1 M sodium potassium tantrate (10 mL) was added and the 
solution stirred overnight, warming to room temperature. The organic solution was extracted 
with dichloromethane (3x10 mL), washed with H2O (10 mL), and brine (10 mL). The organic 
layer was dried over Na2SO4, decanted, and concentrated in vacou to afford a light brown solid. 
The crude material was purified by ISCO MPLC (gradient: 0% to 30% ethyl acetate in hexane), 
followed by a second purification by ISCO MPLC (gradient: 0% to 40% dichloromethane in 
hexane) to afford aldehyde 3.53.  
1H NMR (CDCl3) δ 9.83 (s, 1H), 8.30 (d, 1H, J=1.5 Hz), 8.15 (d, 2H, J=1.5 Hz) 
 
 
1-(3,5-diiodo-2-(prop-2-yn-1-yloxy)phenyl)ethanol, S3.5 
In a dried 50-mL, round-bottomed flask equipped with a stirring bar, aldehyde 3.52 (85.4 mg, 
0.207 mmol) was dissolved in dry THF (3 mL). The solution was cooled to -78 °C and methyl 
magnesium bromide (3.0 M in diethyl ether, 55 µL, 0.166 mmol) was added dropwise.  The 
solution stirred at -78 °C for 1 h, and then warmed to room temperature. The reaction was 
H
OO
I
I
3.52
OHO
I
I
THF, -78 °C
45%
MeMgBr
S3.5
 210 
quenched with H2O and acidified with 1N HCl. The aqueous solution was extracted with 
dichloromethane (3x10 mL), washed with H2O (10 mL), brine (10 mL), and dried (Na2SO4). 
After filtration, the solution was concentrated in vacou to afford an oil. The crude material was 
purified by ISCO MPLC (gradient: 10% to 40% ethyl acetate in hexane) to afford S3.5 (32.2 mg, 
45% yield).  
1H NMR (CDCl3) δ 8.02 (d, 1H, J=2.1 Hz), 7.79 (d, 1H, J=2.1 Hz), 5.30 (q, 1H, J=6.5 Hz), 4.71 
(d, 2H, J=2.4 Hz), 2.58 (t, 1H, J=2.4 Hz), 1.46 (d, 3H, J=6.5 Hz) 
 
 
1-(3,5-diiodo-2-(prop-2-yn-1-yloxy)phenyl)ethanone, S3.6 
A dried 50-mL, round-bottomed flask equipped with a stirring bar was purged with nitrogen gas. 
Alcohol S3.5 (32.0 mg, 0.0748 mmol) was dissolved in dry dichloromethane (5 mL) in a 
nitrogen atmosphere. Next pyridinium chlorochromate (PCC, 32.2 mg, 0.150 mmol) and a small 
amount of celite was added, and the solution continued to stir under nitrogen for 2.5 h. Upon 
completion, the solution was filtered through a pad of celite, and the celite was washed with 
dichloromethane. The organic solution was washed with 1N HCl (3x10 mL), brine (10 mL), and 
dried (Na2SO4). After filtration, the solution was concentrated in vacou to afford a brown oil. 
The crude material was purified by ISCO MPLC (gradient: 10% to 40% ethyl acetate in hexane) 
to afford ketone S3.5 (white solid, 18.8 mg, 59% yield).  
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1H NMR (CDCl3) δ 8.24 (d, 1H, J=2.2 Hz), 7.87 (d, 1H, J=2.2 Hz), 4.69 (d, 2H, J=2.4 Hz), 2.65 
(s, 3H), 2.53 (t, 1H, J=2.4Hz) 
 
 
1-(2-hydroxy-3,5-diiodophenyl)ethanone, 3.54 
A dried 25-mL, round-bottomed flask equipped with a stirring bar was purged with nitrogen gas. 
Ketone S3.6 (18.8 mg, 0.0441 mmol) was dissolved in dry dichloromethane (1 mL) in a nitrogen 
atmosphere. Next boron tribromide (1M in dichloromethane, 88.2 µL) was added dropwise and 
the solution stirred under nitrogen for 1.5 h. Upon completion, the reaction was quenched with 
cold H2O. The organic solution was extracted with ethyl acetate (3x10 mL), and the combined 
organic solutions were washed with H2O (10 mL), brine (10 mL), and dried (Na2SO4). After 
filtration, the solution was concentrated in vacou to afford a brown residue. The crude material 
was purified by ISCO MPLC (gradient: 0% to 30% ethyl acetate in hexane) to afford ketone 3.54 
(yellow solid, 3.6 mg, 21% yield).  
1H NMR (CDCl3) δ 13.11 (s, 1H), 8.21 (d, 1H, J=2.0 Hz), 8.00 (d, 1H, J=2.0 Hz), 2.65 (s, 3H) 
 
OO
I
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OOH
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